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Introduction and outline of this thesis
Adapted from: “Danger in the Intensive Care Unit: DAMPs in 
critically ill patients”
Kim Timmermans, Matthijs Kox, Gert Jan Scheffer, Peter Pickkers
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The immune system is a complex network consisting of many elements primarily 
aimed to protect the human body from invading pathogens. An important feature 
of the immune system is the ability to distinguish between entities it should react 
to, such as bacteria and viruses, and those it should ignore, such as the host’s 
healthy tissue 1. Cells of the innate immune system, such as macrophages and 
dendritic cells, discriminate between these and mount an initial non-specific 
immunologic response 2. Furthermore, these antigen presenting cells (APCs) 
subsequently instruct lymphocytes that orchestrate a specific adaptive immune 
response 2. If these systems function as intended, an effective and appropriate 
immune response is mounted that eliminates the threat, but does not cause 
collateral damage to organs. The immune system detects invading pathogens 
through recognition of so-called “Pathogen Associated Molecular Patterns” 
(PAMPs) by Pattern Recognition Receptors (PRRs). PAMPs are parts of microbes, 
such as lipopolysaccharide (LPS), a major component of the outer membrane of 
gram-negative bacteria, or e.g. β-glucan, a cell-wall component of fungi. Examples 
of PRRs include Toll-Like receptors (TLRs), NOD-like receptors (NLRs), and C-type 
lectin Receptors (CLRs), to which specific PAMPs bind. However, it has become 
clear that PRRs can also be activated by so-called so-called “Danger-Associated 
Molecular Patterns” (DAMPs). In the studies described in this thesis, we focused 
on immunologic roles and mechanisms of action of DAMPs in critically ill patients. 
Next to a pro-inflammatory response, triggering of the immune system could 
also lead to an anti-inflammatory response, called immunoparalysis, that leaves 
patients susceptible for secondary infections. We have studied those aspects 
in several groups of critically ill patients, namely those suffering from trauma, 
cardiac arrest, leukemia, and sepsis. Furthermore, we performed pre-clinical 
studies in mice on the role of DAMPs and underlying mechanisms of ventilator-
induced inflammation, and assessed interactions between ligation of different 
PRRs in vitro. Finally, immunologically inactive biomarkers were studied in trauma 
patients.
The Danger Model and DAMPs
Clearly, the immune system can discriminate between self and non-self to a great 
extent 1, however, as presented by Polly Matzinger in their ‘Danger Model’, it is 
assumed that the immune system does not primarily discriminate between self 
and non-self, but rather between safe and dangerous 3, 4. This model describes 
how APCs are activated by danger signals, or DAMPs, that are released by injured, 
threatened, or dead cells, or originate from the extracellular matrix. Of interest, 
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for example apoptosis does not result in the release of DAMPs as leakage of cell 
components, intracellular substances, or other molecules is prevented in this 
controlled manner of cell death 5. However, if cells die in an uncontrolled fashion, 
such as necrosis or rupture by physical force, cellular contents and debris, some 
of which are DAMPs, are released into the surrounding tissue and/or circulation 
5. In a similar fashion, the extracellular matrix can be disrupted, resulting in the 
release of components which act as DAMPs. Cells can also actively release DAMPs 
when under threat 6. DAMPs can be constitutively expressed or inducible as well 
as intracellular or secreted 5. Taken together, it is clear that DAMPs that activate 
or influence immune responses can be released in a multitude of situations 
and in many different ways, thereby forming a large group of biologically active 
molecules, that as such could also serve as biomarkers or therapeutic targets.
Several criteria, some of which overlap, have been put forward that molecules 
should fulfil to qualify as DAMP 6, 7. These can be summarized into: 1. The molecule 
is released rapidly following a triggering event. 2. The purified molecule induces 
an inflammatory response at physiological concentrations, and is particularly 
potent in vivo. 3. Selective elimination or neutralization of the molecule inhibits 
the biological activity of dead cells in in vitro and in vivo assays. 4. The molecule 
has both chemotactic as well as APC-activating effects. However, not all molecules 
generally accepted as DAMPs fulfil all these criteria.
A broad range of DAMPs meeting these criteria have been described in the 
literature, indicating that the Danger Model, originally described as a theoretical 
model 3, 4, plays an important role in regulation of immune responses. As a result, 
in recent years, the involvement of DAMPs in immune responses has gained 
increasing attention. This is of great relevance in critically ill patients, in whom 
trauma- or surgery-related cell damage, hypoxia, ischemia, and infections may 
result in extensive release of DAMPs. As many patients in the intensive care 
unit suffer from immune system-related complications 8, DAMPs could play 
an important role in the prognosis of these patients and represent possible 
therapeutic targets. As such, further understanding of the mechanisms behind 
DAMP release and DAMP-induced immune responses is warranted. 
Hereby, we provide an overview of several well-described DAMPs (High Mobility 
Group Box 1, heat shock proteins, s100 proteins, and nucleic acids) and their 
effects on the immune system. Furthermore, we discuss the role of DAMPs as 
markers and therapeutic targets in several conditions frequently encountered 
in the intensive care unit, such as sepsis, trauma, ventilator-induced lung injury 
(VILI), and cardiac arrest. An overview of observational human studies and animal 
intervention studies relevant to intensive care-related conditions is provided in 
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Tables 1 and 2, respectively. Moreover, the mechanisms of release and receptor 
binding capacity of DAMPs are summarized in Figure 1.
Well-described DAMPs
High Mobility Group Box 1 
High Mobility Group Box 1 (HMGB1) is an archetypal DAMP, previously referred 
to as HMG-1 or amphoterin 9. The “High Mobility Group” of nuclear proteins was 
discovered more than 40 years ago and owes its name to rapid electrophoresis 
mobility properties in polyacrylamide gels 10. HMGB1 is an ubiquitous nuclear 
protein, functioning as a DNA chaperone under physiological conditions 11. 
Moreover, it reduces protein aggregation induced by heat or chemical stress in 
the cytoplasm 12. However, HMGB1 also exhibits cytokine-like properties when 
secreted, as it triggers innate immune responses, mediates inflammatory response 
in later stages 13, and influences immunological processes like autophagy and 
apoptosis 14. 
HMGB1 can be secreted in two ways: actively by inflammatory cells such as 
macrophages 13, and passively by necrotic and apoptotic cells 15. In the latter 
case, HMGB1 diffuses out of the nucleus when membrane integrity is lost 15, 16. 
HMGB1 consists of two homologous DNA-binding domains, the A-box and 
B-box, of which the B-box is related to the cytokine-like properties of HMGB1 17. 
Extracellular HMGB1 acts via a multitude of pathways, among others the binding 
of several pattern recognition receptors and subsequent NF-κB activation. HMGB1 
acts as a ligand for various pattern recognition receptors, including RAGE, TLR2, 
TRL4 and TLR9 18-21. Moreover, it interacts with other pro-inflammatory mediators, 
such as LPS, LTA and CpG, to enhance TLR-4-, TLR2- and TLR9-mediated immune 
responses, respectively 22-24.
S100 proteins
The family of S100 proteins, or calgranulins, consists of 24 members 25 and 
their name is derived from their solubility in 100% ammonium sulfate solution 
26. Intracellularly, S100 proteins play an important role in the regulation of 
various processes, such as cell proliferation and differentiation, apoptosis, Ca2+ 
homeostasis and energy metabolism 25. However, several S100 family members, 
e.g. S100A8 (also known as calgranulin A or MRP-8), S100A9 (Calgranulin B or MRP-
14, which can form a dimer with S100A8 extracellularly) 27, S100A12 (calgranulin 
C or EN-RAGE) 28, and S100B 29 can be released extracellularly and subsequently 
exert pro-inflammatory effects 30, 31. S100A8 and A100A9 are secreted by 
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granulocytes, monocytes, keratinocytes, and epithelial cells in inflammatory 
settings 30, 32-34. S100A12 is exclusively expressed in granulocytes 35. Passive release 
of S100 proteins as a result of necrosis occurs in conjunction with release of other 
DAMPs in this setting 36, 37. Interestingly, S100 proteins cannot be secreted via the 
classical Golgi-route due to their structure that lacks the corresponding signal 
sequence 38. Their active release, for example from activated monocytes, occurs 
via an alternative tubulin-dependent pathway 38. 
After release, S100A8/9 interacts both with TLRs and RAGE to exhibit its effects, 
while S100A12 and S100B interact primarily with RAGE 39-42. Both will result in 
NFκB-mediated production of pro-inflammatory cytokines 39, 41. It appears likely 
that other receptors can be activated as well 43. Both proteins also upregulate 
ICAM-1 and VCAM-1 expression on endothelial cells 39, 44. Moreover, both S100A8/
A9 and S100A12 exert antibacterial/antiparasitic activity 45, 46. Although S100A8/
A9 and S100A12 are released under similar conditions, no interactions between 
both have been demonstrated 35. S100B is a brain-specific S100 protein, that has 
both neurotrophic and proapoptotic effects 47.
Heat-shock proteins
Heat-shock proteins (HSPs) are molecular chaperones present in the cytosol that 
are induced by both hyper- and hypothermia, but also by a variety of other stress 
factors (e.g. UV radiation, heavy metals, pathogens, and physiological stresses) 
48. They can prevent cell death through a mechanism known as the heat shock 
response 49. This response mainly comprises binding of unfolded, misfolded, or 
mutated proteins for transport to and refolding in the endoplasmic reticulum 
50, 51. Dendritic cells can distinguish stressed apoptotic cells from non-stressed 
apoptotic cells by detecting the presence of HSPs on the plasma membrane 52. 
HSP family members are named after their molecular weight (in kDa), of which 
the HSP70 family is the most extensively studied 53. 
The stress-induced HSP70, both known as “HSP70” and “HSP72” in the literature 53, 
can be released into the circulation within minutes following an insult 54. HSPs can 
be released both passively and actively. Passively, HSPs originate from necrotic 
or damaged cells. However, HSPs can also be released actively in the absence of 
necrotic or damaged cells, for example by immune cells 55-57, or in psychological 
stress situations 58. Exosomes 55, 59 and surface membrane lipid rafts 60, 61 play an 
important role in the active release of HSPs.
After release, HSP70 is able to bind to both TLR2 and TLR-4 62 in a CD14-dependent 
manner 63, 64. Moreover, HSP70 binds to CD36 65, CD40 66, CD91 67, Lox-1 68 and SR-A 
69, on a range of cells, mainly those of the innate immune system 65, 69, 70. On the 
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other hand, HSP70 does not bind to T-lymphocytes 71. Interestingly, HSP70 also 
inhibits HMGB1 release, thereby attenuating the HMGB1-induced inflammatory 
response and tissue damage 72.
Nucleic acids
Naturally, nucleic acids are present in all cells. The nucleus contains DNA coding 
for all proteins through transcription of mRNA and subsequent translation. 
Moreover, the endosymbiotic theory suggests that mitochondria originate from 
free-living bacteria, and as such, mitochondria have their own DNA (mtDNA) 73. 
Nuclear DNA (nDNA), RNA, and mtDNA can bind to TLRs and as such stimulate the 
production of pro-inflammatory cytokines 74-76. 
Nucleic acids are released into the circulation after rupture or necrosis of cells 77. 
However, active release, both spontaneous and during cell death, has also been 
described 78. The exact mechanisms behind active release of nucleic acids remain 
to be further elucidated.
Double stranded DNA is able to bind to RIG-I or DAI (DNA-dependent activator 
of IFN-regulatory factors), mRNA to TLR3 76, 79, and TLR-9 specifically recognizes 
unmethylated CpG sequences present in high amounts in mtDNA 80, 81. As such, 
the release of nucleic acids exert inflammatory effects. However, as the receptors 
involved are mainly present intracellularly, internalization by cells such as APCs 
is often necessary for nucleic acids to function as a DAMP 82. As such, it has been 
suggested that for nucleic acids to function as a DAMP, release of other DAMPs, 
such as HMGB1, is required. Furthermore, nucleic acids also affect the activity of 
other DAMPs, thereby increasing their inflammatory potential 82.
Other DAMPs
Hyaluronan or Hyaluronic Acid is an important extracellular matrix component, 
existing in both a low molecular weight (LMW) and high molecular weight (HMW) 
form 83. The latter is an important molecule in cell adhesion and tissue architecture 
84. Under inflammatory conditions, HMW hyaluronan is broken down into LMW 
hyaluronan and/or LMW hyaluronan de novo synthesis occurs through hyaluronan 
sytnhase-3 (HAS-3) 83. LMW hyaluronan mainly exerts pro-inflammatory effects 
through binding of TLR2 and TLR-4 85, whereas HMW hyaluronan exerts anti-
inflammatory properties 85, 86. 
Micro- and nanoparticles are produced by many different cell types in response to 
cell activation or cell death and are also suggested to function as DAMPs 87. These 
particles are formed if components, e.g. single-stranded RNA and protamine, 
are mixed or if monocytes are stimulated with unesterified cholesterol 88, 89. The 
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immune system can distinguish the size of the particles in order to initiate an 
antiviral (nano) or antibacterial/antifungal (micro) directed immune response 88.
Figure 1 – Mechanisms of DAMP release and receptor ligation in intensive-care related 
conditions RAGE = receptor for advanced glycation endproducts; TLR = Toll-like receptor; DAI = 
DNA-dependent activator of IFN-regulatory factors; RIG-1 = retinoic acid-inducible gene 1
DAMPs in intensive care-related conditions 
Sepsis
Sepsis is the leading cause of death in the intensive care unit 90, generally 
characterized by an early hyperinflammatory phase and a subsequent 
immunosuppressive phase, known as ‘immunoparalysis’, that can last for days 
or even weeks 8. More recent evidence suggests that the hyperinflammatory 
and immunoparalytic phases develop simultaneously 91, 92. Especially in the 
hyperinflammatory reaction in sepsis, PAMPs play an important role in the 
inflammatory response. However, DAMPS are released as well, contributing 
to initiation and/or propagation of the immune response in sepsis 93. Previous 
studies in primates suggest that ongoing tissue damage and DAMP release occurs 
Chapter 1
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during lethal bacterial sepsis 94, making it difficult to distinguish between PAMP- 
and DAMP-related responses in those patients.
HMGB1 is one of the most well-studied DAMPs in sepsis. Plasma HMGB1 level 
correlates with the degree of organ dysfunction that occurs in late-phase sepsis 
and may discriminate between survivors and non-survivors in both murine 
endotoxemia and human sepsis 13, 95. Furthore, in mice, neutralization of HMGB1 
dose-dependently reverses endotoxic shock and established sepsis, prevents 
organ injury, and increases survival 13, 96. However, in a prospective study assessing 
HMGB1 release over time in patients with sepsis, severe sepsis, or sepsis shock, the 
HMGB1 plasma level (measured up to day 6) was markedly lower in septic patients 
who died compared with survivors 97. As these data are contradictory, one might 
speculate that HMGB-1 shows dual release characteristics: higher in dying subjects 
(vs. survivors) in acute sepsis and lower in a more persistent (“chronic”) sepsis 
scenario. HSPs, of which HSP70 is the most well-studied in this context, appear to 
impact the development of sepsis and septic shock, and genetic variations in the 
HSP genes have been demonstrated to influence outcome of sepsis 98-100. However, 
animal studies that have investigated HSP70 neutralization in sepsis have yielded 
contradictory results, therefore no definite conclusions on the role of HSP70 in 
sepsis can be drawn 101, 102. S100 proteins S100A8/A9 also appear to be involved 
in the pathophysiology of sepsis. Their plasma level is increased in patients with 
severe sepsis as well as in healthy volunteers after administration of endotoxin, 
an experimental model mimicking many hallmarks of the systemic inflammatory 
response observed in septic patients 103. Furthermore, S100A8/A9 deficient mice 
exhibit a reduced systemic inflammatory response after endotoxin administration 
41, and inhibition of S100A8/A9 prevents lethality in murine sepsis 41. Plasma DNA 
levels (both nuclear and mitochondrial) are elevated in septic patients as well, and 
correlate with mortality 104. Likewise, plasma mtDNA level increases during the 
course of lethal sepsis in primates 94, although an observational study in sepsis 
patients did not confirm these results 105. In a recent murine study, administration 
of DNAses (to remove free nucleic acids from the circulation) resulted in decreased 
coagulation and inflammation, suppression of organ damage, and improved 
outcome in a cecal ligation and puncture sepsis model 161. These findings suggest 
a detrimental role of nucleic acids in sepsis. Furthermore, plasma hyalorunan level 
is increased in septic shock patients, are higher in non-survivors compared with 
survivors, and correlate with inflammatory cytokine levels in those patients 106. 
Interestingly, the administration of HMW hyaluronan appears to reduce sepsis-
induced lung injury in rats 107. 
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Trauma
Multiple trauma often elicits a systemic inflammatory response syndrome and can 
also result in the development of immunoparalysis 108, 109. Apart from the direct 
effects of the initial injury itself, the subsequent immunological complications are 
partly responsible for trauma-induced morbidity and mortality. Due to the trauma-
induced cell damage, large amounts of DAMPs are released into the circulation, 
which, in the absence of invading pathogens are believed to be responsible for 
the observed immunological responses 110. 
HMGB1 appears to be an important DAMP in the inflammatory response observed 
following trauma and/or severe bleeding. HMGB1 level is increased early after 
trauma, and non-survivors demonstrate a higher plasma level compared with 
survivors 111. Furthermore, animal studies have revealed that HMGB1 elicits an 
immune response after trauma in a TLR-4-dependent manner 112. Neutralization of 
HMGB1 improves outcome in various animal models of trauma and hemorrhagic 
shock 113-116. Heat shock proteins are also implicated in trauma, and are suggested 
to exert beneficial effects, as a higher HSP70 plasma level correlates with 
increased survival in these patients 54. Furthermore and possibly related to this, 
they appear to play a neuroprotective role in spinal cord injury 117. Furthermore, 
several S100 proteins are released following trauma. For example, S100A8 and 
S100A9 induce an inflammatory response following damage of peripheral nerves 
118. Interestingly, blunt trauma survivors demonstrate higher plasma S100A8/A9 
level compared with non-survivors, suggesting a protective role of S100 proteins 
following trauma 119. S100B is released after traumatic brain injury and appears 
a promising marker for the diagnosis of brain damage or spinal cord injury 36, 120. 
Release of mtDNA is also suggested to play a role in trauma. The plasma level 
of mtDNA is increased following trauma 121, 122. Furthermore, in rats, intravenous 
administration of mitochondrial DAMPS, consisting of mtDNA and formyl 
peptides, resulted in a systemic inflammatory reaction and lung injury in a TLR9-
dependent manner 122. Finally, plasma hyalorunan concentration was higher in 
trauma patients compared with healthy controls and correlated with markers for 
impaired coagulation 123. To date, no studies have been undertaken to investigate 
the effects of neutralization of S100 proteins, mtDNA, or hyaluronan in (animal 
models of ) trauma. 
Ventilator-induced Lung Injury 
Mechanical ventilation is an essential part of intensive care medicine, although 
it may also cause ventilator-induced lung injury (VILI) 124. VILI is characterized by 
a sterile inflammatory response in the lungs resulting in tissue damage that may 
Chapter 1
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HMGB1 HSP
Sepsis Sepsis: non-survivors plasma 
HMGB1 vs. survivors 13
Sepsis: plasma HMGB1 over time: 
survivors, non-survivors 95
(Severe) sepsis+septic shock: 
plasma HMGB1 during 1 
week after admittance, plasma 
HMGB1 non-survivors 97
Severe sepsis: plasma HSPA12B 
vs. sepsis/SIRS
Non survivors plasma HSPA12B 
vs. survivors 99
HSP70 gene polymorphisms 
influence outcome 100
Trauma Trauma patients with 
hemorrhagic shock: Plasma 
HMGB1113
Severe trauma patients: Plasma 
HMGB1, correlated with injury 
severity, SIRS, and complement 
activation. Non-survivors plasma 
HMGB1 vs survivors 111
Trauma patients, ventilated 2+ 
days, Injury Severity Score ≥16: 
Plasma HSP72: low plasma 
HSP72: survival 54
VILI Short-term MV (5h): BALF 
HMGB1 not altered, Long-term 
MV (days): BALF HMGB1, no 
difference between infected and 
non-infected lung in unilateral 
ventilator-associated pneumonia 
132
Acute lung injury/ARDS: HSP72 
plasma and pulmonary edema 
fluid.
Preserved alveolar epithelial fluid 
clearance: HSP72 135
Cardiac 
arrest
Cardiac arrest patients: HMGB1 
in cerebrospinal fluid of patients 
with worse neurological 
outcome. No differences in 
serum 150
Cardiac arrest: Plasma HSP70, 
correlated with immunoparalysis 
154
Acute myocardial infarction: 
serum HSP70, correlated with 
IL-6 and IL-8  157
Table 1 – Observational human studies on DAMPs in intensive care-related conditions 
ARDS=acute respiratory distress syndrome; BALF=bronchoalveolar lavage fluid
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S100 proteins Nucleic acids
Severe sepsis or LPS injection in 
healthy volunteers: Plasma S100A8/
A9 Peritonitis: Abdominal fluid 
S100A8/A9 vs. plasma 103
Sepsis and septic shock mtDNA = 
healthy controls 105
Chronic spinal cord injury (SCI): 
S100A12, S100A8, S100A9 in wound 
fluid vs non-SCI patients 120
Trauma: Plasma mtDNA 121, 122
ARDS: S100A12 expression in lung, 
in BALF 137, 138
LPS inhalation in healthy volunteers: 
S100A12 in BALF 137
S100A8/A9 to S100A12 ratio in BALF: 
different between chronic and acute 
lung disease 138
Not investigated.
Cardiac arrest: plasma S100A12, 
correlated with immunoparalysis 154
Cardiac arrest: S100B worse 
neurological outcome serum 150
Acute myocardial infarction: Plasma 
S100A1 155
Cardiac arrest: plasma nDNA 154
Myocardial infarction: plasma 
mtDNA 156
Continuation Table 1
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sustain respiratory failure and, in severe cases, can spread systemically, resulting 
in multi organ dysfunction syndrome (MODS) 125. Even protective ventilation 
strategies that do not cause direct mechanic tissue damage have been shown to 
elicit an inflammatory response and subsequent lung injury 126. The mechanisms 
behind this so-called ‘biotrauma’ 127 are assumed to be related to the mechanical 
ventilation-induced release of DAMPs and the subsequent activation of the 
immune system. It is known that activation of TLR-4 plays an important role in the 
development of VILI 126, as does activation of NF-κB 128. Furthermore, synergistic 
detrimental effects of a primary insult, for instance bacterial sepsis, and mechanical 
ventilation has been demonstrated multiple times 129-131. Moreover, the direct 
involvement of several DAMPs in VILI have been demonstrated, as outlined below.
In patients, HMGB1 level in bronchoalveolar lavage fluid (BALF) increases in 
response to mechanical ventilation 132, 133. Furthermore, when administered 
intratracheally in mice, HMGB1 exerts inflammatory effects, while neutralization 
results in less inflammation and lung injury 133, 134. HSPs also appear to play a 
role in the pathogenesis of VILI. For example, increased level of extracellular 
HSP72 in BALF and plasma of acute lung injury patients has been reported 135. 
Furthermore, murine studies have revealed that HSP72 exerts its inflammatory 
effects via TLR-4 136. Concerning the S100 protein family, both S100A9 and 
S100A12 (EN-RAGE) are increased in BALF of patients with ARDS compared with 
healthy controls 137, 138, although no studies have been undertaken to investigate 
the effects of neutralization of HSPs or S100 proteins in VILI. Concerning nucleic 
acids, previous studies have shown that acid aspiration results in profoundly 
increased mtDNA level in BALF of mice 139, and that exogenous administration 
of mtDNA in the lungs or circulation of rats and mice elicits inflammatory lung 
injury in a TLR9-dependent manner 140, 141. However, the effect of endogenous 
mtDNA release or neutralization during mechanical ventilation and its role in 
ventilator-induced inflammation has not yet been investigated. Low molecular 
weight (LMW) hyaluronan was also found to be increased in BALF of patients with 
acute respiratory distress syndrome (ARDS) 142. Moreover, inhibiting synthesis 
of LMW hyaluronan in septic ventilated mice resulted in reduced lung injury 143, 
suggesting possible therapeutic potential in ventilated critically ill patients. 
Cardiac arrest
Survival after cardiac arrest is low, even when return of spontaneous circulation 
is achieved 144-147. In part, this is due to the development of the post-cardiac arrest 
syndrome, a condition demonstrating similarities to severe sepsis 148, 149. DAMPs 
are assumed to play an important role in the pathogenesis of this complication. 
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Both HMGB1 and S100B concentrations in spinal fluid and serum are increased 
in patients following cardiac arrest, and are associated with poor neurological 
outcome 150, 151. In contrast to these observation, several animal studies have 
demonstrated that HMGB1 promotes regeneration and recovery if injected into 
the heart after myocardial infarction 152, 153. Plasma levels of S100A12, HSP70, 
nDNA, and mtDNA are also increased following cardiac arrest and out-of-hospital 
resuscitation, and especially HSP70 level is associated with the development 
of immunoparalysis 154. Increased plasma levels of S100A1, HSP70, and mtDNA 
have also been reported after myocardial infarction 155-157, and mtDNA level 
correlated with the development of immunoparalysis 156. To date, apart from the 
abovementioned studies on intracardial HMGB1 injections, treatment options 
targeting DAMPs in cardiac arrest have not been studied.
In conclusion, a wide range of DAMPs are implicated in disease states frequently 
encountered in critically ill patients. Nevertheless, research on therapeutic 
interventions targeting DAMPs is in its infancy, especially in humans, and faces 
challenges in discriminating between beneficial and harmful effects of DAMPs, as 
the relationship between DAMP release and outcome is not always unambiguous 
36, 104, 119, 123. Before progress can be made in this respect, increased knowledge 
is warranted on the multiple functions of and interactions between different 
DAMPs in critical illness. Along these lines, as many different DAMPs binding to 
different pattern recognition receptors can be released simultaneously, increased 
knowledge on interactions between these signaling receptors is required as well. 
Next to therapeutic targets, DAMPs may represent suitable biomarkers in intensive 
care-related conditions. For example, in sepsis, a marker that discriminates 
between the bacterial phase and the sterile SIRS phase is highly warranted to 
determine nature and timing of treatment strategies in those patients 8. Nuclear 
DNA and mtDNA concentrations in plasma may represent a promising marker 
for this purpose 94. In trauma patients, S100B protein appears to be the most 
valuable marker for the differential diagnosis in traumatic brain injury 36, 120, 158. 
Other biomarkers, that are immunologically inactive, in contrary to DAMPs, could 
also be of value in this respect.
Moreover, caution is warranted in translating the results obtained in animal 
models, such as those described in Table 2, to patients in the ICU. Major differences 
exist between the immune system of animals and humans, and a clinical setting 
is often not comparable to a standardized setting used in animal models. This has 
contributed to disappointing results of many clinical trials in the past. For instance, 
although a wide variety of anti-inflammatory therapies showed very promising 
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HMGB1 HSP
Sepsis
E.
co
li/
CL
P
CLP (mice): anti-HMGB1: 
survival. HMGB1 
administration: mortality 13
CLP (rats): Glutamin-induced 
enhanced HSP expression: lung 
tissue metabolic function, 
mortality.
Additional inhibition of HSPs by 
quercetin: no survival effect of 
glutamine 102
En
do
to
xe
m
ia Lethal endotoxemia (mice): 
inhibition of HSPs by quercetin: 
mortality, Plasma TNF-α and IL-
1β 101
Trauma Bilateral femur fracture (mice): 
anti-HMGB1: inflammation, 
no effects in TLR4-deficient 
mice 112
Hemorrhage (30% blood 
loss, mice): anti-HMGB1 
administration: NFκB+cytokines 
in lung, lung accumulation of 
neutrophils 114
Hemorrhagic shock (MAP 
25-30 mmHg, mice): anti-
HMGB1: survival, bacterial 
translocation from gut, 
plasma IL-6+IL-10 113
Liver I/R (mice): anti-HMGB1: 
liver damage , no effects in 
TLR4-deficient mice. HMGB1 
administration: liver damage 
116
Not investigated.
Table 2 – Animal intervention studies on DAMPs in intensive care-related conditions  
I/R=ischemia/reperfusion; CLP=cecal ligation and puncture; MAP=mean arterial pressure
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S100 proteins Nucleic acids
E.coli abdominal sepsis (mice): S100A8/
A9 knockout mice protected 41
E.coli abdominal sepsis (mice): S100A9 
deficient mice exhibit improved 
defense and decreased systemic 
inflammation 103
CLP (mice): DNase treatment: 
coagulation+inflammation, organ 
damage, survival 161
Lethal endotoxemia: S100A8/A9 
knockout mice protected 41
Intraneural injection of S100A8/A9 into 
the sciatic nerve (rats): myeloid cell 
migration into the nerve 118
Not investigated.
Continuation Table 2
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HMGB1 HSP
VILI 4h mechanical ventilation (30 
ml/kg, rabbits): anti-HMGB1: 
oxygenation, microvascular 
permeability, neutrophil influx, 
TNF-α in bronchoalveolar lavage 
fluid (BALF) 133
Endotoxin-induced lung injury 
(mice): anti-HMGB1: neutrophil 
influx, pulmonary edema, no 
effect on pulmonary IL-1β, TNF-α, 
MIP-2 134
Inhalation of Hsp72 (mice): 
bronchoalveolar lavage fluid 
(BALF) KC, TNF-α, neutrophil 
recruitment . No effect in TLR4-
deficient mice 136
Ca rd i a c 
arrest
Myocardial infarction (mice), 
HMGB1 administration: recovery 
of cardiac performance 152, 153
Not investigated.
Continuation Table 2
results in preclinical sepsis models, none of these have eventually proved to be of 
benefit in actual septic patients 159, 160.
Taken together, although additional studies are warranted to confirm applicability 
in clinical practice, research into DAMPs is a promising field to develop tools that 
can eventually have an impact on care, especially of critically ill patients.
Outline of this thesis
The first part of this thesis is entitled “DAMPs in critically ill patients” and comprises 
studies on DAMPs, immune responses, and the relationship between these two 
in several ICU-related diseases. In chapter 2, the role of DAMPs in the impaired 
immune response observed in a large cohort of trauma patients is investigated. 
A similar impaired immune response, which is related to DAMP release, is studied 
in cardiac arrest patients, as described in chapter 3. In chapter 4, DAMP release 
induced by chemotherapy and its effects on impaired immune responses in 
patients with acute leukemia is evaluated. In septic shock patients, the mechanisms 
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S100 proteins Nucleic acids
Not investigated. Gastric acid aspiration (mice): mtDNA 
in bronchoalveolar lavage fluid (BALF) 
 139
Intratracheal administration of mtDNA 
(mice): pulmonary inflammation, 
effects abrogated by TLR9-inhibitor or 
siRNA 141
Intratracheal administration of mtDNA 
(rats), lung inflammation and injury, 
TLR9 expression, nDNA: no effects 140
Acute myocardial infarction (mice): 
intracardiac S100A1 injection: 
normalization of ICAM1 and collagen.
Anti-S100A1: infarct size, left 
ventricular functional performance 
post-MI 155
Not investigated.
Continuation Table 2
(markers of inflammation, shock, and organ damage) through which the DAMPs 
mtDNA and nDNA have an impact on mortality were studied, the results of which 
are presented in chapter 5. As outlined above, different DAMPs can trigger various 
PRRs simultaneously. In chapter 6, the interactions between those receptors and 
the extent to which these interaction pathways are evolutionary conserved are 
investigated. 
The second part of this thesis entitled “DAMPs and ventilator-induced 
inflammation” focuses on the sterile inflammatory response induced by 
mechanical ventilation, and the role of DAMPs in this process. Chapter 7 concerns 
the role of mtDNA and its receptor TLR9 in ventilator-induced inflammation in 
mice. Chapter 8 comprises a murine study on the immunological mechanisms 
of mechanical ventilation-induced inflammation, proposing a mechanism for 
activation of the pro-inflammatory cytokine IL-1β in this process.
Next to the DAMPs described in this thesis, several other immunologically inactive 
molecules could serve as biomarkers to predict outcome or complications in the 
trauma population we have studied in this thesis. In part three of this thesis, 
Chapter 1
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entitled “Biomarkers in trauma”, two of these markers are investigated. Chapter 
9 describes the temporal relationship between trauma and intestinal damage 
during the first days of hospital admission using the biomarker intestinal fatty 
acid binding protein (iFABP), and the factors that play a role in the development of 
intestinal damage in these patients. In chapter 10, results on the predictive value 
of soluble urokinase plasminogen activator receptor (suPAR, an inflammation-
associated marker frequently described in several ICU populations) for mortality 
in trauma patients is presented.
This thesis is concluded by a general discussion and future perspectives of the 
findings presented in this thesis and a summary.
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Abstract
Purpose Danger-associated molecular patterns (DAMPs) released following 
trauma could contribute to an immune suppressed state that renders patients 
vulnerable towards nosocomial infections. We investigated DAMP release in 
trauma patients, starting in the pre-hospital phase, and assessed its relationship 
with immune suppression and nosocomial infections.
Methods Blood was obtained from 166 adult trauma patients at the trauma 
scene, ER, and serially afterwards. Circulating levels of DAMPs and cytokines were 
determined. Immune suppression was investigated by determination of HLA-
DRA gene expression and ex vivo LPS-stimulated cytokine production.
Results Compared with healthy controls, plasma levels of nuclear DNA (nDNA) 
and heat shock protein-70 (HSP70), but not mitochondrial DNA were profoundly 
increased immediately following trauma, and remained elevated for 10 days. 
Plasma cytokines were increased at the ER, and levels of anti-inflammatory IL-10, 
but not of pro-inflammatory cytokines peaked at this early time-point. HLA-DRA 
expression was attenuated directly after trauma, and did not recover during the 
follow-up period. Plasma nDNA (r=-0.24, p=0.006) and HSP70 (r=-0.38, p<0.0001) 
levels correlated negatively with HLA-DRA expression. Ex vivo cytokine production 
revealed an anti-inflammatory phenotype already at the trauma scene which 
persisted in the following days, characterized by attenuated TNF-α and IL-6, and 
increased IL-10 production. Finally, higher concentrations of nDNA and a further 
decrease of HLA-DRA expression were associated with infections.
Conclusions Plasma levels of DAMPs are associated with immune suppression, 
which is apparent within minutes/hours following trauma. Furthermore, 
aggravated immune suppression during the initial phase following trauma is 
associated with increased susceptibility towards infections.
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Introduction
The survival of multiple trauma patients has improved significantly during the 
past decades 1. However, despite improvements in both traffic safety and pre- 
and in-hospital management, severe trauma remains a main cause of death 
among young people worldwide 2. In 2014, 25,845 people were killed and over 
203,500 seriously injured in road accidents in the EU alone 3. Roughly, trauma-
related mortality can be divided in two categories. Early deaths are mainly 
attributed to neurological damage or severe blood loss directly related to the 
trauma. The patients that survive the initial trauma often develop nosocomial 
infections or sepsis 4, representing a significant cause of late mortality in trauma 
patients. The increased susceptibility of trauma patients to develop infections 
is mediated by a suppressed state of the immune system that develops after 
trauma 4-9 . Two frequently used hallmarks of the immune suppressed state after 
trauma are attenuated production of cytokines by leukocytes ex vivo stimulated 
with Pathogen Associated Molecular Patterns (PAMPs) such as LPS, and decreased 
leukocyte HLA-DR expression 6, 8, 10-13.
Release of Danger Associated Molecular Patterns (DAMPs), which can elicit an 
immune response very similar to the response to PAMPs from invading pathogens 
in sepsis 14, 15, could contribute to immune suppression in trauma patients. DAMPs 
can both be actively released by ischaemic cells as danger signals or originate 
from damaged or dead cells as debris 16, 17. An example of a DAMP that can be 
released in case of cell damage is mitochondrial DNA (mtDNA), which can trigger 
an immune response via Toll-like receptor 9 18, 19. Moreover, heat shock protein 
(HSP)-70 is released following trauma 20, and has been shown to induce immune 
cell deactivation 21. Furthermore, previous studies have indicated that free nuclear 
DNA (nDNA) in plasma is a marker for cell damage or death, because it is one of 
the many cell components released if a cell is ruptured 19, 22. Therefore, it might be 
an indicator of general DAMP release. However, the role of these DAMPs in the 
immune response after trauma and the possible development of a suppressed 
state of the immune system is unknown. 
Taken together, although immune suppression and nosocomial infections are 
frequently described phenomena in trauma patients, the role of DAMPs that 
trigger pro- and anti-inflammatory responses remains elusive. The aim of this 
study was to investigate the release of DAMPs following trauma, starting in 
the very early (pre-hospital) phase, and to assess its relationship with immune 
suppression and nosocomial infections.
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Methods
Study population
Adult trauma patients (n=166) admitted to the trauma care unit at the ER of 
the Radboud University Nijmegen Medical Centre were included in the study. 
Exclusion criteria were expected risks of blood sampling at the trauma scene 
(e.g. jeopardizing the clinical handling of the patient), known HIV/AIDS, known 
malignancies, and use of steroids (all dosages and types of administration) or other 
immunomodulatory medication previously to the trauma. SDD was administered 
to all patients who were admitted to the ICU (n=101), as part of standard ICU 
protocol. Therefore, comparisons between ICU patients who did and did not 
receive antibiotics could not be made. Of the patients who were not admitted to 
the ICU (n=65), only 7 received (prophylactic) antibiotics; this group size does not 
allow for statistical analysis. Furthermore, comparing patients that did not receive 
antibiotics (and thus by definition were not admitted to the ICU) with patients that 
did receive antibiotics (all ICU patients and the 7 non-ICU patients that received 
antibiotics) does not yield meaningful information, because of major differences 
in trauma/disease severity, placement of catheters, intubation etc.
The study was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent 
(CMO2011/380, NL38169.091.11). All patients or legal representatives were 
informed about the study details at the first opportunity, usually within 1 day 
after admission. The local ethical committee that approved the study protocol 
agreed that it was not possible to do this at an earlier stage. Written informed 
consent was obtained from the patient or his/her legal representative if vena 
puncture was necessary to obtain blood samples. All determinations and data 
handing were performed under the guidelines of The National Institutes of Health 
and in accordance with the declaration of Helsinki and its later amendments.
Control samples (n=12) were obtained from healthy male volunteers (median 
age 22 [range 19-27]) participating in an experimental human endotoxemia trial 
(CMO2012/455, NCT01835457). Samples were obtained from the control group 
at baseline, before administration of endotoxin. Written informed consent was 
obtained from all of these volunteers prior to screening and inclusion in the study.
Sample and data collection
Blood was sampled shortly after trauma at the trauma scene by the Helicopter 
Emergency Medical Services (HEMS) before hospital admission (‘pre-hosp’) if 
applicable, at arrival at the Emergency Room (ER), and at day 1, 3, 5, 7 and 10 
51
2
DAMPs and immune suppression in trauma patients
following trauma. The HEMS response time (time between notification of the 
HEMS team and arrival at the trauma scene) was 16 [12-19] minutes. Time spent 
at the trauma scene by the HEMS team was 23 [15-29] minutes and the interval 
between sampling at the trauma scene (time-point pre-hosp) and sampling at 
the ER was 39 [33-45] minutes.
Lithium Heparin (LH) anti-coagulated blood was obtained for ex vivo stimulation 
experiments as described below, which were performed immediately after 
sampling. Ethylenediaminetetraacetic acid (EDTA) and LH anti-coagulated blood 
was centrifuged after withdrawal at 1,600xg at 4⁰C for 10 minutes, after which 
plasma was stored at -80⁰C until further analysis. EDTA plasma for real time 
quantitative PCR (qPCR) analysis was centrifuged again at 16,000xg at 4⁰C for 10 
minutes to remove potential remaining cells and cell debris. The supernatant was 
stored at -80⁰C until further analysis. Blood for mRNA analysis was sampled in 
PAXgene blood RNA tubes (Qiagen, Valencia, CA, USA) and stored according to 
the manufacturer’s instructions.
Clinical parameters and demographic data were obtained from electronic patient 
files. Injury Severity Scores (ISS) were supplied by the Regional Emergency 
Healthcare Network. Infection within 28 days was defined as the presence of fever 
and/or other infectious symptoms (pain, swelling, erythema) with leukocytosis 
and positive cultures and/or another visible or otherwise proven infection focus 
corresponding with the symptoms of the patient. The attending physicians were 
blind to the immune investigation results as these assays were performed after 
collection of all samples from each patient.
Plasma DAMP levels
Plasma from double-centrifuged EDTA anti-coagulated blood was diluted 1:1 
with phosphate buffered saline solution (PBS) after which DNA was isolated 
using the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA, USA), using the 
‘Spin Protocol’ as described by the manufacturer. Isolated DNA was stored at 
-20⁰C until further analysis. qPCR was performed using iQ SYBR Green PCR 
Master Mix (Bio-Rad Laboratories, Hercules, CA, USA) on a CFX96 Real-Time PCR 
Detection system (Bio-Rad Laboratories, Hercules, CA, USA). A primer pair specific 
for the GAPDH gene present in all nucleated cells of the body was used for 
quantification of nuclear (n)DNA levels: forward 5’-AGCACCCCTGGCCAAGGTCA-3’, 
reverse 5-CGGCAGGGAGGAGCCAGTCT-3’, For quantification of mitochondrial 
(mt)DNA levels, the following primer pair specific for the mitochondrially 
encoded NADH dehydrogenase 1 (MT-ND1) gene was used: forward 
5’-GCCCCAACGTTGTAGGCCCC-3’ and reverse 5’AGCTAAGGTCGGGGCGGTGA-3’. 
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Primer pairs were obtained from Biolegio (Nijmegen, the Netherlands). Samples 
were analyzed in duplicate and DNA isolated from blood obtained from a healthy 
volunteer was used on each plate as a calibrator (CV% of 1.48% [GAPDH] and 
0.41% [mtDNA] between plates). Plasma nDNA and mtDNA levels are expressed 
as fold-change relative to the calibrator sample using the formula 2^ΔCt.
Plasma concentrations of HSP70/HSPA1A were determined batchwise using 
ELISA according to the manufacturer’s instructions (R&D systems, Minneapolis, 
MN, USA).
Plasma cytokine concentrations
Plasma concentrations of pro-inflammatory cytokines Tumor Necrosis Factor 
(TNF)-α, Interleukin (IL)-6, and IL-8, and the anti-inflammatory cytokine IL-10 
were analyzed batchwise in plasma obtained from EDTA anti-coagulated blood 
using a simultaneous Luminex assay according to the manufacturer’s instructions 
(Milliplex; Millipore, Billerica, MA, USA). 
Ex vivo cytokine production
Leukocyte cytokine production capacity was determined by challenging whole 
blood from the patients with LPS ex vivo using an in-house developed system with 
pre-filled tubes described in detail elsewhere 25. Briefly, 0.5 mL of blood was added 
to tubes pre-filled with 2 mL culture medium as negative control or 2 mL culture 
medium supplemented with 12.5 ng/mL Escherichia coli lipopolysaccharide (LPS, 
serotype O55:B5 [Sigma Aldrich, St Louis, MO, USA], end concentration: 10 ng/
mL). Cultures were incubated at 37°C for 24 hours, centrifuged, and supernatants 
were stored at -80 C until analysis. Concentrations of TNF-α, IL-6, and IL-10 were 
determined batchwise by ELISA, according to the manufacturer’s instructions 
(R&D systems, Minneapolis, MN, USA). Ex vivo cytokine production data were 
censored at time of infection diagnosis, because infections can induce immune 
alterations.
HLA-DRA mRNA expression
RNA was isolated from blood collected in Paxgene blood RNA tubes (Qiagen, 
Valencia, CA, USA). cDNA was synthesized from total RNA using the iScript 
cDNA Synthesis Kit (Bio-rad, Hercules, CA, USA). Subsequent qPCR analysis was 
performed using TaqMan gene expression assays (Life Technologies, Paisley, UK) 
for the reference gene peptidylpropylisomeras B (PPIB) (#Hs00168719_m1) and 
HLA-DRA (#Hs00219575_m1) on a CFX96 Real-Time PCR Detection system (Bio-
Rad, Hercules, CA, USA). We chose PPIB based on its stability in inflammatory 
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conditions in peripheral whole blood 26 and previous use as a reference gene for 
HLA-DRA 27. We chose the HLA-DRA gene because it was shown to correlate well 
with flow cytometric analysis of mHLA-DR 27-29, an established marker of immune 
suppression. HLA-DRA expression levels are expressed as fold-change relative 
to the expression of PPIB in the same sample using the formula 2^ΔCt. HLA-
DRA data were censored at time of infection diagnosis, because infections can 
decrease HLA-DR expression. 
Statistical analysis
Data presented in tables and text are expressed as median [interquartile 
range] and data in figures as geometric mean±95% CI. Mann-Whitney U and 
Fischer exact tests were used to investigate differences between two groups 
as appropriate. Differences between patient data at the various time-points 
and data of healthy controls were performed using Kruskal-Wallis with Dunn’s 
post-hoc tests. Differences between time-to-infection curves were tested using 
Log-rank (Mantel-Cox) tests. A Cox proportional hazard model was used to 
adjust the relationship between HLA-DRA expression and time-to-infection 
for the usual clinical confounders age and ISS 10. Correlations were calculated 
using Spearman correlation. All analyses were performed with available data 
of the corresponding time-points. Due to missing values at certain time-points 
or patients that were lost to follow-up, patient numbers in the analyses vary. 
Principal component analysis was performed to explore the expected covariation 
between multiple laboratory variables and their relationship with injury severity, 
thereby preventing the need to list all individual correlations 30. No imputation 
was used, as missing values were judged to be non-random, i.e. blood for [X] was 
sampled at day [Y] and could therefore not be obtained in patients who died 
early. Instead, a core dataset of variables and patients without missing values was 
established. Measurements were log-transformed, mean-substracted and z-score 
was calculated on which principal component analysis was performed based on 
the singular value distribution in a Python script. All other statistical analyses were 
performed using SPSS statistics version 22 (IBM Corporation, Armonk, NY, USA) 
and Graphpad Prism version 5 (Graphpad Software, La Jolla, USA). A p value of 
<0.05 was considered statistically significant.
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Results
Patient characteristics
A total of 166 patients were included between August 2010 and May 2013, of 
which the characteristics are listed in Table 1. The majority of patients suffered 
from head/neck or chest injury. 
Total (n=166)
Gender Male: n=123 (74%)
Female: n=43 (26%)
Age (years) 50 [31-67]
Injury Severity Score
Head/Neck injury (ISS region 1)
Face injury (ISS region 2)
Chest injury (ISS region 3)
Abdomen or pelvic contents injury (ISS region 4)
Extremities or pelvic girdle injury (ISS region 5)
External injury (ISS region 6)
26 [17-37]
n=129, 78%
n=47, 28%
n=96, 58%
n=44, 27%
n=78, 47%
n=77, 46%
ICU admission *
Mechanical ventilation *
Vasopressor therapy *
ICU length of stay (days)
n=101 (61%)
n=96 (95%)
n=35 (35%)
3 [1-7]
Corticosteroids administered * n=8 (5%)
Transfusion of blood products* n=24 (14%)
Hospital length of stay (days) 8 [1-17]
28-day survival n=127 (77%)
28-day survival (among initial trauma survivors) n=127/147 (86%)
Table 1 – Patient characteristics Initial trauma survivors were defined as patients who 
survived the initial 7 days following trauma. Vasopressor therapy always consisted of 
noradrenaline. Corticosteroids included all types of administration. Blood products included 
erythrocytes, thrombocytes, and fresh frozen plasma. * admitted to, or used within 28 days 
after hospital admission.
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Plasma DAMPs
Plasma nDNA levels were profoundly increased at time-points pre-hospital 
and ER compared with healthy controls (Figure 1A). Although levels decreased 
in the later phase, they remained elevated during the entire follow-up period. 
Plasma mtDNA levels were also elevated in trauma patients compared with 
healthy controls (Figure 1B), although this increase was not as pronounced and 
only reached statistical significance at two time-points. Similar to nDNA, plasma 
HSP70 concentrations in trauma patients were highest shortly after trauma and 
decreased later on, but nevertheless remained elevated compared with healthy 
controls at all time-points (Figure 1C).
Plasma cytokines
Plasma TNF-α concentrations in trauma patients were not elevated at any time-
point compared with levels found in healthy controls and did not change over 
time (supplementary Figure 1). Plasma IL-6 levels were elevated from time-
point ER until day 7 post-trauma (Figure 1D), while IL-8 levels were slightly, but 
significantly increased compared with healthy controls from time-point ER and 
remained elevated during the entire follow-up period (Figure 1E). Both cytokines 
showed highest levels at day 1. Plasma IL-10 concentrations in trauma patients 
showed a distinct peak at the ER, and remained significantly higher compared 
with healthy controls until day 1 (Figure 1F). Plasma nDNA levels measured at the 
ER correlated with plasma IL-8 (r=0.40, p<0.0001, n=121), IL-6 (r=0.47, p<0.0001, 
n=121), and IL-10 (r=0.45, p<0.0001, n=121) concentrations at the same time-
point. Plasma HSP70 levels at the ER correlated with plasma IL-8 (r=0.40, p<0.0001, 
n=100), IL-6 (r=0.45, p<0.0001, n=100), and IL-10 (r=0.48, p<0.0001, n=100) levels 
at that time-point. 
Supplementary Figure 1 – Plasma TNF-α 
levels Plasma levels of TNF-α in trauma 
patients and healthy controls. The number 
of patients/controls included at each time-
point is indicated below each time-point. 
The number of patients/controls included 
at each time-point is indicated below each 
time-point. * indicates p<0.05 compared 
with healthy controls. pre-hosp = pre-
hospitally, ER = Emergency room.
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Figure 1 – Plasma DAMP and cytokine levels Plasma levels of nDNA 
(nuclear DNA, indicator of general DAMP release, panel A), mtDNA 
(mitochondrial DNA, DAMP, panel B), HSP70 (DAMP, panel C), and 
cytokines (panels D-F) in trauma patients and healthy controls. The 
number of patients/controls included at each time-point is indicated below 
each time-point. The number of patients/controls included at each time-
point is indicated below each time-point. * indicates p<0.05 compared 
with healthy controls. pre-hosp = pre-hospitally, ER = Emergency room.
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Immune suppressed state
HLA-DRA mRNA expression in trauma patients was profoundly suppressed at 
all time-points compared with healthy controls (Figure 2A). Plasma nDNA and 
HSP70 levels negatively correlated with HLA-DRA expression at time-point ER (r=-
0.24, p=0.006, n=130, and r=-0.38, p<0.0001, n=106, respectively), while plasma 
mtDNA levels did not correlate with HLA-DRA expression (r=-0.09, p=0.33, n=130). 
Ex vivo cytokine production capacity was investigated in a subgroup of patients 
(n=36), whose characteristics were comparable to the entire patient cohort 
(supplementary Table 1). The capacity of leukocytes to produce pro-inflammatory 
cytokines TNF-α and especially IL-6 upon ex vivo stimulation with LPS was severely 
suppressed at the trauma scene and during the first days of hospital admission 
compared with healthy controls (Figure 2, panels B and C). In sharp contrast, ex 
vivo production of the anti-inflammatory cytokine IL-10 was augmented in the 
first days after trauma compared with healthy controls (Figure 2D). This effect 
remained evident during the entire 10-day follow-up period (data not shown). 
Ex vivo TNF-α and IL-6 production at the ER correlated positively with HLA-DRA 
expression (r=0.43, p=0.02, n=30, and r=0.58, p=0.001, n=30, respectively). This 
was not the case for ex vivo IL-10 production (r=0.22, p=0.25, n=30).
Relationship between injury severity, DAMPs, cytokines, and HLA-DRA 
To comprehensively investigate the relationship between injury severity and 
the mediators measured, we performed principal component analysis on data 
of nDNA, mtDNA, HSP70, IL-10, IL-6, IL-8, TNF-α, and HLA-DRA expression at the 
ER. In concordance with the individual correlations shown, the first principal 
component (PC1) had high loadings in the same direction of plasma nDNA, 
HSP70, IL-10, IL-6, IL-8, and TNF-α levels, while HLA-DRA had a smaller negative 
loading. PC1 had a total explained variance of 46% and correlated with ISS (r=0.64 
p<0.0001, supplementary Figure 2). 
Susceptibility towards infections
Thirty-three patients (20%) developed an infection during the first 28 days 
following trauma (characteristics of infected and non-infected patients provided 
in supplementary Table 2, part I). Time until infection was 7 [4-12] days. Types 
of infection were pneumonia (n=21), wound infection (n=5), meningitis (n=4), 
urinary tract infection (n=2), central line infection (n=1), empyema (n=1), 
bacteremia eci (n=1), paronychia (n=1), and unknown (n=1). Four patients suffered 
from two infections. Eighteen out of 21 patients with pneumonia were intubated 
at hospital admission and 15 at the moment of pneumonia diagnosis. Gender, 
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age, injury severity and injury location were comparable between patients who 
developed an infection within 28 days and those who did not. However, patients 
who developed an infection following trauma were more frequently admitted to 
the ICU, received more transfusions, and required a longer length of stay, both at 
the ICU and in the hospital. Furthermore, vasopressor therapy and corticosteroid 
use tended to be higher in patients who developed an infection. 28-Day survival 
was higher in patients who developed an infection compared with those who did 
not, likely due to direct trauma-related deaths. Indeed, when analyzing the data 
of patients who survived the initial phase after trauma, no difference in 28-day 
survival was observed (supplementary Table 2, part II). ISS was slightly higher in 
patients who survived the initial phase after trauma and developed an infection, 
Total (n=36)
Gender Male: n=31 (86%)
Female: n=5 (14%)
Age (years) 51 [29-60]
Injury Severity Score
Head/Neck injury (ISS region 1)
Face injury (ISS region 2)
Chest injury (ISS region 3)
Abdomen or pelvic contents injury (ISS region 4)
Extremities or pelvic girdle injury (ISS region 5)
External injury (ISS region 6)
26 [18-41]
n=31, 86%
n=10, 28%
n=19, 53%
n=7, 19%
n=12, 33%
n=15, 42%
ICU admission *
Mechanical ventilation *
Vasopressor therapy *
ICU length of stay (days)
n=25 (69%)
n=23 (92%)
n=16 (64%)
3 [1-9]
Corticosteroids administered * n=1 (3%)
Transfusion of blood products* n=6 (17%)
Hospital length of stay (days) 6 [1-12]
28-day survival n=25 (69%)
Supplementary Table 1 - Characteristics of patients in which ex vivo cytokine 
production was investigated Vasopressor therapy always consisted of noradrenaline. 
Corticosteroids included all types of administration. Blood products included erythrocytes, 
thrombocytes, and fresh frozen plasma. * admitted to, or used within 28 days after hospital 
admission.* admitted to, or used within 28 days after hospital admission.
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Figure 2 – Markers of immune suppression Leukocyte HLA-DRA mRNA expression in 
trauma patients and healthy controls, expressed as fold change compared with PPIB (panel 
A). Cytokine concentrations in supernatants after 24 hours of whole-blood LPS stimulation in 
patients during the first 3 days after trauma and in healthy controls (panels B, C, and D). The 
number of patients/controls included at each time-point is indicated below each time-point. 
* indicates p<0.05 compared with healthy controls. pre-hosp = pre-hospitally, ER = Emergency 
room.
and these patients were more frequently admitted to the ICU. Furthermore, 
vasopressor therapy, transfusions and corticosteroids were more frequently used, 
and ICU and hospital length of stay were increased in these patients.
Plasma mtDNA and nDNA levels at ER were higher in patients who developed an 
infection within 28 days compared with patients who did not (2.5 [1.4-6.6] vs. 1.4 
[0.5-4.0] fold change, p=0.046 for mtDNA, and 265.7 [30.7-1131.3] vs. 61.9 [11.7-
367.5] fold change, p=0.02 for nDNA). For HSP70, no differences were observed 
between these two groups (57.4 [26.0-79.8] vs. 47.2 [33.9-72.0] ng/mL, p=0.89).
Previous studies indicate that the change in HLA-DR expression over time better 
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Supplementary Table 2 - Patient characteristics according to the development of infections 
within 28 days. Initial trauma survivors were defined as patients who survived the initial 7 days 
following trauma. Vasopressor therapy always consisted of noradrenaline. Corticosteroids included 
all types of administration. Blood products included erythrocytes, thrombocytes, and fresh frozen 
plasma. * admitted to, or used within 28 days after hospital admission.* admitted to, or used within 
28 days after hospital admission. Data of patients who developed an infection in the upper and 
lower parts of the table are identical, because all these patients survived the initial 7 days after 
trauma.
predicts outcome and/or development of infections than absolute values of HLA-
DR 10, 29, 31. Accordingly, we investigated the relationship between change in HLA-
DRA expression (increase or decrease between ER and day 3) and infections in a 
subgroup of patients from our cohort for which HLA-DRA data was available on 
these time-points . Patients exhibiting a decrease in HLA-DRA expression (ratio 
< 1) more likely developed an infection compared with patients who showed an 
increase (ratio > 1, Figure 3). The relationship between a decrease in HLA-DRA 
expression and development of infection remained apparent after correcting 
for age and ISS (hazard ratio [95% CI] of 3.02 [1.02-8.93], p=0.046). Furthermore, 
ICU and hospital length of stay were increased in patients with decreasing HLA-
Supplementary figure 2 – Correlation between injury severity and principal 
component 1 Correlation between Injury Severity Score and the first principal component 
(PC1), to which IL-10, IL-6, IL-8, TNF-α, nDNA, and HSP70 contributed more than the expected 
average.
63
2
DAMPs and immune suppression in trauma patients
DRA expression, while other characteristics were not significantly different 
(supplementary Table 3).
Figure 3 – Relationship between change in HLA-DRA expression and development 
of infections during the first 28 days following trauma Thirty-three (20%) patients 
developed an infection within 28 days following trauma. Patients exhibiting a decrease 
in HLA-DRA expression between ER and day 3 (ratio < 1) were more likely to develop an 
infection compared with those who showed an increase (ratio > 1). Symbols placed on lines 
indicate censored patients because of death. 
Discussion
This study demonstrates that multi-trauma patients exhibit a suppressed state 
of the immune system already at the trauma scene, thus before admission of the 
patient to the hospital. This is characterized by low HLA-DRA expression and an 
anti-inflammatory cytokine pattern, both in- and ex vivo. Furthermore, we show 
that DAMPs are present in large quantities in the circulation during the pre-
hospital phase and shortly after admission, and that DAMP levels are associated 
with the extent of immune suppression. Finally, our data demonstrate that further 
aggravation of immune suppression in the initial phase after trauma is associated 
with increased susceptibility towards infections. A conceptual representation 
of how DAMP release may lead to increased susceptibility towards infections 
following trauma is presented in Figure 4. 
The pronounced general release of DAMPs, reflected by plasma nDNA levels, in 
the pre-hospital phase of trauma was associated with the immune suppression 
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observed in our cohort of trauma patients. Although an observational study such 
as the current does not allow to draw conclusions concerning cause and effect, 
our data suggests that DAMPs play a role in the suppressed state of the immune 
system. There are some data in support of this. HSP70 is known to induce LPS 
tolerance in monocytes, an in vitro phenomenon showing similarities to in vivo 
immune suppression 21. Accordingly, we found a inverse relation between plasma 
HSP70 levels and HLA-DRA expression. Moreover, previous studies have suggested 
an immunomodulatory role for mtDNA in trauma patients 18, 32. Of interest, while 
levels of mtDNA were increased after trauma, this increase was relatively modest. 
Levels of circulating nDNA were much higher, and unlike mtDNA, correlated 
with HLA-DRA expression, indicating that mtDNA release is not one of the major 
factors behind immune suppression in trauma patients. Previous studies that 
demonstrated much higher mtDNA concentrations in plasma had much smaller 
patient numbers (n=15 18 and n=38 32) and used only a single 1600g centrifugation 
step 18, 32. Chiu et al demonstrated that double centrifugation of plasma (at 1600g 
and 16000g, as performed in our study) is necessary to remove residual cells, each 
containing thousands of copies of the mitochondrial genome, making the results 
from one-spin protocol studies less reliable 33. One could argue that a difference in 
injury severity could explain the difference, as Zhang et al included only patients 
with ISS>25 18. However, Lam et al included a majority of patients with ISS<16 32, 
making it unlikely that the lower injury severity in our study population (median 
ISS of 26) explains the lower levels of mtDNA found. 
Our study further shows that the early immune response following trauma has 
a distinct anti-inflammatory phenotype. Plasma levels of the archetypal pro-
inflammatory mediator TNF-α were not increased whatsoever and increases in 
other pro-inflammatory cytokines such as IL-8 and IL-6 were relatively modest 
and peaked at later time-points. In sharp contrast, the anti-inflammatory 
cytokine IL-10 was produced rapidly following trauma and already reached peak 
levels at arrival in the ER. Of interest, in a previous study, trauma patients that 
were considered “immunoparalytic” based on HLA-DR expression on alveolar 
macrophages displayed higher IL-10 levels in BAL fluid 34. IL-10 attenuates 
the immune response in several ways, for example through inhibition of the 
production of proinflammatory cytokines, such as TNF-α and IL-6 35. In our study, 
the initial IL-10 peak was followed by a peak in IL-6, which reached highest levels at 
day 1 following trauma. IL-6 is most renowned for its pro-inflammatory properties, 
although in trauma it is suggested that continuous IL-6 release accounts for the 
up-regulation of anti-inflammatory mediators, such as prostaglandin E2, IL-1 
Chapter 2
66
Figure 4 – Conceptual figure of 
how DAMP release may lead 
to increased susceptibility 
towards infections following 
trauma Trauma results in the 
release of DAMPs, including, 
but not limited to nDNA 
and HSP70. Subsequently, 
DAMPs bind to (intracellular) 
receptors on immune cells 
such as macrophages, which 
induces a predominantly 
anti-inflammatory response 
characterized by IL-10 release. 
In turn, this leads to immune 
suppression, indicated by 
decreased monocytic HLA-DR 
expression as well as reduced 
production of TNF-α/IL-6 and 
increased production of IL-10 
upon ex vivo stimulation with 
LPS. Alternatively, DAMPs can 
exert direct immunosuppressive 
effects, such as HSP70-induced 
LPS-tolerance in monocytes. All 
these events take place in the 
very early (pre-hospital) phase 
following trauma. In the hospital, 
aggravated immune suppression 
is associated with increased 
susceptibility towards infections, 
consequent prolonged ICU and 
hospital length-of-stay, and 
increased late mortality.    
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receptor antagonist, IL-10 and transforming growth factor (TGF)-β and thereby 
also exhibits anti-inflammatory properties 36, 37. These findings indicate that 
immune suppression sets in directly after the injury. The mechanisms initiating 
this immediate anti-inflammatory response remain to be elucidated, although 
these findings are in agreement with the current paradigm of the immune 
response during sepsis. In sepsis, it is now generally accepted that, instead of 
a previously assumed biphasic inflammatory response, consisting of an initial 
pro-inflammatory response and a subsequent compensatory anti-inflammatory 
response, a simultaneously occurring pro- and anti-inflammatory response is 
present 38. Others have shown that the production of pro-inflammatory cytokines 
by leukocytes ex vivo stimulated with LPS is severely attenuated following trauma 
11, 13. Herein, we confirm these findings and demonstrate that the production of 
IL-10 is increased in these patients, with both phenomena already apparent at 
the trauma scene. This distinct anti-inflammatory phenotype ex vivo in the early 
phase following trauma corroborates our in vivo findings. 
In keeping with previous work, our data reveal that HLA-DRA expression is 
decreased following trauma 6, 8, 10, 12, 13. We importantly extend these findings by 
showing that this event takes place already before hospital admission and that 
DAMPs are associated with this phenomenon. The increased IL-10 levels early on 
following trauma might play a role in the decreased HLA-DRA expression, as IL-
10 is known to reduce macrophage function. Furthermore, in accordance with 
an earlier study 13, we demonstrate that low HLA-DRA levels were associated 
with decreased production of pro-inflammatory cytokines in response to ex vivo 
stimulation of leukocytes with LPS. Several studies on small cohorts of trauma 
patients have investigated the relationship between HLA-DR expression and 
infectious complications 6, 8, 12, 13. Some have found (trends towards) associations 
between low HLA-DR expression and infections 6, 13, while others have not 12. One 
study showed that reduced expression of HLA-DR on alveolar macrophages, 
but not on circulating leukocytes was associated with nosocomial pneumonia 
8. However, concerning the relation with outcome and/or development of 
infections, studies in trauma patients, septic patients, and in a cohort of ICU 
patients with various conditions have revealed that recovery of HLA-DR, rather 
than absolute values, is important 10, 29, 31. In keeping with this, we found that a 
further decrease of HLA-DRA expression between admission and day 3 predicts 
development of infections. Taken together, these data suggest that aggravated 
immune suppression following the initial hit increases the risk of infection after 
trauma. Nevertheless, the anti-inflammatory phenotype present directly after 
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trauma might also have beneficial effects through limiting excessive inflammation 
and thereby organ damage. As such, whether this phenotype is solely detrimental 
or has homeostatic features as well remains to be determined.
Our study has several limitations. First, inherent to this type of study, a substantial 
number of patients were lost to follow-up, e.g. because of discharge from the 
hospital or transfer to another hospital (in most cases due to recovery), or death 
(although mortality was low in our cohort). Therefore, if alterations in parameters 
observed initially in patients amend in those who recover, this could be missed. 
However, this does not affect the main conclusions of the manuscript as these are 
based on data obtained at early time-points or and data of a subgroup of patients 
with a follow up of several days. Another weakness of the current work typical for 
the multi-trauma patient population studied is the heterogeneity of the patients. 
Second, the use of plasma nDNA levels as a marker of general DAMP release could 
be debated, as it is possible that specific DAMPs display other release or clearance 
patterns and not necessarily follow plasma nDNA concentrations. Future studies 
focusing on the extensive range of DAMPs important in trauma could shed more 
light on this phenomenon and the importance of individual DAMPs in trauma. 
Third, we used expression of the HLA-DRA gene in whole blood leukocytes as a 
marker of immune suppression, while most studies have used HLA-DR expression 
on the surface of monocytes determined using flow cytometry for this purpose. 
Flow cytometric analysis requires rapid analysis after sampling and the constant 
availability of a flow cytometer, which was not feasible in our setting, especially 
with regard to the samples obtained at the trauma scene. Nevertheless, the use 
of gene expression data is a limitation, as posttranscriptional effects can also 
affect HLA-DRA expression. Furthermore, next to monocytes, other cells present 
in whole blood may also express the HLA-DRA gene to various extents and/or 
may exhibit different kinetics of expression, although there is little known on this 
subject in the context of immune suppression. In several studies in septic patients, 
a population which is, similar to ours, highly heterogeneous and likely exhibiting 
profound changes in leukocyte counts and differentiation over time, HLA-DRA 
gene expression was not corrected for leukocyte counts/differentiation 27-29, 39. 
Also, we do not have adequate data on daily leukocyte counts and differentiation 
in our cohort, as these were not regularly measured in the majority of patients. 
Nevertheless, the aforementioned studies in septic patients have shown that gene 
expression of HLA-DRA correlates well with flow cytometric analysis of mHLA-DR, 
with correlation coefficients ranging from 0.74 to 0.84 27-29, although in one of 
these, a more moderate, but still highly significant correlation coefficient of 0.53 
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was found 39. Therefore, we feel qPCR analysis of HLA-DRA in our study is a reliable 
indicator of HLA-DR expression and immune suppression. Yet, we acknowledge 
that the lack of data on leukocyte counts is a limitation, because, next to possible 
effects on HLA-DR gene expression data, lymphopenia also represents a hallmark 
of immune suppression.
Finally, our control group consisted of solely young male volunteers. Especially 
with regard to the phenomenon of immunosenescence 40, this could have biased 
our results. However, when we compared levels of DAMPs and immunological 
parameters across 5 age categories (<28 [n=33], 28-42 [n=33], 43-56 [n=34], 57-70 
[n=32], and >70 [n=32]), or between males and females within our patient cohort, 
we found no differences in any of the parameters at any of the measured time-
points. Also, we did not assess the functionality of the adaptive immune system, 
for instance using functional assays such as proliferation or cytokine release by 
T-cells.
In conclusion, we demonstrate that trauma results in release of DAMPs, and that 
this is associated with to an acute predominantly anti-inflammatory response and 
a suppressed state of the immune system. In trauma patients, these events take 
place already before hospital admission and the observed immune suppressed 
state is not preceded or accompanied by a pronounced pro-inflammatory phase. 
Aggravated immune suppression, as indicated by further decrease of HLA-DRA 
expression is associated with the development of nosocomial infections in this 
patient population. 
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Abstract
 
Objective After cardiac arrest, patients are highly vulnerable towards infections, 
possibly due to a suppressed state of the immune system called immunoparalysis. 
We investigated if immunoparalysis develops following cardiac arrest and whether 
the release of danger associated molecular patterns (DAMPs) could be involved.
 
Design Observational study.
Setting ICU of a university medical center.
Patients Fourteen post-cardiac arrest patients, treated with mild therapeutic 
hypothermia for 24 hrs and 11 control subjects.
Measurements and main results Plasma cytokines showed highest levels within 
24 hours after cardiac arrest and decreased during the next 2 days. In contrast, ex 
vivo production of cytokines IL-6, TNF-α, and IL-10 by LPS-stimulated leukocytes 
was severely impaired compared with control subjects, with most profound 
effects observed at day 0, and only partially recovering afterwards. Compared 
with incubation at 37°C, incubation at 32°C resulted in higher IL-6 and lower 
IL-10 production by LPS-stimulated leukocytes of control subjects, but not of 
patients. Plasma nuclear DNA, used as a marker for general DAMP release, and 
the specific DAMPs EN-RAGE and HSP-70 were substantially higher in patients at 
days 0 and 1 compared with control subjects. Furthermore, plasma HSP70 levels 
were negatively correlated with ex vivo production of inflammatory mediators IL-
6, TNF-α, and IL-10. EN-RAGE levels only showed a significant negative correlation 
with ex vivo production of IL-6 and TNF-α, and a borderline significant inverse 
correlation with IL-10. No significant correlations were observed between plasma 
nDNA levels and ex vivo cytokine production.
Conclusions Release of DAMPS during the first days after cardiac arrest is 
associated with the development of immunoparalysis. This could explain the 
increased susceptibility towards infections in cardiac arrest patients. 
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Introduction
Survival after cardiac arrest is low, even after return of spontaneous circulation 
is achieved 1-4. This is partly due to the development of the post-cardiac 
arrest syndrome, a condition demonstrating similarities to severe sepsis and 
characterized by a systemic ischemia/reperfusion response, brain injury, 
myocardial dysfunction, and persistent precipitating disease 5, 6. Furthermore, 
post-cardiac arrest patients are highly vulnerable towards infections, which occur 
in 46 to 76% of patients 7-9. Leukocytes of patients after cardiac arrest show a 
diminished capacity to produce pro-inflammatory cytokines in response to ex 
vivo stimulation with bacterial antigens, and a reduced expression of monocytic 
HLA-DR, observations consistent with the development of immunosuppression 
10-12. This immunosuppressive phenotype in cardiac arrest patients bares 
similarities to sepsis-induced immunoparalysis, a profoundly suppressed state 
of the immune system following the initial infection which accounts for the 
increased risk for secondary infections in septic patients 11-13. Likewise, the 
increased vulnerability towards infections after cardiac arrest might be due to the 
development of immunoparalysis. However, hitherto only one small study to date 
has investigated this phenonemon 10 and it is unknown which factors contribute 
to the development of immunoparalysis in these patients. 
Danger associated molecular patterns (DAMPs) can be actively released by 
ischemic cells as danger signals or originate from damaged or dead cells as 
debris 14, 15. A large number of different DAMPs have been identified, of which 
several have been shown to exert immunomodulatory effects. For instance, 
mitochondrial DNA (mtDNA) can trigger immune responses via Toll-like receptor 
9 16, 17, EN-RAGE, a DAMP from the S100 protein family, modulates inflammation via 
inhibition of matrix metalloproteinases and chemotaxis 18, and HSP (Heat Shock 
Protein) 70 exerts anti-inflammatory properties 19, 20. Also, previous studies have 
indicated that free nuclear DNA (nDNA) in plasma is a marker for cell damage 
or death, as it is one of the many cell components released if a cell is ruptured 
21, 22. Therefore, it might be an indicator of DAMP release in general. The role of 
DAMPs in modulation of the immune response post-cardiac arrest has not been 
investigated.
Another factor that might play a role in development of post-cardiac arrest 
immunoparalysis is hypothermia, which has been identified as an independent 
risk factor for the development of infections 8. However, no effects of mild 
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therapeutic hypothermia (MTH) on ex vivo leukocyte responses to bacterial 
antigens and HLA-DR expression were found 10. Interestingly, hypothermia has 
been shown to induce HSP70 23-25.
The aim of this study was to assess if DAMP release in general, reflected by plasma 
levels of nDNA, and levels of the specific DAMPs (mtDNA, EN-RAGE, and HSP70) 
are increased following cardiac arrest. Furthermore, we assessed whether DAMPs 
are associated with the development of immunoparalysis, reflected by ex vivo 
leukocyte responses. Finally, we investigated if possible immunosuppressive 
effects of hypothermia in leukocytes obtained from cardiac arrest patients can be 
reversed by ex vivo rewarming. 
 
Materials and Methods
Study population
We performed a prospective observational study in 14 patients successfully 
resuscitated from an out-of-hospital cardiac arrest and treated with MTH for 24 
hours. The study has been carried out in the Netherlands in accordance with 
the applicable rules concerning the review of research ethics committees and 
informed consent. The local ethics committee reviewed the study and waived 
the need for approval. All patients or legal representatives were informed about 
the study details. All study procedures were conducted in accordance with the 
declaration of Helsinki including current revisions and Good Clinical Practice 
guidelines.
All patients of 18 years or older were eligible for the study if they were comatose 
(Glasgow Coma Scale ≤ 6) after return of spontaneous circulation and if the 
suspected cause of the arrest was of cardiac origin. Patients were excluded in 
case of thrombolytic therapy, refractory cardiogenic shock, an anticipated life 
expectancy < 24 hrs, an active infection at the time of inclusion, hematological 
disease, use of immunosuppressive drugs, or suffering from other conditions 
known to influence the immune response (e.g. auto-immune diseases).
Control samples were obtained from volunteers (n=11, 6 male/5 female, median 
age 65 [range 36-76]) visiting the out-patient clinic for anesthesiology intake and 
screening prior to elective surgery or elective spectroscopy. Written informed 
consent was obtained from all of these volunteers before blood sampling.
Patient management
All patients were admitted to the ICU of a tertiary care university hospital in 
Nijmegen, The Netherlands, and treated according to the local protocol. If 
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necessary, a coronary angiogram and a percutaneous coronary intervention were 
performed before admission to the ICU. All patients were cooled to 32-34°C by 
rapid infusion of 30 ml/kg bodyweight of cold Ringer’s lactate at 4°C followed 
by external cooling using two water-circulating blankets (Blanketroll II, Cincinatti 
Subzero, The Surgical Company, Amersfoort, The Netherlands). Temperature 
was measured continuously with a rectal temperature probe (YSI Incorporated 
401, vd Putte Medical, Nieuwegein, The Netherlands) and maintained at 32-
34°C for 24 hrs, followed by passive rewarming to normothermia (defined as 
37°C). All patients were sedated with midazolam and/or propofol and morphine 
during hypothermia. Sedation and analgesics were stopped as soon as the body 
temperature was ≥ 36.5°C. In case of shivering, patients were paralyzed using 
intravenous bolus injections of rocuronium.
All patients were intubated and mechanically ventilated aiming at a PaO2 > 75 
mm Hg and a PaCO2 between 34 and 41 mm Hg. The radial or femoral artery was 
cannulated for monitoring of blood pressure and sampling of arterial blood. Mean 
arterial blood pressure was maintained between 80-100 mmHg, and diuresis was 
aimed at > 0.5 ml/kg/hr. If necessary, patients were treated with volume infusion 
and dobutamine and/or (nor)epinephrine intravenously. 
Serum concentrations of sodium, potassium and magnesium were maintained 
within the normal range. All patients were treated with continuous insulin 
infusion therapy to keep blood glucose levels between 6-8 mmol/l. Haemoglobin 
concentration was kept ≥ 6.0 mmol/l. None of the patients were treated with anti-
inflammatory drugs or steroids.
Sample and data collection
Demographic data and clinical parameters were collected from electronic 
patient files. Blood was sampled from the arterial catheter within 24 hours 
after admission (day 0, during MTH), and at day 1 and 2. Lithium-heparin (LH) 
anticoagulated blood was obtained for ex vivo stimulation experiments, which 
were performed immediately after withdrawal. Ethylenediaminetetraacetic acid 
(EDTA) anticoagulated blood was immediately centrifuged after withdrawal at 
1,600 x g at 4⁰C for 10 minutes, after which plasma was stored at -80⁰C until further 
analysis. Plasma for real time quantitative PCR (qPCR) analysis was centrifuged 
again at 16,000 x g at 4⁰C for 10 minutes to remove potential remaining cells and 
debris. The supernatant was stored at -80⁰C until further analysis. 
Nuclear and mitochondrial DNA quantification in plasma
Plasma from double-centrifuged EDTA anticoagulated blood was diluted 1:1 
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with phosphate buffered saline solution (PBS) after which DNA was isolated 
using the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA, USA), using the 
‘Spin Protocol’ as described by the manufacturer. Isolated DNA was stored at 
-20⁰C until further analysis. qPCR was performed using the CFX Real-Time PCR 
Detection system (Bio-Rad Laboratories, Hercules, CA, USA). The GAPDH gene 
was used for amplification of nDNA (Forward 5’-AGCACCCCTGGCCAAGGTCA-3’, 
Reverse 5’’-CGGCAGGGAGGAGCCAGTCT-3’). For mtDNA quantification, the 
following primers were used: forward 5’-GCCCCAACGTTGTAGGCCCC-3’ and 
reverse 5’AGCTAAGGTCGGGGCGGTGA-3’. The PCR reaction mixture consisted of 5 
µl isolated DNA, 5.5 µl nuclease free water, 12.5 µl iQ SYBR Green PCR Master Mix 
(Bio-Rad Laboratories, Hercules, CA, USA) and 1 µl forward and reverse primer. 
Samples were analyzed in duplicate and a fresh aliquot of DNA isolated from 
blood obtained from a healthy volunteer was used in each plate as a calibrator. 
Plasma nDNA and mtDNA quantities are expressed as fold change relative to the 
expression of the same gene in the calibrator sample.
Plasma cytokine and DAMP concentrations
Plasma concentrations of Tumor Necrosis Factor (TNF)-α, Interleukin (IL)-2, IL-
4, IL-6, IL-8, IL-10, IL12p70, IL-1β, Interferon (IFN)-γ, IL-1 receptor antagonist (IL-
1RA), and Monocyte Chemoattractant Protein (MCP)-1 were analyzed batchwise 
using a simultaneous Luminex assay according to the manufacturer’s instructions 
(Milliplex; Millipore, Billerica, MA, USA). Plasma concentrations of HSP70/HSPA1A 
and EN-RAGE/S100A12 were determined batchwise using ELISA according to 
the manufacturer’s instructions (R&D systems, Minneapolis, MN, USA and MBL 
international, Woburn, MA, USA, respectively). 
Ex vivo cytokine production
Leukocyte cytokine production capacity was determined by challenging whole 
blood from the patients with LPS ex vivo using an in-house developed system 
with pre-filled tubes described in detail elsewhere 26. Briefly, 0.5 mL of blood was 
added to tubes pre-filled with 2 mL RPMI culture medium or 2 mL culture medium 
supplemented with 12.5 ng/mL LPS (end concentration of LPS: 10 ng/mL). 
Tubes were incubated at 37°C (patient samples at days 0, 1, and 2, and samples 
from controls) and 32°C (patient samples at day 0 and samples from controls) 
for 24 hours, centrifuged, and supernatant was stored at -80°C until analysis. 
Concentrations of TNF-α, IL-6 and IL-10 were determined by ELISA, according to 
the manufacturer’s instructions (R&D systems, Minneapolis, MN, USA). 
Automated leukocyte counts differentiation were performed in EDTA 
81
3
DAMPs and immunoparalysis in cardiac arrest patients 
anticoagulated blood using routine analysis methods (flow cytometric analysis 
on a Sysmex XE-5000). Ex vivo produced cytokines were normalized for monocyte 
count since these are the main producers of cytokines in whole blood stimulations 
27.
Statistical analysis
Data are expressed as mean±SEM or median [range], according to their distribution 
as determined using the Shapiro-Wilk test. Kruskal Wallis with post hoc Dunn’s test 
(plasma cytokines or DAMP levels) or one-way ANOVA with post-hoc Dunn’s test 
(ex vivo cytokine production) were used to test for significant differences between 
controls and patients at days 0, 1 and 2. According to the distribution of the data, 
Mann-Whitney U or Student’s T-tests were performed for every outcome variable 
in both patients (data from day 0) and controls to investigate gender-based 
differences. Correlation coefficients were calculated using Bland and Altman’s 
method for calculating correlation coefficients with repeated observations 28. 
Statistical analysis was performed using Graphpad Prism 5 software (Graphpad 
Software, La Jolla, USA) and SPSS Statistics 20 (IBM, NY, USA). A p-value of <0.05 
was considered statistically significant.
Results
Patient characteristics
Patients characteristics are summarized in Table 1. Norepinephrine and midazolam 
was used in all patients. Furthermore, sufentanil was used in 13/14 patients, 
dobutamin in 7/14, milrinon in 3/14, and metoprolol in 11/14.
No difference between controls and patients were observed in plasma cytokine 
concentrations of IFN-γ, IL-2, IL-4, IL-12p70, and IL-1β. Plasma IL-10, IL-1RA, IL-6, 
IL-8, MCP-1, and TNF-α showed highest plasma levels at day 0, and levels were 
significantly higher compared with controls on days 0 and 1 (Figure 1). In the 
next two days, plasma levels gradually decreased and returned to concentrations 
comparable with those found in controls on day 2.
No gender-based differences were observed for any of the outcome variables in 
both patients (data from day 0) and controls.
 
Plasma DAMP levels
Compared with controls, plasma levels of HSP70, EN-RAGE and nDNA were 
significantly increased on day 0 and 1. Plasma mtDNA levels were only slightly, 
but significantly increased at day 0 and 2 in cardiac arrest patients compared with 
controls (Figure 2).
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Gender Male n=10 (71.4%)
Female n=4 (28.6%)
Age (years, median[range]) 63.5 [38-84]
BMI*(kg/m2, median[range]) 24.8 [23.0-28.9]
Time to ROSC (min, median[range]) Unknown: n=5
20 [10-40]
SAPS (median[range]) 66.5 [26-103]
APACHE (median[range]) 24 [15-39]
Initial rhythm VF n=12 (85.7%)
asystoly n=2 (14.3%)
In-hospital mortality N=5 (35.7%)
Body temperature (°C, median [range]) Day 0: 33.7 [32.0-35.1]
Day 1: 37.1 [32.5-38.3]
Day 2: 37.4 [37.0-38.0]
   Table 1 - Patient characteristics * BMI was unknown in 2 patients
Figure 1 – Plasma cytokines Plasma cytokine concentrations in controls and cardiac arrest 
patients on days 0, 1, and 2. Data are depicted as geometric mean±95% CI. * indicates p<0.05 
compared with controls calculated using Kruskal-Wallis with post-hoc Dunn’s test.
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Figure 2 – DAMP levels Plasma levels of HSP70 and EN-RAGE, nuclear DNA (nDNA) and 
mitochondrial DNA (mtDNA) in controls and cardiac arrest patients on days 0, 1, and 2. Data 
are depicted as geometric mean±95% CI. * indicates p<0.05 compared with controls calculated 
using Kruskal-Wallis with post-hoc Dunn’s test.
Figure 3 – Ex vivo cytokine production IL-6, TNF-α, and IL-10 production by leukocytes 
stimulated with LPS ex vivo in controls and cardiac arrest patients on days 0, 1, and 2. Data 
are expressed as mean±SEM ng cytokine/109 monocytes. * indicates p<0.05 compared with 
controls calculated using one-way ANOVA with Bonferroni post-hoc test.
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Correlations between DAMPs and ex vivo cytokine production
Plasma HSP70 levels were negatively correlated with ex vivo production of 
inflammatory mediators IL-6, TNF-α and IL-10 (Figure 5, panels A, B and C). EN-
RAGE levels showed a significant negative correlation with ex vivo production of 
IL-6 and TNF-α, and a borderline significant inverse correlation with IL-10 (Figure 
5, panels D, E, and F). No significant correlations were observed between plasma 
nDNA and ex vivo cytokine production (r=-0.34, p=0.21; r=-0.35, p=0.20 and r=-
0.20, p=0.46, for IL-6, TNF-α and IL-10, respectively).
Plasma levels of nDNA significantly correlated with plasma HSP70 levels (r=0.50, 
p=0.03), but not with EN-RAGE or mtDNA levels (r=0.37, p=0.12 and r=-0.23, 
p=0.41, respectively).
FIgure 4 – Ex vivo incubation 32°C or 37°C IL-6, TNF-α, and IL-10 production by leukocytes 
stimulated with LPS ex vivo at 32°C or 37°C in controls and cardiac arrest patients at day 0 
(Pts Day 0). Data are expressed as mean±SEM ng cytokine/109 monocytes. * indicates p<0.05 
according to paired T-tests. 
Ex vivo cytokine production
In cardiac arrest patients, the ex vivo production of cytokines IL-6, TNF-α, and IL-10 
was severely impaired in comparison with controls (Figure 3). This effect was most 
pronounced for the pro-inflammatory cytokine TNF-α. The suppressed response 
was most profound at day 0 and only partially recovered in the following days. 
In controls, incubation at 37°C resulted in reduced IL-6 production (p=0.0002) 
and a trend towards reduced TNF-α production (p=0.14), while IL-10 production 
was increased (p=0.02) compared with incubation at 32°C. No differences were 
observed between both incubation temperatures in the patient group (Figure 4). 
Ex vivo TNF-α production at 37°C at day 0 was significantly decreased in patients 
treated with dobutamin compared with patients not receiving dobutamin 
(1.03±0.19 vs 3.35±0.12 ng/109 monocytes, p=0.004). 
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Figure 5 – Correlations between circulating DAMPs and ex vivo cytokine production 
R and p values calculated using spearman correlation on combined data from days 0, 1 and 2. 
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Discussion
In the present study, we demonstrate that plasma levels of nDNA, a marker for 
general DAMP release, and the specific DAMPs HSP70 and EN-RAGE are increased 
within 24 hours after cardiac arrest and remained elevated during the following 
days. Furthermore, we confirm increased plasma cytokine levels within 24 hours 
after cardiac arrest and a subsequent decline in the following days. In contrast, 
production of cytokines by leukocytes stimulated ex vivo displayed an inverse 
pattern: a severely impaired response at day 0 followed by partial recovery. These 
findings are indicative of immunoparalysis in cardiac arrest patients. Moreover, 
circulating levels of EN-RAGE and especially HSP70 inversely correlated with ex 
vivo cytokines production. 
Our study suggests that during the first days of hospital admission after cardiac 
arrest, ongoing cell damage results in the continuous release of DAMPs in the 
circulation and that these DAMPS account for the observed immunoparalysis. 
Immediately after cardiac arrest, the increased plasma DAMP levels probably result 
from direct cardiac cell damage following ischemia/reperfusion injury. However, 
the uptake and clearance of dead cells is a highly efficient process mediated by 
macrophages that results in complete clearance of plasma DNA within 24 hours 
29. Because plasma nDNA, HSP70, and EN-RAGE remained elevated during the 
first two days after cardiac arrest, ongoing cell damage during hospital admission 
is likely to induce continuous DAMP release in these patients. Alternatively, 
extensive cell death has been suggested to induce apoptosis of macrophages 
after phagocytosis of the dead cells or cellular debris, which could lead to the 
release of nuclear contents (both of the phagocytosed cells and the macrophage 
itself ) into the circulation 29. Although mtDNA gained much attention as a DAMP 
to induce inflammation in e.g. trauma patients 17, our study demonstrates that 
mtDNA, in contrast to HSP70 and EN-RAGE, is not one of the DAMPs released in 
large quantities in post-cardiac arrest patients.
The observed difference between plasma nDNA and mtDNA concentrations in 
this study is remarkable, as one would expect that cells release both substances 
when damaged. Three possible mechanisms could explain these differences. 
First, mitochondria could be cleared before cell death occurs via a process 
called mitophagy 30. Second, intact mitochondria instead of free mtDNA could 
be released into the plasma. A third and final possibility is that mtDNA could be 
cleared at a much higher rate compared with nDNA, because of rapid recognition 
and phagocytosis due to its bacterial-like appearance. Additional studies are 
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warranted to gain more insight in the mechanisms of cell death post-cardiac 
arrest and the release of mitochondria or mtDNA in this process. 
Our data demonstrate that circulating leukocytes display a suppressed phenotype 
during the first days after cardiac arrest, reflected by decreased production of 
cytokines upon stimulation with LPS. Ex vivo cytokine production was inversely 
related to plasma levels of EN-RAGE and especially HSP70, implicating that these 
DAMPs contribute to the observed compromised immune function. HSP70 
showed the strongest inverse relationship with pro-inflammatory cytokines 
production and interestingly, this HSP has been shown to induce endotoxin 
tolerance in monocytes in vitro 20. Endotoxin tolerance is characterized as a 
reduced capacity to respond to LPS stimulation following a previous exposure 
to LPS 20, 31, 32, and has many similarities to immunoparalysis 33. The fact that, 
despite the apparent immunosuppression, plasma cytokines are still elevated 
compared with controls and the lack of a relationship between nDNA levels 
and the ex vivo immune response, suggests that both immunostimulatory and 
immunosuppressive DAMPs are released. Taken together, these results indicate 
cardiac arrest patients show signs of immunoparalysis, possibly as a result of 
DAMP release, of which especially HSP70 appears to play an important role. The 
immunoparalysis observed has been previously described in sepsis patients 34, 
35. In this respect, the declining plasma cytokine levels in spite of still-elevated 
DAMP levels on days 1 and 2 might reflect immunoparalysis of the tissue-resident 
compartment, which has been shown before to remain immunoparalytic for 
much longer than circulating leukocytes 36. No relation with DAMP release has 
previously been described in this patient group, although multiple studies 
in trauma patients, with major DAMP release at the time of injury, indicates a 
relationship between the release of DAMPs and immunoparalysis 37-39. 
Worldwide, MTH is frequently employed in patients after cardiac arrest and is 
part of the standard care in our hospital. Interestingly, MTH has been suggested 
to attenuate pro-inflammatory cytokine production 40, 41, and could therefore 
contribute to the development of immunoparalysis in these patients. This is 
however not supported by a recent study that demonstrated no differences in ex 
vivo cytokine responses or HLA-DR expression between patients treated with and 
without MTH 10. Studies into the effects of temperature on ex vivo LPS-induced 
cytokine production showed conflicting results as well 42, 43. We did not find any 
effects of ex vivo rewarming of leukocytes obtained from patients during MTH on 
cytokine production. However, we did observe an effect of incubation temperature 
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on ex vivo cytokine production in the control group. These findings might suggest 
that the phenotype of leukocytes is altered by in vivo hypothermia, and that this 
effect cannot be reversed by ex vivo rewarming of cells. This is nevertheless not in 
line with the findings of enhanced pro-inflammatory cytokine production upon 
incubation at 32°C, a phenotype dissimilar to that observed in cardiac arrest 
patients. Therefore, MTH appears not to be the main cause of reduced immune 
function in these patients. Interestingly, HSP70, which correlates with the extent 
of immunoparalysis in the present study, is induced by hypothermia 25. Along 
these lines, the profoundly increased levels of HSP70 on day 0 might be partly 
explained by the MTH-treatment at this time-point. 
This study has several limitations. The medication used by our patients might 
influence the immunoparalysis observed. Patients receiving dobutamin 
displayed lower ex vivo TNF-α production compared to patients not treated with 
dobutamin. However, the fact that the untreated group still demonstrated a vast 
decrease in ex vivo TNF-α production compared with controls suggest that the 
role of dobutamin in the development of immunoparalysis is limited. Moreover, 
the study population is highly heterogeneous and the sample size does not allow 
a multiple regression analysis including multiple DAMPs or patient factors, such 
as age. Due to the small sample size, no relevant clinical outcome measures, such 
as infections or survival, could be assessed as well. Finally, as this is a correlative 
observational study, no definite conclusions can be drawn concerning possible 
mechanisms behind DAMP release, e.g. ischemia/reperfusion or hypoxia, and the 
related immunoparalysis. 
Conclusions
In conclusion, DAMPs are continuously released during the first days after 
cardiac arrest, and levels of the specific DAMPs EN-RAGE and especially HSP70 
are inversely correlated with the extent of immunoparalysis. This suggests that 
DAMPs in general, and particularly HSP70, are involved in development of 
immunoparalysis. The observed immunoparalysis could play an important role 
in the susceptibility towards infections in cardiac arrest patients but could also 
represent a protective mechanism to limit secondary tissue damage.
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Abstract
Chemotherapy may result in the release of Danger Associated Molecular Patterns 
(DAMPs), which can cause deactivation of the immune system, a phenomenon 
known as immunoparalysis. We investigated if DAMPs are released following 
chemotherapy and their relationship with markers of immunoparalysis in 
leukemia patients. In 6 patients with acute myeloid leukemia or myelodysplastic 
syndrome, several DAMPs and inflammatory cytokines in the circulation as well as 
markers of immunoparalysis (leukocyte cytokine production capacity and HLA-DR 
expression) were determined before and 4-6 hours, 2, 4, 6, and 8 days following 
chemotherapy initiation. Immunoparalysis markers were also determined in 
12 healthy control subjects. Compared with healthy controls, plasma levels of 
nuclear DNA (a marker of general DAMP release) in patients were profoundly 
increased before chemotherapy and further increased 4-6 hours afterwards, while 
the specific DAMP mitochondrial DNA only showed a trend towards increased 
levels. Circulating cytokine levels did not change following chemotherapy. Finally, 
leukocyte cytokine production capacity and HLA-DR expression were similar 
between patients and healthy controls until day 4, when leukocytes were virtually 
absent in the circulation. In conclusion, in the early phase following chemotherapy 
in leukemia patients, increased DAMP release does not induce immunoparalysis.
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Introduction
The standard treatment for acute haematological malignancies usually includes 
chemotherapy 1. This treatment is aimed to reduce tumour burden and to 
induce long-term remission, but at the same time renders patients increased 
vulnerable for infections, both from invading pathogens and from endogenous 
flora or viral reactivations 2. It is well known that chemotherapy-induced immune 
cell destruction is the major contributor to this decreased immune function 3. 
However, defective immune function in remaining cells has also been described, 
for example in neutrophils and T-lympohocytes 4, 5.
Chemotherapy used to treat haematological malignancies may result in the 
release of so-called Danger Associated Molecular Patterns (DAMPs) 6. These 
DAMPs elicit an immune response in a similar manner as Pathogen Associated 
Molecular Patterns (PAMPs) derived from invading pathogens in infectious 
diseases such as sepsis 7, 8, but may subsequently also result in deactivation of 
the immune system, a phenomenon known as immunoparalysis in the sepsis 
field 9, 10. Two major hallmarks of immunoparalysis that are related to immune 
cell dysfunction are attenuated production of cytokines by leukocytes ex vivo 
stimulated with PAMPs such as LPS, and decreased leukocyte HLA-DR expression 
9, 11. As such, DAMP-induced leukocyte immune dysfunction could contribute 
to the decreased function of the remaining immune cells in leukemia patients 
treated with chemotherapy. 
The aims of this study were to quantify the amount of DAMPs in the circulation 
before and after initiation of chemotherapy in patients with acute leukemia, and 
to assess leukocyte cytokine production capacity and HLA-DR expression in these 
patients. This enabled us to establish the relationship between DAMP levels and 
immunoparalysis. 
Materials and Methods
Study population
We performed a prospective observational study in 6 patients aged >18 years and 
diagnosed for the first time with acute myeloid leukemia (AML) or myelodysplastic 
syndrome (MDS). Exclusion critera: active infection at the time of inclusion, use of 
immunosuppressive drugs, suffering from other conditions known to influence 
the immune response (e.g. auto-immune diseases).
The study was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. 
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All study procedures were conducted in accordance with the declaration of 
Helsinki including current revisions and Good Clinical Practice guidelines.
Control samples (n=12) were obtained from healthy male volunteers (median 
age 22 [range 19-27]) participating in the control group of an experimental 
endotoxemia trial 12 at baseline, before administration of endotoxin. Written 
informed consent was obtained from all volunteers prior to screening and 
inclusion in the study.
Sample and data collection
Demographic data and clinical parameters were collected from electronic patient 
files. Blood was sampled from the venous catheter at baseline on day 1 (before 
start of chemotherapy), 4-6 hours after start of chemotherapy, and at days 2, 
4, 6 and 8. Lithium-heparin (LH) anticoagulated blood was obtained for ex vivo 
whole blood stimulation experiments, which were performed immediately after 
withdrawal. Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was 
immediately centrifuged after withdrawal at 1,600 x g at 4⁰C for 10 minutes, after 
which plasma was stored at -80⁰C until cytokine analysis. Plasma for nDNA and 
mtDNA quantification by real time quantitative PCR (qPCR) was centrifuged again 
at 16,000 x g at 4⁰C for 10 minutes to remove potential remaining cells and debris. 
The supernatant was stored at -80⁰C until analysis. Blood for HLA-DR quantification 
by qPCR was sampled in Paxgene blood RNA tubes (Qiagen, Valencia, CA, USA) 
and stored according to the manufacturer’s instructions.
DAMP quantification in plasma
A large variety of different (and probably many yet unidentified) DAMPs are 
released in case of cell damage 7. Therefore, we measured general markers of cell 
damage (plasma nuclear DNA [nDNA], plasma lactate dehydrogenase [LDH], and 
urate) as indicators of general DAMP release 13. Moreover, we quantified plasma 
mitochondrial DNA (mtDNA), a known DAMP that can trigger Toll-Like receptor 
(TLR) 9 14.
Plasma from double-centrifuged EDTA anticoagulated blood was diluted 1:1 
with phosphate buffered saline solution (PBS), after which DNA was isolated 
using the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA, USA), using the 
‘Spin Protocol’ as described by the manufacturer. Isolated DNA was stored at 
-20⁰C until further analysis. qPCR was performed using the CFX Real-Time PCR 
Detection sytem (Bio-Rad Laboratories, Hercules, CA, USA). The GAPDH gene 
was used for amplification of nDNA (Forward 5’-AGCACCCCTGGCCAAGGTCA-3’, 
Reverse 5’’-CGGCAGGGAGGAGCCAGTCT-3’). For mtDNA quantification, the 
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following primers were used: forward 5’-GCCCCAACGTTGTAGGCCCC-3’ and 
reverse 5’AGCTAAGGTCGGGGCGGTGA-3’. The PCR reaction mixture consisted of 5 
µl isolated DNA, 5.5 µl nuclease free water, 12.5 µl iQ SYBR Green PCR Master Mix 
(Bio-Rad Laboratories, Hercules, CA, USA) and 1 µl forward and reverse primer. 
Samples were analyzed in duplicate and DNA isolated from blood obtained from 
the same healthy volunteer was used in each plate as a calibrator. Plasma nDNA 
and mtDNA quantities are expressed as fold change relative to the calibrator 
sample.
Plasma LDH and urate concentrations were determined using routine analysis 
methods also used for patient samples in clinical practice (ARCHITECT chemistry 
analyzer).
Ex vivo whole blood stimulation
Leukocyte cytokine production capacity was determined by stimulating whole 
blood with LPS ex vivo using an in-house developed system with pre-filled tubes 
described in detail elsewhere 15. Briefly, 0.5 mL of blood was added to tubes pre-
filled with 2 mL culture medium or 2 mL culture medium supplemented with 12.5 
ng/mL LPS (end concentration of LPS: 10 ng/mL). Cultures were incubated at 37° 
for 24 hours, centrifuged at 2000 x g for 10 minutes at 4 ⁰C, and supernatants were 
stored at -80°C until analysis. 
Cytokine analysis
Plasma concentrations of Tumor Necrosis Factor (TNF)-α, Interleukin (IL)-6, IL-
10, IL-8, Interferon (IFN)-γ, and IL-1 receptor antagonist (IL-1RA) were analyzed 
batchwise using a simultaneous Luminex assay according to the manufacturer’s 
instructions (Milliplex; Millipore, Billerica, MA, USA). Concentrations of TNF-α, IL-6 
and IL-10 in supernatants of ex vivo stimulated whole blood were determined 
batchwise by ELISA, according to the manufacturer’s instructions (R&D systems, 
Minneapolis, MN, USA).
HLA-DR expression
RNA was isolated from blood collected in in Paxgene blood RNA tubes (Qiagen, 
Valencia, CA, USA). cDNA was synthesized from total RNA using the iScript 
cDNA Synthesis Kit (Bio-rad, Hercules, CA, USA). Subsequent qPCR analysis was 
performed using TaqMan gene expression assays (Bio-rad, Hercules, CA, USA) for 
the housekeeping gene PPIB (#Hs00168719_m1) and HLA-DR (#Hs00219575_m1) 
on a CFX96 Real-Time PCR Detection system (Bio-Rad, Hercules, CA, USA). HLA-DR 
was expressed as fold change relative to PPIB.
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Statistical analysis
Data are expressed as mean±SEM or median [range or interquartile range (IQR)], 
according to their distribution (determined using the Kolmogorov-Smirnov 
test). Unpaired Student’s T-tests or Mann–Whitney U tests were used to assess 
differences between healthy controls and patient samples. Statistical analysis was 
performed using Graphpad Prism 5 software (Graphpad Software, La Jolla, USA). 
A p-value of <0.05 was considered statistically significant.
 
Results and Discussion
Patient characteristics are described in table 1. 
Sex (male/female)
- Male
- Female 
n=1
n=5
Disease classification 
- MDS-RAEB2
- AML
o FAB M1
o FAB M4  
n=2
n=4
n=2
n=2
% blasts (median [range]) 47.5 [18-77] 
Age (median [range]), yrs 55.5 [47-62] 
Chemotherapy
- Cytarabin (200 mg/m2)
- Idarubicin (12 mg/m2)
- Clofarabin (10 mg/m2) 
n=6 
n=6
n=2
Relevant co-medication
- Hydrea (day -3 to 8)
- Allopurinol (day 0 to 8) 
n=3
n=0
Table 1 - Patient Characteristics
As expected, leukocyte numbers gradually decreased after chemotherapy; at 
day 4 virtually no circulating leukocytes were present anymore (Figure 1A). Urate 
levels were within the reference range for our hospital (0.15-0.35 mmol/L) at all 
time-points (data not shown). Plasma LDH levels were slightly increased both 
before and after chemotherapy compared with the reference range for our 
hospital (<250 U/l, Figure 1B). Likewise, plasma levels of nDNA were significantly 
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increased in leukemia patients before chemotherapy, and these further increased 
4-6 hours after start of chemotherapy (Figure 1C). These data are suggestive of 
cell damage and DAMP release related to both the haematological disease and 
chemotherapy. From day 4 onwards, plasma nDNA levels substantially decreased, 
probably related to the almost complete absence of leukocytes in the circulation. 
Levels of the specific DAMP mtDNA tended to increase following chemotherapy, 
but this did not reach statistical significance (p=0.07)(Figure 1D).
Before start of chemotherapy, plasma concentrations of some, but not all cytokines 
Figure 1 - DAMP release in leukemia patients Leukocyte counts (A) and plasma levels of 
LDH, nDNA and mtDNA (B, C, D). Data are depicted as median±interquartile range (Panel A+B) 
or mean±SEM (Panel C+D). ‘Before CT’ indicates before start chemotherapy. ‘After CT’ indicates 
4-6 hours after start chemotherapy. *indicates p<0.05 compared with healthy controls. 
were above the detection limit (3.2 pg/ml) in leukemia patients: TNF-α: 13.1 pg/ml 
[7.8-22.8], IL-6: 22.1 pg/ml [4.0-39.2], IL-10: 11.6 pg/ml [8.2-35.9], and IL-1RA: 22.7 
pg/ml [22.7-53.8]. Plasma cytokine levels did not change immediately following 
chemotherapy, indicating that no systemic inflammatory response was induced 
by the treatment (data not shown). LPS-induced ex vivo cytokine production 
until day 2 after chemotherapy was not significantly different compared with 
healthy controls (Figure 2, panels A, B, and C). From day 4 onwards, ex vivo 
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cytokine responses were below the detection limits of the assays, related to the 
very low numbers of leukocytes present in the circulation at the corresponding 
time points. Ex vivo cytokine production patterns were similar at all time points 
between patients who were treated with hydrea and those who were not. Finally, 
no differences in HLA-DR expression were observed between patients until day 2 
post-chemotherapy and healthy controls (Figure 2D). No RNA could be isolated 
from blood at later time points, again related to the virtually complete absence of 
leukocytes in the circulation. 
Figure 2 – Leukocyte function in leukemia patients Ex vivo cytokine response to LPS (A, B, 
C), and leukocyte HLA-DR mRNA expression (D). Data are depicted as median±IQR. ‘Before CT’ 
indicates before start chemotherapy. ‘After CT’ indicates 4-6 hours after start chemotherapy.
Although defective immune function in leukemic cells has been described before 
4, 5, we demonstrate that cytokine production capacity and HLA-DR expression are 
not affected by DAMP release in leukemia patients treated with chemotherapeutic 
agents.
In conclusion, in the early phase following chemotherapy in leukemia patients, 
increased DAMP release does not induce immunoparalysis. 
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Abstract
Background Plasma levels of the danger-associated molecular patterns (DAMPs) 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been shown to be 
related to sepsis mortality. However, the intermediate factors and/or mechanisms 
contributing to this relation are largely unknown. Our aim was to determine 
whether plasma levels of nDNA and mtDNA are related to the markers of 
inflammation, severity of shock, and organ damage in septic shock patients. 
Moreover, we investigated the relationship between plasma levels of nDNA/
mtDNA and inflammatory cytokines during experimental human endotoxemia, 
a model of systemic inflammation in humans in vivo mimicking some of the 
hallmarks of early sepsis.
Methods Blood was sampled from the onset of septic shock until day 28 in 
121 septic shock patients and from one hour before endotoxin administration 
until eight hours afterwards in 12 healthy volunteers. Plasma concentrations 
of 5 cytokines and circulating levels of nDNA and mtDNA were measured, and 
correlations with shock-related parameters and markers of organ damage were 
investigated.
Results In septic shock patients plasma cytokine concentrations, as well as nDNA 
and mtDNA levels, were increased at the onset of septic shock and remained 
elevated. During the first 5 days of septic shock, nDNA levels consistently correlated 
with plasma cytokine concentrations as well as with the shock-related parameter 
norepinephrine infusion rate and markers of organ damage (total bilirubin and 
creatinine). Experimental human endotoxemia also resulted in increased levels 
of plasma nDNA and mtDNA, but to a lesser extent than in septic shock patients. 
Furthermore, nDNA levels correlated with pro-inflammatory cytokines during 
endotoxemia.
Conclusions Our findings indicate a relationship between plasma nDNA levels 
and the inflammatory response. Furthermore, nDNA levels correlate with markers 
of shock and organ damage in septic shock patients. It remains to be determined 
whether nDNA is merely a marker or directly involved in the pathophysiology of 
septic shock. 
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Introduction
Sepsis is the leading cause of death in intensive care units (ICUs), accounting for 
more deaths than breast cancer, lung cancer, and prostate cancer combined 1. The 
development of sepsis is generally characterized by a simultaneously occurring 
hyperinflammatory and immunosuppressive reaction 2. Pathogen associated 
molecular patterns (PAMPs) play an important role in the inflammatory response 
during sepsis, particularly in the hyperinflammatory reaction. However, danger 
associated molecular patterns (DAMPS) are released as well, contributing to 
initiation and/or propagation of inflammation 3, 4. For instance, ongoing tissue 
damage and DAMP release have been demonstrated during lethal bacterial sepsis 
in primates, suggesting that both PAMP - and DAMP-related responses play a role 
in septic patients 4.
Nucleic acids released in the plasma during sepsis could serve as DAMPs. Both 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) are released passively into 
the circulation after rupture or necrosis of cells 5, but active release has also been 
described 6-8. mtDNA is of particular interest as a DAMP, as the endosymbiotic 
theory suggests that mitochondria originate from bacteria, and as such have 
their own DNA that strongly resembles bacterial DNA 9. Both nDNA and mtDNA 
can bind to Pattern Recognition Receptors (PRRs) and thereby induce production 
of inflammatory cytokines 10. Next to this possible role in initiation and/or 
propagation of inflammation, nucleic acids might also reflect the degree of shock 
and organ damage, and thus outcome in septic shock patients. Indeed, plasma 
nDNA and mtDNA levels have been shown to be related to sepsis mortality in 
several studies 11, 12. However, the intermediate factors and/or mechanisms 
contributing to this relation have only sparsely been studied. 
The aim of this study was to determine whether plasma nDNA or mtDNA levels 
are related to markers of inflammation, severity of shock, and organ damage, all 
of which are important hallmarks of sepsis that contribute to mortality. Moreover, 
we investigated the relationship between plasma levels of nDNA/mtDNA and 
inflammatory cytokines during experimental human endotoxemia, a model of 
systemic inflammation in humans in vivo mimicking some of the hallmarks of 
early sepsis 13, 14.
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 Methods
Study population
We performed a prospective observational study in 121 adult patients with 
newly developed septic shock between April 2012 and June 2014. Patients 
were included in the study according to conventional criteria for septic shock: a 
suspected infection and 2 or more SIRS criteria as well as requiring vasopressor 
therapy to maintain blood pressure 15, 16. Patient characteristics are summarized 
in Table 1. 
Gender Male n=71 (58.7%)
Female n=50 (41.3%)
Age (years, median[range]) 66 [19-92]
APACHE II (median[range]) 23 [11-45]
ICU length of stay (days, median [range]) 7 [1-97]
Hospital length of stay (days, median [range]) 26 [1-137]
28-days-mortality N=54 (44.6%)
Sepsis focus
- Urinary tract
- Lung
- Abdomen
- Venous/Arterial catheter
- Other
n=12 (9.9%)
n=55 (45.5%)
n=37 (30.6%)
n=6 (5.0%)
n=26 (21.5%)
Table 1 – Patient Characteristics
The study was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. 
All patients or legal representatives were informed about the study details. 
We also analyzed samples from 12 healthy male volunteers (median age 22 
[range 19-27]) who participated in an experimental human endotoxemia study 
(NCT01835457 17. These samples were obtained from subjects of the control 
group who, besides LPS, did not receive any intervention. A detailed protocol of 
the endotoxemia study is described elsewhere 17. Briefly, lipopolysaccharide (LPS, 
US Standard Reference Endotoxin Escherichia Coli O:113) was administered as an 
intravenous bolus injection at a dose of 2 ng/kg body weight in one minute at T = 
0 hours. The subjects received 1.5 L 0.9% NaCl during one hour starting one hour 
before endotoxin infusion (pre-hydration) as part of our standard endotoxemia 
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protocol 18, followed by 150 ml/h until 6 hours after endotoxin infusion and 75 
ml/h until the end of the experiment, 8 hours after infusion. The endotoxemia 
study was approved by the local ethics committee and written informed consent 
was obtained from all volunteers prior to screening and inclusion in the study. All 
study procedures were conducted in accordance with the declaration of Helsinki 
including current revisions and Good Clinical Practice guidelines.
Sample and data collection
Demographic data as well as clinical and laboratory parameters of patients 
(except for cytokine, nDNA, and mtDNA levels) were collected from electronic 
patient files. Blood from patients was sampled from the arterial catheter within 
24 hours after diagnosis of septic shock (day 1). Further sampling took place as 
long as patients were admitted to the ICU on days 3, 5, 7, 9, 14, 21, and 28. Blood 
from healthy volunteers that underwent human endotoxemia was sampled from 
the arterial catheter 1 hour before LPS administration (T=-60), just before LPS 
administration (T=0), and 30, 60, 90, 120, 240, 360, and 480 minutes afterwards.
Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was centrifuged 
immediately after withdrawal at 1,600 x g at 4⁰C for 10 minutes, after which 
plasma was stored at -80⁰C until further analysis. Plasma for real time quantitative 
PCR (qPCR) analysis of nDNA and mtDNA levels was centrifuged again at 16,000 
x g at 4⁰C for 10 minutes to remove potential remaining cells and debris. The 
supernatant was stored at -80⁰C until further analysis. 
Plasma cytokine concentrations
Plasma concentrations of Tumor Necrosis Factor (TNF)-α and Interleukin (IL)-6, 
IL-8, IL-10, and IL-1 receptor antagonist (IL-1RA) were analyzed batchwise using 
a simultaneous Luminex assay according to the manufacturer’s instructions 
(Milliplex; Millipore, Billerica, MA, USA). 
Nuclear and mitochondrial DNA quantification in plasma
Double-centrifuged EDTA plasma was diluted 1:1 with phosphate buffered saline 
solution (PBS) after which DNA was isolated using the QIAamp DNA Blood Midi 
Kit (Qiagen, Valencia, CA, USA), using the ‘Spin Protocol’ as described by the 
manufacturer. Isolated DNA was stored at -20⁰C until further analysis. qPCR was 
performed on a CFX96 Real-Time PCR Detection system (Bio-Rad Laboratories, 
Hercules, CA, USA). A primer pair specific for the GAPDH gene present in all 
nucleated cells of the body was used for quantification of nDNA levels: Forward 
5’-AGCACCCCTGGCCAAGGTCA-3’, Reverse 5’’-CGGCAGGGAGGAGCCAGTCT-3’. 
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For quantification of mtDNA levels, the following primer pair specific for the 
mitochondrially encoded NADH dehydrogenase 1 (MT-ND1) gene was used: forward 
5’-GCCCCAACGTTGTAGGCCCC-3’ and reverse 5’AGCTAAGGTCGGGGCGGTGA-3’. 
Primers were obtained from Biolegio (Nijmegen, the Netherlands). The PCR 
reaction mixture consisted of 5 µl isolated DNA, 5.5 µl nuclease free water, 12.5 
µl iQ SYBR Green PCR Master Mix (Bio-Rad Laboratories, Hercules, CA, USA) and 
1 µl forward and reverse primer. Samples were analyzed in duplicate and a fresh 
aliquot of DNA isolated from blood obtained from a healthy volunteer was used 
in each plate as a calibrator (CV% of 1.9% (GAPDH) and 3.1% (mtDNA) between 
plates). Plasma nDNA and mtDNA quantities are expressed as fold change relative 
to the expression of the same gene in the calibrator sample. 
Statistical analysis
Data are expressed as median [range/interquartile range (IQR)], according to their 
non-parametric distribution as determined using the Shapiro-Wilk test. Kruskal-
Wallis with Dunn’s post hoc tests were used to evaluate differences in plasma 
cytokine and DAMP levels between septic shock patients and healthy controls 
(samples obtained from healthy volunteers at baseline [T=-60, 1 hour before 
LPS administration]). Friedman with Dunn’s post hoc tests were used to evaluate 
differences between baseline (T=-60) and other time-points during endotoxemia. 
Correlation coefficients were calculated using Spearman correlation. Statistical 
analysis was performed using Graphpad Prism 5 software (Graphpad Software, La 
Jolla, USA) and SPSS Statistics 20 (IBM, NY, USA). A two-sided p-value of <0.05 was 
considered statistically significant. 
Results
Septic shock patients
At virtually all time-points, plasma cytokine levels were higher in patients 
compared with those found in healthy controls before LPS administration (Figure 
1, panels A-E), with highest levels observed at day 1. 
At day 1, plasma nDNA levels were profoundly increased compared with healthy 
controls, and remained elevated during the next 28 days (Figure 2A). Although 
a similar pattern was observed for mtDNA, the increase was far less pronounced 
(Figure 2B). There were no differences in the nDNA/mtDNA ratio between controls 
and patients at any of the time-points (data not shown). Furthermore, plasma 
levels of nucleic acids at all time-points studied were similar between patients 
whose medical history included cancer and/or autoimmune diseases (n=57, 
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47%), conditions associated with increased levels of circulating nucleic acids 19, 20, 
and those in which it did not (data not shown).
Plasma nDNA levels correlated consistently with both pro- and anti-inflammatory 
cytokine concentrations in the initial phase of septic shock (Table 2). Moreover, 
Figure 1 – Plasma concentrations of inflammatory cytokines in septic shock Plasma 
levels of pro- (A-C) and anti-inflammatory (D+E) cytokines in septic shock patients and healthy 
controls. Data are expressed as median±IQR. Day 1, n=109; Day 3, n=87; Day 5, n=61; Day 7, 
n=46; Day 9, n=38; Day 14, n=28; Day 21, n=21; Day 28, n=13. * indicates p<0.05 compared 
with controls.
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plasma nDNA levels correlated with the shock-related marker norepinephrine 
dose as well as with creatinine and total bilirubin (markers of kidney and liver 
damage, respectively, Table 2). Although plasma mtDNA concentrations also 
showed a few statistically significant correlations with some of these parameters, 
no consistent effects were observed (Table 2). 
Healthy volunteers during human endotoxemia
Following LPS administration, plasma levels of both pro- and anti-inflammatory 
cytokines profoundly increased (Figure 3). 
nDNA levels were significantly increased compared with baseline from T=90 
minutes onwards (Figure 4A). Plasma mtDNA levels demonstrated a similar pattern, 
although a significant difference with baseline values was observed only at T=180 
minutes (Figure 4B). There were no differences in the nDNA/mtDNA ratio over 
time (data not shown). Peak nDNA levels correlated with peak IL-6 levels (r=0.72, 
p=0.008), whereas a similar trend was observed for the other pro-inflammatory 
cytokines (TNF-α:r=0.52, p=0.08; IL-8: r=0.55, p=0.07). No relationship between 
peak levels of nDNA and anti-inflammatory cytokines was found (IL-10: r=0.02, 
p=0.93, IL-1RA: r=0.02, p=0.96). Finally, no correlations between peak levels of 
plasma mtDNA and any of the studied cytokines were found (TNF-α: r=-0.25, 
p=0.42; IL-6: r=-0.06, p=0.85; IL-8: r=-0.34, p=0.26; IL-10: r=-0.52, p=0.08; IL-1RA: 
r=-0.32, p=0.31).
Figure 2 – Plasma concentrations of DAMPs in septic shock Plasma levels 
of DAMPs nDNA (panel A) and mtDNA (panel B) in septic shock patients and 
healthy controls. Data are expressed as median±IQR. Day 1, n=121; Day 3, 
n=92; Day 5, n=68; Day 7, n=50; Day 9, n=41; Day 14, n=29; Day 21, n=20; Day 
28, n=16. * indicates p<0.05 compared with controls.
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nDNA mtDNA Patients
In
fla
m
m
at
io
n
TNF-α
Pro-
inflam.
Day 1 r=0.34 p<0.001
Day 3 r=0.36 p=0.001
Day 5 r=0.21 p=0.111
Day 1 r=0.08 p=0.44
Day 3 r=0.13 p=0.23
Day 5 r=0.12 p=0.37
n=109
n=86
n=61
IL-6
Pro-
inflam.
Day 1 r=0.21 p=0.03
Day 3 r=0.21 p=0.06
Day 5 r=-0.02 p=0.91
Day 1 r=0.08 p=0.41
Day 3 r=-0.06 p=0.59
Day 5 r=-0.09 p=0.51
n=109
n=86
n=61
IL-8
Pro-
inflam.
Day 1 r=0.34 p<0.001
Day 3 r=0.37 p=0.001
Day 5 r=0.24 p=0.63
Day 1 r=0.16 p=0.11
Day 3 r=0.03 p=0.77
Day 5 r=0.08 p=0.56
n=109
n=86
n=61
IL-10
Anti-
inflam.
Day 1 r=0.30 p=0.001
Day 3 r=0.34 p=0.002
Day 5 r=0.27 p=0.04
Day 1 r=0.08 p=0.43
Day 3 r=0.08 p=0.50
Day 5 r=0.16 p=0.22
n=109
n=86
n=61
IL-1RA
Anti-
inflam.
Day 1 r=0.38 p<0.001
Day 3 r=0.41 p<0.001
Day 5 r=0.25 p=0.06
Day 1 r=0.20 p=0.045
Day 3 r=0.20 p=0.08
Day 5 r=0.21 p=0.11
n=109
n=86
n=61
Leukocyte 
count
Day 1 r=0.10 p=0.29
Day 3 r=0.42 p<0.001
Day 5 r=0.32 p=0.01
Day 1 r=0.53 p=0.57
Day 3 r=0.13 p=0.24
Day 5 r=0.31 p=0.02
n=119
n=91
n=60
Sh
oc
k
N o r e p i -
nephrine
dose
Day 1 r=0.40 p<0.001
Day 3 r=0.30 p=0.004
Day 5 r=0.19 p=0.13
Day 1 r=0.31 p=0.001
Day 3 r=0.14 p=0.19
Day 5 r=0.14 p=0.28
n=117
n=94
n=62
MAP Day 1 r=-0.08 p=0.35
Day 3 r=-0.08 p=0.45
Day 5 r=-0.10 p=0.42
Day 1 r=-0.19 p=0.04
Day 3 r=-0.12 p=0.24
Day 5 r=-0.12 p=0.33
n=121
n=92
n=68
O
rg
an
 d
am
ag
e
Creatinine
Kidney
Day 1 r=0.28 p=0.002
Day 3 r=0.30 p=0.006
Day 5 r=0.29 p=0.03
Day 1 r=0.14 p=0.14
Day 3 r=0.12 p=0.13
Day 5 r=0.11 p=0.39
n=120
n=85
n=59
T o t a l 
bilirubin 
Liver
Day 1 r=0.36 p=0.003
Day 3 r=0.32 p=0.11
Day 5 r=0.57 p=0.05
Day 1 r=0.21 p=0.10
Day 3 r=0.04 p=0.86
Day 5 r=0.18 p=0.56
n=63
n=26
n=12
Table 2 – Correlations between DAMPs and markers of inflammation, organ damage, and 
shock in patients with septic shock Correlation coefficients were calculated between plasma 
levels of DAMPs and the various markers on corresponding days. Significant correlations are 
highlighted in grey. Cytokine and nucleic acid levels are depicted in Figures 1 and 2. On days 1 ,3, 
and 5, median [IQR] leukocyte counts were 14.0 [8.1-21.2], 11.4 [7.1-19.5], and 12.4 [7.6-17.2] X 
109/L, norepinephrine dose was 0.19 [0.10-0.50], 0.17 [0.10-0.30], and 0.1 [0.06-0.40] ug/kg/min, 
MAP was 74 [67-80], 77 [72-85], and 78 [71-88] mmHg, creatinine was 123 [74-230], 107 [66-227], 
and 104 [69-196] µmol/L, and bilirubin was 19 [12-35], 26 [13-86], and 26 [16-44] µmol/L. 
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Figure 3 – Plasma concentrations of inflammatory cytokines during experimental 
human endotoxemia Plasma levels of pro- (A-C) and anti-inflammatory (D+E) cytokines 
in healthy volunteers during endotoxemia. Data are expressed as median±IQR. * indicates 
p<0.05 compared with time-point T=-60.
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Discussion
Herein, we demonstrate that plasma levels of nDNA and mtDNA are increased in 
septic shock patients. Furthermore, plasma levels of nDNA, but not mtDNA, are 
related to markers of inflammation, shock, and organ damage in these patients. 
Similar findings were obtained during human endotoxemia: LPS administration 
in healthy volunteers results in increased plasma levels of nDNA and mtDNA, 
although healthy volunteers exhibit lower peak levels compared with septic 
shock patients. Moreover, peak levels of nDNA, but not mtDNA, are related with 
the endotoxin-induced pro-inflammatory cytokine response.
It is generally assumed that nucleic acids are released after rupture or necrosis of 
cells 5. However, our results obtained in the relatively mild human endotoxemia 
model demonstrate that a systemic inflammatory response, which is not expected 
to cause significant cell rupture or necrosis, also results in release of nucleic 
acids. These data suggests that inflammation results in active release of nucleic 
acids. Such active release, both spontaneous and during cell death, has been 
described previously, although the exact mechanisms remain to be elucidated 
6-8. Interestingly, plasma cytokine levels were higher in healthy volunteers during 
endotoxemia compared with septic shock patients, while levels of nucleic acids 
were much lower. While the pathogenesis of septic shock cannot be directly 
compared with experimental human endotoxemia, these differences suggest 
that in septic shock patients nucleic acids are released both actively as a result of 
Figure 4 – Plasma concentrations of DAMPs during endotoxemia Plasma levels of DAMPs 
nDNA (panel A) and mtDNA (panel B) in healthy volunteers during endotoxemia. Data are 
expressed as median±IQR. * indicates p<0.05 compared with time-point T=-60.
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the inflammatory response and passively as a result of cell damage. 
Our data further show that, compared with nDNA, the fold increase in plasma 
levels of mtDNA in sepsis patients compared with healthy controls as well as 
the fold increase observed in healthy volunteers following LPS administration 
is relatively low. Furthermore, mtDNA levels showed neither a relationship with 
inflammatory parameters in both patients and healthy volunteers, nor with 
clinical parameters in patients. These findings suggest that the role of mtDNA 
during sepsis and/or systemic inflammation is limited. nDNA might exert 
immunological effects, possibly via binding of PRRs, e.g. RIG-I (retinoic acid-
inducible gene-I) or DAI (DNA-dependent activator of IFN-regulatory factors), 
both cytosolic receptors for double-stranded DNA 10. In turn, activation of this 
inflammatory cascade may result in aggravation of shock and organ damage. 
However, the fact that higher levels of nDNA were found in septic patients than 
in healthy volunteers during endotoxemia, while concentrations of inflammatory 
cytokines were much lower might indicate that the role of nDNA in initiation 
and/or propagation of the inflammatory response is limited as well. This could 
be due to the fact that DAMP-properties of nucleic acids may be dependent on 
the release of other DAMPs, e.g. HMGB1, and that nucleic acids can also affect 
activity of other DAMPs 21. PRRs recognizing nucleic acids are generally present 
intracellularly, and internalization necessary for receptor-binding is stimulated 
by other DAMPs 21. These interactions underline the fact that multiple complex 
processes take place simultaneously in critically ill patients, making it difficult to 
distinguish causality from epiphenomena and unravel underlying mechanisms in 
observational studies.
This study has several limitations we want to acknowledge. First, the control 
group consist of young males, whereas the patient population comprises both 
males and females in a wide age range. With regard to gender, we investigated 
differences between male and female septic patients for all parameters described 
in this study and only found slightly, but statistically significant, higher levels 
of IL-6 and IL-8 on day 3 in women. No differences on other days were found. 
Therefore it is very unlikely that the presence of both men and women in our 
patient population relevantly biased our results. Concerning age, only 4 patients 
of our patient population fell within the age range of the healthy volunteers 
studied. Therefore, we could not analyze differences between young (i.e. those 
with comparable ages as the healthy volunteers) and old patients.
Second, the observational nature of our study does not permit us to draw definite 
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conclusions as to whether there is a causative relation between nDNA levels, 
inflammation, shock, and organ damage. However, in a recent murine study, 
administration of DNAses (to remove free nucleic acids from the circulation) 
resulted in decreased coagulation and inflammation, suppression of organ 
damage, and improved outcome in a cecal ligation and puncture sepsis model 22. 
These findings suggest a detrimental role of nucleic acids in sepsis. 
Third and finally, although statistically significant, the correlations between nDNA 
and markers of inflammation, shock, kidney, and liver damage in septic patients 
were relatively weak. Therefore caution should be taken when interpreting 
these results. The well-known high heterogeneity of septic shock patients might 
contribute to this. 
In conclusion, plasma levels of nucleic acids mtDNA and especially nDNA are 
increased in septic shock patients and healthy volunteers during experimental 
human endotoxemia, and nDNA levels are related with inflammatory cytokines. 
This suggests that nucleic acids, particularly nDNA, are both actively and passively 
released; as a result of inflammation and cell damage, respectively. Furthermore, 
nDNA levels correlate with markers of shock and organ damage in septic shock 
patients. It remains to be determined whether nDNA is merely a marker or directly 
involved in the pathophysiology of septic shock. 
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Abstract
Introduction Innate immunity activation largely depends on recognition of micro-
organism structures by Pattern Recognition Receptors (PRRs). PRR downstream 
signaling results in production of pro- and anti-inflammatory cytokines and other 
mediators. Moreover, PRR engagement in antigen-presenting cells initiates the 
activation of adaptive immunity. Recent studies suggest that for the activation 
of innate immune responses and initiation of adaptive immunity, synergistic 
effects between two or more PRRs are necessary. No systematic analysis of the 
interaction between the major PRR pathways has been performed to date. In this 
study, a systematical analysis of the interactions between PRR signaling pathways 
was performed.
Methods PBMCs derived from ten healthy volunteers were stimulated with either 
a single, or a combination of two PRR ligands. Known ligands for the major PRR 
families were used: Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-
like receptors (NLRs) and RigI-helicases. After 24h incubation, production of TNFα, 
IL-1β, IL-6, and IL-10 was measured in supernatants by ELISA. The consistency 
of the PRR interactions (both inhibitory and synergistic) between the various 
individuals was assessed.
Results and discussion A number of PRR-dependent signaling interactions were 
found to be consistent, both between individuals and with regard to multiple 
cytokines. The combinations of TLR-2 and NOD-2, TLR-5 and NOD-2, TLR-5 and 
TLR-3, and TLR-5 and TLR-9, acted as synergistic combinations. Surprisingly, 
inhibitory interactions between TLR-4 and TLR-2, TLR-4 and Dectin-1, TLR-2 and 
TLR-9 as well as TLR-3 and TLR-2, were observed. These consistent signaling 
interactions between PRR combinations may represent promising targets for 
immunomodulation and vaccine adjuvant development. 
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Introduction
The first step in mounting an appropriate host defense to infection is the 
recognition of pathogens by the innate immune system. This recognition is 
mediated through so-called pattern recognition receptors (PRRs) expressed on 
the cell membrane of cells of the innate immune system 1, 2. The recognition of 
pathogens by PRRs leads on the one hand to the activation of inflammation, or 
innate host defense, and on the other hand to the initiation of adaptive immunity, 
and eventually to immunological memory, as pursued in vaccination strategies.
PRRs recognize Pathogen-Associated Molecular Patterns (PAMPs), conserved 
motifs derived from a broad spectrum of pathogens, including fungi, bacteria, 
parasites, and viruses 1, 2. Hence, these receptors can provide highly specific 
recognition of a vast range of microbes 3. Recognition of a PAMP by a PRR results 
in the activation of the innate immune system via several intracellular signaling 
pathways that are described in more detail elsewhere 4–6. Several major families of 
PRRs have been described to date, including the Toll-like receptors (TLRs), C-type 
lectin receptors (CLRs), NOD-like receptors (NLRs), and RigI-helicases 7–9. TLRs and 
CLRs are present on the cell membrane and in endosomes, while NLRs and RigI-
helicases are intracellular microbial sensors 2, 10.
Important adaptor molecules of the TLR intracellular pathways are MyD88, TRIF, 
TRAM, and MAL/TIRAP 11. Other adaptor molecules such as Syk and Raf-1 (in the 
case of CLRs) or Rip2/RICK (in the case of some NLRs such as NOD1/NOD2) are also 
involved in intracellular signaling 12, 13. PRRs recruit one or more of these adaptor 
molecules in order to provide specific signaling 5. Activation of signaling pathways 
ultimately leads to the production of pro- and/or anti-inflammatory cytokines, 
such as those mediated by the transcription factors nuclear factor κB (NF-κB) and 
activating factor 1 (AP1), that induce production of inflammatory cytokines and 
shape the subsequent adaptive immune response 7, 14, 15.
Previous studies have indicated that some PRRs are able to interact with each 
other, thereby modulating the magnitude and/or type of cytokine production 
with synergistic or inhibitory effects or both 4, 16–18. However, whether these 
interactions are generally embedded in the innate immune system and biologically 
conserved between different individuals is not known. The identification of 
the most consistent PRR interactions would provide insight into the interplay 
of the signaling pathways that modulate cytokine responses in the majority of 
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the individuals in a population, with important consequences for the design of 
vaccine adjuvants. In this study, we investigated signaling interactions between 
several PRRs in order to identify biologically conserved signaling in cytokine 
responses of innate immune cells. Ultimately, this could lead to combinations of 
PRR agonists that can be used as a vaccine adjuvant. 
Materials and Methods
Volunteers
Blood samples were collected from 10 healthy volunteers. After informed consent 
was obtained, blood was collected into 10-ml EDTA tubes (BD, Plymouth, United 
Kingdom).
PBMC isolation and stimulation with PRR ligands
Peripheral blood mononuclear cells (PBMCs) were isolated as described previously 
19. Briefly, a PBMC fraction was obtained by differential centrifugation over Ficoll-
Paque. PBMCs (5 × 105 cells per well) were incubated for 24 h at 37°C in round-
bottom 96-well plates (Cellstar; Greiner Bio-one, Alphen a/d Rijn, the Netherlands) 
with a single ultrapure PRR ligand or a combination of two. RPMI 1640 Dutch 
modification culture medium (Sigma-Aldrich, Zwijndrecht, the Netherlands) was 
used, which was supplemented with 1% gentamicin, 1% l-glutamine, and 1% 
pyruvate (Life Technologies, Nieuwerkerk, the Netherlands). The concentrations 
of the different ultrapure ligands used are based on literature research and 
experience in our laboratory and are described in Table 1. These concentrations 
give a robust but nonmaximal response of most cytokines if used as a single ligand 
to stimulate PBMCs. This allows detection of increases in cytokine production 
upon combination with another ligand. Therefore, the concentrations used are 
suitable to study synergistic or inhibitory effects.
After stimulation, the plates were centrifuged (8 min, 1,700 rpm, room temperature 
[RT]) and the supernatants were collected and stored at −20°C until analysis. The 
stimulation experiments were performed in duplicate, and supernatants from 
duplicate wells were pooled for cytokine determination using enzyme-linked 
immunosorbent assays (ELISA). Each combination of ligands was used with 
PBMCs of 10 different volunteers.
Enzyme-linked Immunosorbent Assay (ELISA)
Cytokine concentrations in culture supernatants were determined using 
commercially available ELISA kits for tumor necrosis alpha (TNF-α) and interleukin-1 
beta (IL-1β) (R&D Systems, Abingdon, Oxfordshire, United Kingdom) and IL-10 
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and IL-6 (Pelikine Compact; Sanquin Reagents, Amsterdam, the Netherlands). The 
measurements were performed according to the manufacturer’s instructions.
Calculations and statistical analysis
The criteria according to which interactions between two specific signaling 
pathways downstream of activated PRRs were considered synergistic or 
inhibitory were defined before the start of the experiments. A “synergistic effect” 
was defined as a cytokine response to a combination of ligands that was at least 
1.5-fold higher than the sum of the cytokine responses induced by each of the 
individual ligands. An “inhibitory effect” was defined as a cytokine response to a 
combination of ligands that was less than or equal to 0.75-fold of the sum of the 
cytokine responses to each of the individual ligands and lower than the cytokine 
response to a single ligand or to both of the ligands. The definitions of both 
synergy and inhibition are further explained in Figure 1. All other patterns were 
designated “no effect/additive effect.”
Figure 1 – Interaction classifications On the y-axis, production of a cytokine is depicted. 
On the x-axis the ligands (A and B) used to stimulate the PBMCs are depicted; PBMCs were 
stimulated either with a single ligand or a combination of two PRR ligands. To identify a 
synergistic effect, the cytokine production after stimulation with both ligands combined should 
be higher than the value of both single effects together. An inhibitory effect was defined as a 
cytokine response to a combination of ligands that was maximally 0.75-fold the sum of the 
cytokine response to either of the individual ligands and lower than the cytokine response to a 
single or both of the ligands. A cytokine production of the combination of stimuli higher than 
in each of the single stimulations, but not higher than the sum of both is considered additive 
and is thus classified as “no effect/additive effect”
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An effect was considered present (biologically conserved) in the majority of the 
healthy volunteers tested if a type of interaction was demonstrated in at least 7 of 
the 10 subjects. If there was more variation between subjects, it was defined as a 
“variable effect.”
The biologically conserved interactions (depicted in red and blue in Figure 2) 
were analyzed statistically using Wilcoxon matched-pair tests. Sums of cytokine 
concentrations after single-ligand stimulations were compared to cytokine 
concentrations after combined stimulations. Differences were considered 
significant if P < 0.05.
Results
Interaction studies
The interactions between different PRR ligands are depicted in Figure 2. An 
inhibitory effect for comparisons of the production of IL-1β, IL-6, and TNF-α 
between TLR-4 and Dectin-1 (significant for IL-1β and IL-6) as well as TLR-3 and 
TLR-2 was found for IL-1β and IL-6. Similar effects were found for combinations of 
TLR-4 and TLR-2 or TLR-2 and TLR-9 induction of IL-1β production.
The combination of TLR-5 and TLR-9 resulted in synergistic effects for IL-1β and IL-6 
production. Furthermore, synergistic effects on IL-1β, IL-6, and IL-10 production 
were observed for the combinations TLR-2 and NOD-2 (significant for IL-10), TLR-
5 and NOD-2 (significant for IL-10), and TLR-5 and TLR-3 (significant for IL-1β). A 
synergistic effect was also found for IL-10 and IL-6 production after stimulation 
of a combination of TLR-3 and NOD-2 or NOD-2 and Dectin-1 (significant for IL-
10). Stimulation of TLR-5 and Dectin-1 resulted in a synergistic effect on IL-10 
production, but other cytokines showed only variable effects.
Of interest, the synergistic effects of TLR-3 and TLR-5 and of TLR-5 and TLR-9 
stimulation mentioned above were observed in at least 9 of the healthy volunteers 
for IL-1β (significant) and IL-10 production and for IL-1β production (significant), 
respectively (Figure 3).
Several PRRs did not interact with others. In particular, mannose-receptor-
dependent induction of cytokine production seemed independent of activation 
of other PRRs.
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Figure 2 – Overview 
interactions PRRs 
Color indicates type of 
interaction in at least seven 
out of 10 of the healthy 
volunteers. ELISA on 
culture supernatants after 
24 hours of stimulation at 
37⁰C with combinations 
of ligands as specified in 
table 1. * indicates p<0.05 
(Wilcoxon matched 
pairs test, comparison 
of cytokine production 
upon stimulation with 
both ligands with sum of 
cytokine production upon 
stimulation with each of 
the ligands separately).    
Red = Synergistic effect
Green = No effect/additive 
effect
Blue = Inhibitory effect
White = Variable effect
Black = Experiment not 
performed
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Figure 3 – Flagellin interactions PBMCs were stimulated for 24 hours with the indicated 
ligands or combinations of ligands and cytokines were measured in the supernatants by ELISA 
(n=10 volunteers) The bars indicate a synergistic interaction of flagellin with CpG or Poly I:C for 
the production of IL-1β. Data are expressed as medians with interquartile range.
* = significantly different (p<0.05) compared with stimulation with single ligands and the sum 
of both single ligands, # = significantly different (p<0.05) compared with no ligand (RPMI) 
(Wilcoxon matched pairs test).
TLR-2/TLR-4 interaction
The results of our study indicate an inhibitory effect between TLR-2 and TLR-
4 for the production of IL-1β. This is in contrast with previous studies 18, 21–25. In 
order to study the interaction between TLR-2 and TLR-4 in more detail, a dose-
response experiment with lipopolysaccharide (LPS) and Pam3Cys was performed. 
Increasing concentrations of LPS or Pam3Cys resulted in increased IL-1β and 
TNF-α production, but the combination of the two ligands showed an inhibitory 
effect (Figure 4), confirming our initial results.
Interindividual variation
In this study, the interactions between PRRs were highly variable between 
subjects. To illustrate the interindividual variation in PRR signaling interactions, 
the interaction between NOD-2 and TLR-4 for the production of TNF-α in all 10 
healthy volunteers is depicted in Figure 5. In most volunteers, muramyl dipeptide 
(MDP)-induced TNF-α production was around 100 to 200 pg/ml. LPS stimulation 
generally resulted in higher levels of TNF-α than MDP stimulation. The response 
to the combination of the two ligands was highly variable between subjects, 
and no effects/additive effects, inhibitory effects, or synergistic effects on TNF-α 
production were observed in the different volunteers.
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Figure 4 – Dose-response LPS + Pam3Cys PBMCs were stimulated for 24 hours with the 
indicated ligands or combinations of ligands and cytokines were measured in the supernatants 
by ELISA (n=2 volunteers). The bars indicate a different concentration of Pam3Cys, while an 
increasing concentration of LPS is depicted on the x-axis. Increasing concentrations of LPS and 
Pam3Cys resulted in increased IL-1β and TNFα production for single ligands, but no synergistic 
production of either IL-1β or TNF-α was observed if LPS and Pam3Cys were combined. Data are 
depicted as medians.
 Discussion
The aims of this study were to systematically investigate the interactions between 
the best-known PRR pathways on the one hand, and to assess the consistency 
of these effects in various individuals on the other hand. Knowledge on the 
consistency of the synergistic combinations of PRR pathways could be used to 
develop novel vaccine adjuvants that would exert their boosting effect during 
vaccination in the vast majority of the individuals in a population. This study 
resulted in the identification of several combinations of PRR ligands that have this 
potential.
A remarkable, yet not entirely unexpected finding of this study is the large 
variability between healthy individuals. This variation can be attributed to many 
factors. One of these is the genetic background of the individuals tested. There 
are many established variations in genes that are known to influence the function 
and downstream effects of PRRs, which could naturally influence the cytokine 
production after stimulation with PRR ligands 26, 27. This interindividual variation 
has important implications with regard to the design of immunotherapeutic 
approaches based on PRR-mediated effects. For the development of vaccine 
adjuvants based on PRR-ligand combinations, only those combinations that 
result in synergistic cytokine production in the majority of the population are 
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likely to be of therapeutic value.
In this respect, in the present report we identify several consistent PRR interactions 
that were present in the majority of individuals tested. The combinations of 
ligands most consistently associated with synergistic effects were NOD-2 and 
TLR-2, NOD-2 and TLR-5, TLR-3 and TLR-5, and TLR-5 and TLR-9. In particular, the 
interaction of TLR-5 with TLR-3 and TLR-9 was remarkably consistent, since it was 
present in at least 9 of the studied volunteers for all the cytokines studied. These 
combinations could therefore represent candidates for the development of novel 
vaccine adjuvants. In the pursuit of identifying novel vaccine adjuvants to activate 
the immune system, synergy for IL-10 production could be disadvantageous, since 
IL-10 is known to have potent anti-inflammatory effects 28. In that respect, the 
combination of TLR-5 and TLR-9 appears also promising, because IL-1β, but not 
IL-10, is produced in a synergistic manner after engagement of these receptors.
In addition to the synergistic effects of some PRR combinations as detailed 
above, a number of biologically conserved inhibitory combinations were also 
documented: TLR-4 and Dectin-1, TLR-3 and TLR-2, TLR-2 and TLR-9, and TLR-4 and 
TLR-2 result in impaired cytokine production. These findings are surprising, as they 
contradict a number of studies published in the literature suggesting additive or 
even synergistic effects of ligands for these receptors. This is particularly true for 
the TLR-4-TLR-2 costimulation 18, 21–25. We have performed additional experiments 
to assess the validity of our observation, and a dose-response experiment with 
LPS and Pam3Cys confirmed our initial findings. The most likely explanation for 
the difference between our findings and those in previous studies is that we have 
used primary human PBMCs, and we assessed the interindividual consistency of 
these stimulations, while previous studies have mostly used either mouse cells or 
human cell lines 18, 21–25.
Next to these observations regarding the consistency of the biological effect 
of PRR-ligand combinations, additional important observations can be made. 
First, the interaction patterns differed substantially between the four measured 
cytokines. There are relatively more combinations of ligands that exhibit synergism 
in the production of IL-10, IL-1β, and IL-6 than of TNF-α. These differences could 
theoretically be due to the existence of (partly) separate signaling pathways for 
these cytokines. It is also conceivable that a pathway leading to production of one 
cytokine is more biologically conserved than that leading to another cytokine.
Second, it appears that there are several main “intracellular highways” which 
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comprise PRRs that preferentially interact with each other. Multiple PRRs within 
one highway effectively influence each other, while PRRs in different highways do 
not appear to interact. The mannose receptor, for example, appears not to interact 
with the signaling pathways of other PRRs and thus can be regarded as an isolated 
highway. Alternatively, our results of mannose-receptor stimulation could have 
been influenced by the very low number of mannose receptors present on the 
surface of monocytes 29. TLR-4 signaling, although to a lesser extent, also appears 
to represent an isolated pathway: when PBMCs are stimulated with LPS, a relatively 
high number of combinations of ligands result in a noninteractive/additive 
cytokine production. In addition to the mannose-receptor and TLR-4 pathways, 
we can also distinguish a group of receptors which appear to show complex 
interactions with each other, that may be considered a “TLR-2-Dectin-1-NOD-
2-TLR-3-TLR-5 highway.” These receptors seem to interact with each other very 
effectively. TLR-9 also seems to be involved in interactions with the intracellular 
pathways from this group of receptors, but specifically for the induction of IL-
1β and IL-6 production, and to a lesser extent for IL-10 and TNF-α production. 
In particular, cytokine responses through dectin-1 signaling are dependent on 
these interactions, since stimulation with β-glucan alone results in very limited 
cytokine production. Therefore, it is possible that dectin-1 signaling is dedicated 
to the regulation and enforcement of the effect of other PRRs, rather than the 
activation of the immune system by itself.
Several limitations apply to our study. First of all, the molecular mechanisms 
behind the interactions described in the present report have not been explored 
and should be evaluated in future studies. These interactions could be the result 
of intracellular interactions between signaling pathways, but they could also be 
regulated via release of soluble regulatory factors such as cytokines. Furthermore, 
altered expression of receptors by (combinations of ) ligands could also confound 
true interaction effects between these receptors. Future studies that focus on the 
use of the herein-identified combinations of ligands as vaccine adjuvants should 
include specific cytokines with specific properties (e.g., IP-10 or interferon [IFN] for 
the TRIF pathway, or potential indicators for Th1 responses) and detailed data on 
dendritic cells and T cell responses. Finally, multiple time points could be included 
in future studies; in particular, information on early responses (4 to 6 h) would be 
helpful.
In conclusion, the present report provides new information with regard to the 
pathway interactions downstream of PRR signaling that lead to the induction 
137
6
Signaling interactions between pattern recognition receptors
of innate host responses and initiate the adaptive immunity. Unraveling 
these signaling cascades not only is vital for the understanding of the innate 
immune system in general, but also could help to identify new targets for 
immunomodulation 3, 30. Furthermore, the consistency of the biological synergistic 
interactions between several combinations of PRRs may be important to the 
field of vaccine adjuvant research 18. Robust activation of the innate immune 
system, subsequently evoking an adaptive immune response involving memory 
T cells, is vital for the effectiveness of a vaccine. Based on the present data, 
specific combinations such as TLR-5/TLR-3 and TLR-5/TLR-9 appear particularly 
promising, as their synergistic interactions were biologically conserved in the 
majority of the individuals tested in the present study population. Therefore, the 
potential of these combinations of ligands as vaccine adjuvants should be further 
explored to improve vaccination strategies. Nevertheless, care should be taken 
that certain ligand combinations do not result in a too-pronounced immune 
response resulting in tissue damage and organ failure. Hence, future studies 
should take into account the balance between the immune response required for 
immunization and potential harmful effects. 
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Abstract 
Background Exogenous administration of mitochondrial DNA (mtDNA) causes 
inflammatory lung injury in a Toll-like receptor (TLR) 9-dependent manner. We 
investigated whether mechanical ventilation results in endogenous release of 
mtDNA and if TLR9 plays a role in the pulmonary inflammatory response induced 
by mechanical ventilation.
Methods Wild-type and TLR9-/- C57bl/6 mice were ventilated with low (8 ml/kg) 
and high (32 ml/kg) tidal volumes for four hours. Levels of nuclear (nDNA) and 
mtDNA in bronchoalveolar lavage fluid as well as pulmonary concentrations of 
KC, IL-1β, and IL-6 were determined.
Results Cytokine and nDNA, but not mtDNA, levels were increased following 
mechanical ventilation with both tidal volumes. Cytokine concentrations were 
similar between wild-type and TLR9-/- mice.
Conclusions Mechanical ventilation does not result in the release of mtDNA and 
TLR9 is not involved in mechanical ventilation-induced inflammation.
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Introduction
Mechanical ventilation (MV) is an essential part of perioperative and intensive 
care medicine. However, MV can induce an inflammatory response in the lungs 
which compromises pulmonary function, and can result in organ dysfunction 1, 
2. Danger Associated Molecular Patterns (DAMPs) originating from injured or 
dead cells, or from the extracellular matrix are implicated in the pathogenesis 
of MV-induced inflammation and lung injury 3, 4. Possible mechanisms behind 
the release of DAMPs in this setting include stretch due to cyclic opening and 
closing of alveoli and/or direct tissue damage resulting from volu-or barotrauma. 
Mitochondrial DNA (mtDNA) is a DAMP that causes inflammatory lung injury in a 
Toll-like receptor (TLR) 9-dependent manner when administered exogenously in 
the lungs or circulation of rats and mice 5, 6. Furthermore, acid aspiration in mice 
results in profound increase in mtDNA levels in bronchoalveolar lavage (BAL) 
fluid 7. In the present study, we investigated whether MV with low or high tidal 
volumes results in endogenous release of mtDNA and if TLR9 plays a role in the 
MV-induced pulmonary inflammatory response. 
Methods
All experiments were approved by the Regional Animal Ethics Committee in 
Nijmegen. The study has been conducted in a manner that does not inflict 
unnecessary pain or discomfort upon the animals, as outlined by the United States 
Public Health Service Policy on Humane Care and Use of Laboratory Animals and 
the Guide for the Care and Use of Laboratory Animals (1996), prepared by the 
National Academy of Sciences’ Institute for Laboratory Animal Research.
Animals
Age-matched male wild-type C57Bl/6 mice and TLR9-deficient (TLR9-/-) mice 
with a C57Bl/6 background, aged 8 to 14 weeks, weighing 25±4 g were used 
in this study (n=8 per group). Wild-type mice were purchased from Charles 
River laboratories (Leiden, the Netherlands), TLR9-/- mice were obtained from S. 
Akira (Department of Host Defense, Osaka University, Osaka, Amsterdam). The 
mice were housed in a light- and temperature-controlled room under specific 
pathogen-free (SPF) conditions. Standard pelleted chow (SSNIFF Spezialdiäten 
GmbH, Soest, Germany) and drinking water were available ad libitum. Eight mice 
per group were used. 
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Experimental procedures
Mice were anaesthetized using an intraperitoneal injection of 7.5 µl per gram body 
weight of KMA mix (25.5 mg/ml ketamine, 40 µg/ml medetomidine, 0.1 mg/ml 
atropine in saline). Subsequently, the animals were intubated and mechanically 
ventilation was performed using a tidal volume of 8 mL/kg at a frequency of 
170 breaths per minute using a MiniVent ventilator (Hugo Sachs Elektronik-
Harvard Apparatus, March-Hugstetten, Germany) or a tidal volume of 32 mL/kg 
at a frequency of 40 breaths per minute using a Ugo Basile UB7025 ventilator 
(Hugo Sachs Elektronik-Harvard Apparatus, March-Hugstetten, Germany). 
Lipopolysaccharide (LPS) was measured in the mechanical ventilation circuit by 
the Limulus Amebocyte Lysate assay (Cambrex Bio Science, Walkersville, MD, USA; 
detection limit: 0.06 IU/ml) to rule out LPS-induced pulmonary inflammation. All 
animals received 1.5 cm H2O positive end-expiratory pressure (PEEP), and fraction 
of inspired oxygen was set to 0.4. In order to maintain anaesthesia, boluses of 
5.0 µl per gram body weight maintenance KMA mix (3.6 mg/ml ketamine, 4 µg/
ml medetomidine, 7.5 µg/ml atropine in saline) were given every 30 min via an 
intraperitoneally placed catheter. Rectal temperature was monitored continuously 
and maintained between 36.0°C and 37.5°C using a heating pad. After the four-
hour ventilation period, mice were sacrificed by exsanguination. Control mice 
were anaesthetized, but not ventilated, and sacrificed shortly after induction of 
anaesthesia. 
Sample collection and analysis
In wild-type mice, bronchoalveolar lavage (BAL) was performed immediately 
before sacrifice by rinsing the lung with 600 μL of sterile saline via the 
endotracheal tube. BAL fluid was immediately centrifuged at 1,600xg at 4⁰C for 
10 minutes. The supernatant was centrifuged again at 16,000xg at 4⁰C for 10 
minutes to remove potential remaining cells and debris and stored at -80˚C until 
further analysis. DNA isolation and quantification of nuclear DNA (nDNA) and 
mitochondrial DNA (mtDNA) by quantitative PCR was performed as described 
previously 8 using the following primer pairs (obtained from Biolegio, Nijmegen, 
the Netherlands): nDNA (GAPDH): Forward 5’-GCTATCTCATGTTCTTCAGAGTGG-3’, 
Reverse 5’-TACCTTTGTTGTGGTACGTGCATA-3’. mtDNA: forward 
5’-AATCGCACATGGCCTCACAT-’3 and reverse 5’-GAAGTCCTCGGGCCATGATT-’3. 
Samples were analyzed in duplicate and a fresh aliquot of DNA isolated from 
lung tissue homogenate of a non-ventilated mouse was used in each plate as a 
calibrator (between-plate CV% of 0.47% (GAPDH) and 0.36% (mtDNA)). BAL nDNA 
and mtDNA quantities are expressed as fold change relative to the expression of 
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the same gene in the calibrator sample. 
For pulmonary cytokine determination, lung tissue from separate groups of wild-
type and TLR9-/- mice was snap-frozen and stored at -80˚C, after which samples 
were homogenized in Tissue Protein Extraction Reagent (T-PER; Thermo Scientific, 
Rockford, USA) supplemented with complete EDTA-free protease inhibitor 
cocktail tablets (Roche Applied Science, Almere, The Netherlands) using the 
GentleMACS dissociater (Miltenyi Biotec, Leiden, The Netherlands). Homogenates 
were centrifuged (10 min, 16,000g, 4°C), and the supernatant was stored at −80°C 
until cytokine analysis. keratinocyte-derived chemokine (KC, murine equivalent of 
human interleukin (IL)-8) was determined using ELISA (R&D Systems, Minneapolis, 
MN, USA), IL-1β using a radioimmunoassay (RIA) as described previously 9, and IL-
6, IL-10, and Tumor Necrosis Factor alpha (TNF-α) using a simultaneous Luminex 
assay (Milliplex, Millipore, Billerica, MA, USA). Cytokine concentrations were 
normalized to total protein content determined by bicinchoninic acid assay (BCA 
Protein Assay, Life Technologies, Bleiswijk, the Netherlands).
Statistical analysis
Data were not normally distributed, as determined by Shapiro-Wilk tests. 
Differences between groups were analyzed using Kruskal-Wallis and Dunn’s post-
hoc tests. Statistical analysis was performed using Graphpad Prism 5 software 
(Graphpad Software, La Jolla, USA). P-values <0.05 were considered significant. 
Results 
Levels of nDNA, but not of mtDNA were increased after MV with tidal volumes of 
8 or 32 mL/kg compared with unventilated control mice (Figure 1). 
Furthermore, MV with both tidal volumes resulted in increased pulmonary 
concentrations of KC, IL-1β, and IL-6, all important cytokines in the MV-induced 
inflammatory response 10. MV did not result in increased levels of IL-10 and 
TNF-α. Furthermore, no differences in pulmonary cytokine concentrations were 
observed between wild-type and TLR9-/- mice (Figure 2).
Discussion 
This study demonstrates that MV with either low or high tidal volumes does not 
result in mtDNA release into the pulmonary compartment. In accordance with 
this finding, TLR9 does not play a role in the MV-induced inflammatory response. 
Nevertheless, the finding of increased levels of nDNA, a marker for cell damage 
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and/or general DAMP release 8, supports previous findings that DAMPs may play 
a role in the MV-induced inflammatory response 3, 4. The fact that we did not find 
increased mtDNA levels while these have been reported in patients with, and 
animal models of sepsis, trauma, and cardiac arrest could be explained by the 
different mechanisms of cell damage (mechanical stretch or disruption of the cell 
membrane by baro/volutrauma versus crush damage or ischemia of cells) 8, 11-15 
Furthermore, the difference between MV-induced nDNA and mtDNA levels in our 
study suggests different mechanisms of release and/or clearance, which remain 
to be unraveled.
 
Figure 1 – Nucleic acids in BAL fluid of wild-type mice nDNA (A) and mtDNA (B) levels in BAL 
fluid. Data (n=8 per group) are expressed as median±IQR fold change (relative to a calibrator 
sample). * represents p<0.05 compared with the unventilated control group.
Figure 2 – Cytokines in lung homogenates of wild-type and TLR9-deficient mice KC (A), 
IL-1β (B), and IL-6 (C) concentrations in lung tissue homogenates. Data (n=8 per group) are 
expressed as median±IQR pg/mg of total protein. * represents p<0.05 compared with the 
corresponding unventilated control group.
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Abstract
Purpose Mechanical ventilation can cause ventilator-induced lung injury, 
characterized by a sterile inflammatory response in the lungs resulting in 
tissue damage and respiratory failure. The cytokine IL-1β is thought to play an 
important role in the pathogenesis of ventilator-induced lung injury. Cleavage 
of the inactive precursor pro-IL-1β to form bioactive IL-1β is mediated by several 
types of proteases, of which caspase-1, activated within the inflammasome, is 
most important. Herein, we studied the roles of IL-1β, caspase-1, and neutrophil 
factors in the mechanical ventilation-induced inflammatory response in mice.
Methods Untreated wild-type, IL-1αβ knockout and caspase-1 knockout mice, 
pralnacasan (a selective caspase-1 inhibitor)-treated mice, anti-KC-treated mice, 
and cyclophosphamide neutrophil-depleted wild-type mice were ventilated 
using clinically relevant ventilator settings (tidal volume 8 ml/kg). Lungs and 
plasma were collected to determine blood gas values, cytokine profiles and 
neutrophil influx.
Results Mechanical ventilation resulted in increased pulmonary concentrations 
of IL-1β and KC and increased pulmonary neutrophil influx compared with 
non-ventilated mice. Ventilated IL-1αβ knockout mice did not demonstrate this 
increase in cytokines. No significant differences were observed between wild-
type and caspase-1 deficient or pralnacasan-treated mice. In contrast, in anti-KC 
antibody treated mice and neutropenic mice, inflammatory parameters were 
decreased in comparison with ventilated non-treated mice.
Conclusions Our results illustrate that IL-1 is indeed an important cytokine in 
the inflammatory cascade induced by mechanical ventilation. However, the 
inflammasome/caspase-1 appears not to be involved in IL-1β processing in this 
type of inflammatory response. The attenuated inflammatory response observed 
in ventilated anti-KC treated and neutropenic mice suggests that IL-1β processing 
in mechanical ventilation-induced inflammation is mainly mediated by neutrophil 
factors.
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Introduction
Mechanical ventilation is a life-saving therapy, although it can also cause 
ventilator-induced lung injury (VILI) 1. VILI is characterized by a sterile inflammatory 
response in the lungs resulting in tissue damage that may sustain respiratory 
failure. The mechanical ventilation-induced inflammatory response can also 
spread systemically, which in severe cases can result in multi organ dysfunction 
syndrome (MODS) 2. Even protective ventilation strategies that do not cause 
direct mechano-induced tissue damage (baro- or volutrauma) have been shown 
to elicit the release of pro-inflammatory cytokines, recruitment of leukocytes, 
and subsequent lung injury 3, 4. The mechanisms behind this so-called ‘biotrauma’ 
have not yet been completely elucidated. 
Previous studies have demonstrated that the TLR4/TRIF pathway is important in 
the mechanical ventilation-induced inflammatory response 4, 5. Furthermore, it is 
becoming increasingly clear that the pro-inflammatory cytokine interleukin-1β 
(IL-1β) plays a key role in the pathogenesis of the inflammatory response and 
VILI by promoting neutrophil recruitment and by increasing epithelial injury and 
permeability 6-8. Through recognition by the IL-1 receptor (IL-1R), secreted IL-1β, 
but also the cell-associated family member IL-1α, may stimulate production of 
other inflammatory cytokines via IL-1R-associated kinases (IRAKs) and thereby 
positively amplify the inflammatory response 9. However, up till now this has not 
been studied in the context of mechanical ventilation-induced inflammation. 
Upon activation of the innate immune system, e.g. via TLRs, IL-1β is synthesized as 
an inactive precursor molecule, pro-IL-1β, that cannot bind and activate the IL-1R 
10. In order to process pro-IL-1β and form bioactive IL-1β, proteolytic cleavage of 
the N-terminal 116 amino acids from the precursor is required. Caspase-1 is the 
major protein implicated in cleavage of pro-IL-1β 10, 11. 
Caspase-1 exists as an inactive zymogen in cells of myeloid origin (e.g. tissue 
macrophages, dendritic cells) which needs to be activated to perform its proteolytic 
tasks 9. Caspase-1 is also known to be expressed in a wide range of other cell types 
including lung fibroblasts and epithelial cells 12, 13. The inflammasome is a protein 
platform that is responsible for the activation of caspase-1 10, 14. A broad range of 
infectious and autoimmune diseases that involve IL-1β have been associated with 
inappropriate activation of the inflammasome 12, 14, 15, while in several other disease 
models in which IL-1β plays a crucial role, the inflammasome appears not to be 
involved 16, 17. IL-1β processing in these models might rely on neutrophil serine 
proteases, like elastase, granzyme A, cathepsin G or proteinase-3 10, 18-20. Hitherto, 
the role of caspase-1 in processing of IL-1β in the mechanical ventilation-induced 
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inflammatory response is unknown.
We studied the roles of IL-1β, caspase-1, and neutrophil factors in the mechanical 
ventilation-induced inflammatory response in mice ventilated with clinically 
relevant ventilator settings.
 
Materials and methods
All experiments were approved by the Regional Animal Ethics Committee in 
Nijmegen and performed under the guidelines of the Dutch Council for Animal 
Care and the National Institutes of Health. They have therefore been performed 
in accordance with the ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments.
Animals
Age-matched wild-type C57Bl/6 mice and extensively backcrossed caspase-1 
knockout mice or IL-1αβ knockout mice (aged 8-14 weeks, weight 25±4 grams) 
with C57Bl/6 background were used in this study. The mice were housed in a light 
and temperature controlled room under specific pathogen-free (SPF) conditions. 
Standard pelleted chow (1.00 % Ca; 0.22 % Mg; 0.24 % Na; 0.70 % P; 1.02 % K; 
SSNIFF Spezialdiäten GmbH, Soest, Germany) and drinking water were available 
ad libitum. These conditions are similar to previous studies in which this mouse 
model was used 4, 5, 21, 22. 
Experimental design 
IL-1αβ knockout experiments
IL-1 can induce inflammation via activation of the IL-1 receptor. To study whether 
IL-1 is indeed involved in initiation and/or propagation of the inflammatory 
cascade induced by mechanical ventilation, mechanically ventilated IL-1αβ-/- 
mice (n=8) were compared with ventilated wild-type mice (n=8). As controls, non-
ventilated IL-1αβ-/- (n=8) and wild-type mice (n=8) were used.
Caspase-1 experiments
Caspase-1 is able to cleave the inactive precursor pro-IL-1β to form the active 
cytokine IL-1β. To study the role of caspase-1 in the mechanical ventilation-
induced inflammatory response, mechanically ventilated caspase-1 knockout 
mice (n=8) and ventilated wild-type mice treated with the selective caspase-1 
inhibitor pralnacasan (100 mg/kg) (n=8) were compared with ventilated untreated 
wild-type mice (n=8) 23, 24. As controls, non-ventilated caspase-1-/-, pralnacasan-
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treated wild-type and untreated wild-type mice (n=8 per group) were used. 
Anti-KC antibody experiments
Apart from caspase-1, neutrophil serine proteases are also able to process IL-1β. In 
order to investigate whether the attraction of neutrophils by the chemo-attractant 
KC is involved in the inflammatory response elicited by mechanical ventilation, 
mechanically ventilated wild-type mice treated with an intraperitoneal dose of 
100 µg of a neutralizing monoclonal anti-KC antibody (R&D systems, Minneapolis, 
MN, USA) 1 hour before induction of anaesthesia (n=8) were compared with 
ventilated untreated wild-type mice (n=8). As controls, non-ventilated untreated 
wild-type mice (n=8) were used.
Neutrophil depletion experiments
Neutrophil serine proteases are able to process IL-1β. In order to study the possible 
role of neutrophil factors in IL-1β processing in the mechanical ventilation-
induced inflammatory response, mechanically ventilated neutrophil-depleted 
wild-type mice (n=8) were compared with ventilated untreated wild-type mice 
(n=8). As controls, non-ventilated wild-type mice (n=8) were used.
The neutrophil-depleted group was neutrophil-depleted with cyclophosphamide 
as described previously 25, 26.
Experimental procedures
Mice were anaesthetized using an intraperitoneal injection of 7.5 µl per gram 
body weight of KMA mix (25.5 mg/ml ketamine, 40 µg/ml medetomidine, 0.1 mg/
ml atropine in saline). Subsequently, animals were orally intubated, an arterial 
line was placed in the arteria carotis, and the mice were mechanically ventilated 
(MiniVent®, Hugo Sachs Elektronik-Harvard apparatus, March-Hugstetten, 
Germany). The ventilation settings used were based on measured tidal volume 
and respiratory rate during spontaneous ventilation in C57Bl/6 mice 27: a tidal 
volume of 8 ml/kg body weight and a frequency of 150/min. All animals received 
4 cm H2O positive end-expiratory pressure (PEEP) and fraction of inspired oxygen 
was set to 0.4. In order to maintain anaesthesia, boluses of 5.0 μl per gram body 
weight maintenance KMA mix (3.6 mg/ml ketamine, 4 µg/ml medetomidine, 7.5 
µg/ml atropine in saline) were given every 30 minutes via an intraperitoneally 
placed catheter. Rectal temperature was monitored continuously and maintained 
between 36.0⁰C and 37.5⁰C using a heating pad. After the 4 hour ventilation 
period, mice were sacrificed by exsanguination under anaesthesia. The control 
mice were anesthetized, but not ventilated and sacrificed shortly after induction 
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of anaesthesia. Tissue and blood were sampled in order to determine blood gas 
values (only in ventilated mice), cytokine production and neutrophil influx.
Lipopolysaccharide (LPS) was measured in the mechanical ventilation circuit 
by Limulus Amebocyte Lysate testing (Cambrex Bio Science, Walkersville, MD; 
detection limit: 0.06 IU/ml) to rule out contamination and LPS-induced pulmonary 
inflammation.
 
Tissue harvesting
Plasma was isolated by centrifugation at 13000xg for 5 min and stored at -80⁰C. 
Immediately after exsanguination, heart and lungs were carefully removed en 
block via midline sternotomy. The right middle lung lobe was fixed in 4% buffered 
formalin solution overnight at room temperature. The right lung was snap frozen 
in liquid nitrogen and stored at -80⁰C. The left lung was snap-frozen and placed 
in 500 μL lysis buffer containing PBS, 0.5% triton X-100 and protease inhibitor 
(complete EDTA-free tablets, Roche, Woerden, The Netherlands). Subsequently, 
the lungs were homogenized using a polytron and subjected to two rapid freeze-
thaw cycles using liquid nitrogen. Finally, homogenates were centrifuged (10 
minutes, 16000xg, 4 °C) and the supernatant was stored at -80° C until further 
analysis.
Pulmonary neutrophil influx
After overnight incubation in 4% buffered formalin solution, the right middle 
lung lobe was dehydrated, and embedded in paraplast (Amstelstad, Amsterdam, 
The Netherlands). Sections of 4 µm-thickness were used. Enzyme histochemistry 
using chloracetatesterase (LEDER staining) was used to visualize the enzyme 
activity in the neutrophils. Neutrophils were counted manually (10 fields per 
mouse), and after automated correction for air/tissue ratio, the average number 
of neutrophils/cm2 per mouse was calculated.
Biochemical analysis
KC (keratinocyte-derived chemokine, murine equivalent of human IL-8) in lung 
homogenate was determined by enzyme-linked-immunosorbent assay (ELISA) 
(R&D Systems, Minneapolis, MN, USA). Lower detection limit: 160 pg/ml. IL-
1β in lung homogenate was determined using a radioimmunoassay (RIA) as 
described previously 28. In samples of the IL-1αβ (Figure 1) and caspase (Figure 
2) experiments, total protein concentrations in the lung homogenates were 
determined using a BCA protein assay (Thermo Fisher Scientific, Etten-Leur, The 
Netherlands) and cytokine concentrations in the homogenates were normalized 
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for protein concentration and therefore expressed as ng cytokine/µg protein. 
In anti-KC (Figure 3) and neutrophil depletion (Figure 4) experiments, cytokine 
concentrations in lung homogenate were not normalized for total protein content 
due to insufficient sample volume, and therefore expressed as pg/mL. 
Statistical analysis
Data were not normally distributed (determined using Kolmogorov-Smirnov 
and Shapiro-Wilk tests) and therefore expressed as median and range or median 
and interquartile range [IQR]. Differences between groups were analyzed using 
Kruskal-Wallis and Dunn’s post-hoc tests. Statistical analysis was performed using 
Graphpad Prism 5 software (Graphpad Software, La Jolla, USA). P-values < 0.05 
were considered significant. 
 
Results
Mean arterial pressure remained stable and above 65 mmHg in all animals 
throughout the mechanical ventilation period. Blood gas values that were 
obtained at the end of the ventilation period did not indicate substantial lung 
injury (Table 1).
Median IQR
pH 7.36 7.25 – 7.38
PCO2 4.73 4.17 – 5.18
PO2 15.3 14.6 – 17.5
BE -5.5 -7.3 – -4.0
HCO3 20.2 18.3 – 20.7
TCO2 21.0 19.8 – 21.5
sO2% 99% 98 – 99
Lactate 0.98 0.90 – 1.16
Table 1 – Blood gas values after 4 
hours of ventilation Values (median 
and interquartile range [IQR]) from 
a representative ventilated group 
(wildtype ventilated mice used as the 
control group for caspase-1-/- and 
pralnacasan-treated mice). 
Chapter 8
162
Involvement of caspase-1 in the mechanical ventilation-induced 
inflammatory response
Pulmonary neutrophil influx was significantly increased in mechanically 
ventilated mice compared with non-ventilated wild-type and caspase-1-/- mice, 
but no differences were observed between wild-type mice, caspase-1-/- mice 
or pralnacasan-treated mice. Similar to the results described above, 4 hours of 
mechanical ventilation resulted in increased IL-1β and KC concentrations in lung 
homogenates in all groups. However, no significant differences in lung cytokine 
levels were observed between wild-type mice, caspase-1-/- mice or pralnacasan-
treated mice. (Figure 2) 
Involvement of neutrophil factors in the mechanical ventilation-induced 
inflammatory response 
To determine whether neutrophil factors are involved in the mechanical 
ventilation-induced inflammatory response and IL-1β processing, we investigated 
the effects of treatment with an antibody against KC. KC is one of the major factors 
involved in neutrophil attraction to the site of inflammation (chemo-attractants). 
Mechanical ventilation resulted in increased levels of pulmonary neutrophils 
Figure 1 – Involvement of IL1 in the 
mechanical ventilation-induced 
inflammatory response KC levels 
in lung homogenates expressed as 
nanogram cytokine per microgram total 
protein. Data are expressed as box-and-
whiskers plots, with min to max range 
as whiskers. Results of analysis in non-
ventilated (C) and ventilated (V) wild-
type (WT) mice and IL1αβ knock-out (-/-) 
mice are shown. 
Involvement of IL1 in the mechanical ventilation-induced inflammatory 
response
After 4 hours of mechanical ventilation, pulmonary levels of pro-inflammatory 
cytokine KC were significantly increased in wild-type mice compared with non-
ventilated wild-type mice. In contrast, ventilated IL-1αβ knockout mice did not 
show an increase in pulmonary cytokines compared with non-ventilated IL-1αβ 
knockout mice (Figure 1).
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Figure 2 – Involvement of caspase-1 in the mechanical ventilation-induced 
inflammatory response Pulmonary neutrophil counts, expressed as number of neutrophils 
per cm2 tissue and IL-1β and KC levels in lung homogenates, expressed as nanogram cytokine 
per microgram total protein. Data are expressed as box-and-whiskers plots, with min to max 
range as whiskers. Results of analysis in non-ventilated (C) and ventilated (V) wild-type (WT) 
mice, caspase-1 knock-out (-/-) mice and pralnacasan-treated mice are shown. 
(Figure 3). This increase was abrogated by pre-treatment with an anti-KC antibody. 
Furthermore, the mechanical ventilation-induced increase in pulmonary IL-1β 
levels was less pronounced in anti-KC-treated mice compared with untreated 
mice, although this did not reach statistical significance (Figure 3). 
To further confirm the role of neutrophil factors, we investigated the effects of 
mechanical ventilation following neutrophil depletion using cyclophosphamide. 
The effect of cyclophosphamide was visually inspected and no pulmonary 
neutrophils were present (data not shown). As depicted in Figure 4, the mechanical 
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Figure 4 – Effects of neutrophil depletion on the mechanical ventilation-induced 
inflammatory response IL-1β and KC concentrations expressed as pg cytokine/ml lung 
homogenate, measured in non-ventilated (C) and ventilated (V) untreated wild-type (WT) 
and cyclophosphamide-treated neutrophil-depleted mice. Data are expressed as box-and-
whiskers plots, with min to max range as whiskers. 
ventilation-induced increase in pulmonary IL-1β and KC concentrations was 
diminished in neutrophil-depleted mice. 
Our hypothesis regarding the role of IL-1β processing in the inflammatory 
response following mechanical ventilation is illustrated in Figure 5.
 
Figure 3 – Involvement of KC in the mechanical ventilation-induced inflammatory 
response Pulmonary neutrophil counts, expressed as number of neutrophils per cm2 tissue 
and IL-1β concentration expressed as pg cytokine/ml lung homogenate. Data are expressed 
as box-and-whiskers plots, with min to max range as whiskers. Pulmonary neutrophils and IL-
1β concentration in non-ventilated (C) and ventilated (V) untreated wild-type mice (WT) and 
anti-KC antibody treated wild-type (anti-KC) mice are shown. 
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Discussion
Consistent with previous results published by our group 4, 5, 22 and others 29, 30 the 
present study shows that mechanical ventilation using clinical relevant settings 
induces a pulmonary inflammatory response in mice. In addition, our data is in 
support of previous findings that IL-1 plays an important role in initiation and/or 
propagation of the mechanical ventilation-induced inflammatory response, and 
suggests that processing of IL-1β in mechanical ventilation-induced inflammation 
occurs via the release of neutrophil factors and not through caspase-1-dependent 
mechanisms. 
Our finding that caspase-1 does not play a significant role in mechanical 
ventilation-induced inflammation is in contrast to a recent study where the NLRP3 
inflammasome was found to play an important role in the mechanical ventilation-
induced inflammatory response and VILI 31. Several differences between their 
study and ours might explain the different results. First, in the previous study, 
ASC and NLRP3 (components of the inflammasome upstream of caspase-1) 
knockout mice were used and it was shown that mechanical ventilation activated 
caspase-1 in a NLRP3-dependent fashion. Nevertheless, it is very well possible 
that ASC and NLRP3 play other roles in the mechanical ventilation-induced 
inflammatory cascade than merely activating caspase-1. As abrogation and 
inhibition of caspase-1 by either a knockout approach or pralnacasan treatment 
did not have any effect in our model, the role of caspase-1/the inflammasome 
appears not to be as crucial as suggested. Second, differences between wildtype 
and ASC or NLRP3 knockout were only found at a high tidal volume of 15 ml/
kg, known to cause extensive lung damage 22, while no effects were found 
at a low tidal volume of 7.5 ml/kg, which is more representative of the current 
clinical practice and similar to that used in the present study. This suggests that 
the inflammasome might play a more important role at higher tidal volumes 
which lead to apparent lung injury but not in mechanical ventilation-induced 
inflammation at clinically relevant ventilator settings. Interestingly, a more recent 
study from the same group showed that pre-treatment with allopurinol or uricase 
(both degraders of known inflammasome-activating factors 32 did not decrease 
mechanical ventilation-induced inflammation, which is in support of a caspase/
inflammasome-independent mechanism 33. As beneficial effects of uricase and 
allopurinol were observed in terms of alveolar barrier dysfunction, it appears 
plausible that ASC and NLRP3 are involved in VILI via inflammation-independent 
mechanisms. 
The pronounced influx of neutrophils in the lung observed in our experiments 
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Figure 5 – Hypothesis regarding the role of IL-1β processing in the inflammatory 
response following mechanical ventilation. We present the following hypothesis based on 
our results and previous findings. Mechanical ventilation causes mechanotransduction and 
cell and/or tissue damage. This causes the release of DAMPs (Danger Associated Molecular 
Patterns), that activate TLR4 and possibly other pattern recognition receptors. Ligation of 
these receptors induces production of cytokines, most importantly IL-1β. Subsequently, KC is 
produced, leading to neutrophil recruitment to the lungs. Pro-IL-1β processing to bioactive IL-
1β could occur intracellularly by caspase-1, although in our model, it only plays a minor role 
in IL-1β bioactivation, not excluding that it may be involved at the onset of the inflammatory 
process, when very few neutrophils are present. The majority of pro-IL-1β is excreted in the 
inactive form and then cleaved by factors released by neutrophils, such as neutrophil serine 
proteases. Finally, active IL-1β present extracellularly binds to the IL-1R, which in turn leads 
to the production of more cytokines and hence, positive amplification of the inflammatory 
response. As such, a positive feedback loop is activated which could be an explanation for the 
extensive inflammatory response observed following mechanical ventilation. 
Numbers 1 to 4 represent the experiments performed in this study and correspond to the figure 
numbers in this paper. References 4 and 22 refer to previous studies performed by our group.
suggests a major role for these inflammatory cells in the inflammatory cascade 
following mechanical ventilation. Our findings that treatment with an antibody 
against KC or depletion of neutrophils reduced the mechanical ventilation-
induced production of IL-1β and KC indicate an important role for neutrophils in 
initiation and/or propagation of the inflammatory response. In this respect, pro-
IL-1β cleavage in our model is probably achieved through neutrophil factors, such 
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as the serine proteases proteinase-3 (PR-3), elastase or cathepsin G, leading to 
bioactive IL-1β and propagation of the inflammatory response through binding 
of the IL-1-receptor, which in turn leads to production of other inflammatory 
cytokines such as KC 10, 34, 35. Several other IL-1β mediated inflammatory responses 
are described to be partly or completely independent of the inflammasome and 
caspase-1, and possibly dependent on neutrophil factors, including proteinase 
3 and cathepsin G 35. Future studies should focus on the confirmation of our 
hypothesis and the identification of these neutrophil factors.
Our study has several limitations. First, we used cyclophosphamide to deplete 
neutrophils. While this is a widely used method25, 26, 36, 37, cyclophosphamide 
treatment may also result in depletion of other cell types that play a role in 
mechanical ventilation-induced inflammation 38, 39. Nevertheless, our data of 
mice treated with an anti-KC antibody underline the importance of neutrophils 
in this process. Second, no histological slides to perform neutrophil counts were 
collected in the IL-1αβ-/- experiments to investigate whether these knockout mice 
were still able to recruit neutrophils. Finally, we can not exclude the possibility that, 
next to mechanical ventilation, the procedures related to the instrumentation/
ventilation (e.g. intubation, arterial cannulation) also induce inflammation to 
a certain extent. However, we have previously shown that the inflammatory 
response is aggravated when mice are ventilated with these parameters for a 
longer period of time or when higher tidal volumes are used, suggesting that the 
inflammatory response is mainly ventilation-induced. 
In conclusion, our results indicate that IL-1 signaling is important in mechanical 
ventilation-induced inflammation. We show that following mechanical ventilation, 
IL-1β bioactivation is not caspase-1 dependent, but appears to be mediated by 
neutrophil factors, leading to a positive amplification loop and further propagation 
of the inflammatory response. Further elucidation of the precise mechanism of 
IL-1β processing in mechanical ventilation-induced inflammation could provide 
novel targets for the future treatment of VILI 40. 
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Abstract
Background Both the initial trauma and the subsequent hemodynamic 
instability may contribute to intestinal damage, which is of great importance 
in (immunological) post-trauma complications. The study assesses intestinal 
damage using the biomarker intestinal Fatty Acid Binding Protein (iFABP) in 
trauma patients during the first days of their hospital admission and the risk 
factors involved.
Methods Plasma iFABP levels were measured in blood samples obtained from 
adult multiple trauma patients (n=93) at the trauma scene by the helicopter 
emergency medical services (HEMS), at arrival at the emergency room (ER), 
and at days 1, 3, 5, 7, 10, and 14 after trauma and related to injury severity and 
hemodynamic parameters.
Results Plasma iFABP concentrations showed highest levels immediately following 
trauma at time points HEMS and ER. Non-survivors demonstrated higher iFABP 
levels at the ER compared with survivors. Furthermore, iFABP values at the ER 
correlated with ISS and patients suffering from abdominal trauma demonstrated 
significantly higher iFABP concentrations in comparison to patients with other 
types of trauma or healthy controls. Also, patients presenting with a MAP <70 
mmHg at the ER, demonstrated significantly higher plasma iFABP concentrations 
in comparison with patients with a normal (70-99 mmHg) or high (>100 mmHg) 
MAP, or healthy controls. Finally, patients with a low Hb (<80% of reference value) 
displayed significantly higher iFABP concentrations in comparison with patients 
with a normal Hb or healthy controls.
Conclusions Plasma iFABP levels, indicative of intestinal injury, are increased 
immediately after trauma in patients with abdominal trauma, low MAP, or low 
Hb, and are related to the severity of the trauma. As intestinal injury is suggested 
to be related to late complications, such as MODS or sepsis in trauma patients, 
strategies to prevent intestinal damage following trauma could be of benefit to 
these patients. 
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Introduction
Trauma is one of the main causes of death worldwide. In 2000, 9% of deaths and 
12% of disease burden could be attributed to trauma. Moreover, 50% of trauma-
related deaths are young people between the ages of 15 and 44 years 1, 2. Roughly, 
trauma deaths can be divided into two types. Early deaths can be attributed to the 
direct effect of trauma, such as blood loss or neurological damage. Late mortality 
on the other hand, is to an important extent due to complications secondary to 
the trauma 3, 4.
Among other organ systems, the digestive system is affected by the trauma. Direct 
abdominal trauma, ischemia induced by hemodynamic insufficiency, or a systemic 
inflammatory response can result in intestinal damage. Mesenteric ischemia has 
high mortality numbers and is very difficult to diagnose in an early stage 5. One 
of the deleterious consequences of intestinal damage is altered gut permeability, 
which can result in translocation of bacteria 6, 7. The transit of bacteria through 
the intestinal wall can subsequently lead to a hyperinflammatory response, and 
ultimately, multi organ dysfunction syndrome (MODS) 7, 8. 
Intestinal Fatty Acid Binding Protein (IFABP) is a protein exclusively expressed by 
enterocytes. It is released into the circulation following enterocyte damage and 
has shown to be a good marker for the early identification of intestinal ischemia 
and damage 9, 10. 
Although previous studies have demonstrated increased intestinal permeability 
to be related to trauma severity 9, 11, 12, the timeframe in which this intestinal 
damage occurs remains unknown. Moreover, it has been described that the 
presence of shock could induce intestinal damage. However, it remains unclear 
whether this effect is attributable to low hemoglobin levels due to hemorrhage 
or low blood pressure, or both. The aim of this study was to assess the temporal 
relationship between trauma and intestinal damage using the biomarker iFABP 
during the first days of hospital admission, and to determine which factors play a 
role in the development of intestinal damage in these patients. 
 
Methods
The study was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. 
The protocol was approved by the local ethics committee of the Radboud 
University Medical Centre (protocol ID NL38169.091.11). All patients or their legal 
representatives were informed about the study details. Written informed consent 
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was obtained in the event that venipuncture was necessary to obtain blood 
samples. 
All study procedures were performed under the guidelines of The National 
Institutes of Health and in accordance with the declaration of Helsinki and its later 
amendments.
Subjects
Adult trauma patients (n=93) admitted to the trauma care unit at the emergency 
room (ER) of the Radboud University Medical Centre between march 2011 and 
may 2012 were included in the study. Exclusion criteria were known HIV/AIDS, 
malignancies, and use of steroids or other immunosuppressive medication.
Follow-up was prematurely terminated mainly because of death, discharge, 
transfer to another hospital or because no written informed consent could be 
obtained.
Samples from 13 healthy volunteers (age median 27 [range 22 - 34], 4 female, 9 
male) were used as controls.
Sample collection
Blood was sampled shortly after trauma by the Helicopter Emergency Medical 
Services (HEMS) (if present on the trauma scene and deemed feasible by the 
trauma physician on site), at arrival at the Emergency Room (ER), and at days 1, 
3, 5, 7, 10, and 14 following trauma. Lithium Heparin anticoagulated blood was 
centrifuged after withdrawal at 1,600 x g at 4⁰C for 10 minutes, after which plasma 
was stored at -80⁰C until further analysis.
Data collection
Plasma iFABP concentrations were determined by ELISA (detection limits 187.2-
12000 pg/ml) according to the manufacturers’ instructions (HyCult Biotech, Uden, 
the Netherlands). 
Injury Severity Scores (ISS) were obtained via the regional trauma administration. 
Patient characteristics, injury mechanisms, Simplified Acute Physiology Score II 
(SAPS II) scores, hemoglobin (Hb) levels and mean arterial pressure (MAP) were 
obtained from the electronic patient file.
Data analysis
Distribution of data was determined using Kolmogorov-Smirnov tests. In order 
to calculate the deviation from normal Hb, patient Hb values were divided by the 
reference values (males 6.8 mmol/L, females 6.0 mmol/L), yielding a percentage 
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of reference Hb level per patient.
Groups were compared using Mann-Whitney U tests or Kruskal-Wallis tests with 
Dunn’s multiple comparison post hoc test, as appropriate. After log transformation 
of iFABP data, Pearson correlation coefficients were calculated between ISS and 
plasma iFABP levels. Statistical analysis was performed using Graphpad Prism 5 
software (Graphpad Software, La Jolla, USA). A p value of <0.05 was considered 
statistically significant.
 
Results
Patient characteristics 
A total of 93 patients were included, of which the characteristics are listed in Table 
1. The majority of patients suffered from head/neck injury and/or chest injury, 
and fall from height was the predominant injury mechanism. A total of 16/93 
patients (17%) suffered abdominal trauma. Two patients of the study population 
developed sepsis at the ICU.
iFABP levels after trauma
Plasma iFABP concentrations showed highest levels at time points HEMS and 
ER. Concentrations decreased in the following days, with a significant decrease 
observed at day 3 compared with time points HEMS and ER. (Figure 1A) No 
statistically significant difference was observed between healthy controls and all 
trauma patients combined, although in subgroups of trauma patients significantly 
higher iFABP levels were observed (detailed below).
Non-survivors demonstrated significantly higher iFABP levels at ER in comparison 
with survivors (Figure 1B). No differences in ER iFABP levels were observed 
between males and females (p=0.9). Furthermore, no correlation was observed 
between age and ER iFABP levels (r=-0.01, p=0.9).
Relation between the severity and nature of trauma and iFABP levels 
Injury Severity Score (ISS) was positively correlated with the plasma iFABP 
concentration measured at the ER (Figure 1C, r=0.34, p=0.002), indicating that 
more severe trauma is associated with higher iFABP levels. Furthermore, patients 
suffering from abdominal trauma displayed significantly higher plasma iFABP 
concentrations at the ER in comparison with patients with non-abdominal trauma 
at the same time point (Figure 2A). Moreover, patients with abdominal trauma 
demonstrated significantly higher iFABP levels in comparison with healthy 
controls at both time points HEMS and ER (p=0.04, n=16 and p=0.0004, n=14 
respectively).
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When classifying patients with abdominal trauma using the abbreviated injury 
scale (AIS) 13, more severe abdominal trauma appeared to be associated with 
higher plasma iFABP concentrations at the ER, however, statistical analysis was 
not possible due to the low number of patients with abdominal trauma (Figure 
2B).
 
Gender Male: N=64 (68.8%)
Female: N=29 (31.2%)
Age (median [range]) 50 [18-95]
28-day survival N=71 (76.3%)
ICU length of stay (median [range]) 3 [0-35] days
Injury Severity Score (median [range])
Head/Neck injury (ISS region 1)
Face injury (ISS region 2)
Chest injury (ISS region 3)
Abdomen or pelvic contents injury (ISS region 4)
Abdominal trauma (AIS region 5)
Extremities or pelvic girdle injury (ISS region 5)
External injury (ISS region 6)
25 [1-66]
N=71, 76.3%
N=25, 26.9%
N=54, 58.1%
N=27, 29%
N=16, 17.2%
    Score 2: N=7
    Score 3: N=7
    Score 4: N=2
N=43, 46.2%
N=45, 48.4%
Trauma Mechanism
Fall from height
Car/Truck accident
Pedestrian/Cyclist accident
Motorcycle accident
Penetrating injury
Burn
Industrial accident
N=27, 29.0%
N=25, 26.9%
N=24, 25.8%
N=10, 10.8%
N=5, 5.4%
N=1, 1.1%
N=1, 1.1%
Table 1 – patient characteristics
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Figure 1 - iFABP levels after trauma A. Plasma iFABP concentrations in trauma patients and 
healthy controls. Data are represented as median and interquartile range. p-value calculated 
using Kruskall-Wallis test and * indicates p<0.05 using Dunn’s post-hoc test. HEMS = Helicopter 
Emergency Medical Services, ER = Emergency room. B. Plasma iFABP concentrations in trauma 
patients at the ER in survivors and non-survivors. P value calculated using Mann-Whitney test. 
C. Correlation between Injury Severity Score (ISS) and plasma iFABP levels at the ER. R and 
p-values calculated using Pearson correlation. 
Figure 2 - Relation between the nature and severity of trauma and iFABP levels A. 
Plasma iFABP concentrations measured at the ER in patients with abdominal trauma and 
non-abdominal trauma. Data are represented as median and interquartile range. p-value 
calculated using Mann-Whitney U-test. B. Plasma iFABP concentrations measured at the ER in 
relation to abdominal abbreviated injury scale (AIS). 
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Relation between hemodynamic parameters and iFABP levels 
Patients with a MAP below 70 mmHg at the ER displayed higher iFABP levels 
compared with patients with a normal (70-100 mmHg) or high (>100 mmHg) 
MAP at the ER (Figure 3A). Patients with a MAP below 70 mmHg showed higher 
iFABP levels compared with healthy controls at both time points HEMS and ER 
(p=0.02, n=3 and p=0.007, n=8, respectively). Furthermore, patients with an 
Hb lower than 80% of the lower limit of the normal value for their sex showed 
increased iFABP levels compared with patients with an Hb level that was higher 
than 80% of the normal value (Figure 3B). Patients with an Hb < 80% of reference 
value displayed significantly higher iFABP levels compared with healthy controls 
at both time points HEMS and ER (p=0.04, n=5 and p=0.0004, n=13, respectively). 
No correlation was observed between Hb at ER and MAP at ER (r=0.09, p=0.34).
Figure 3 – Relation between hemodynamic parameters and iFABP levels A.Plasma iFABP 
concentrations measured at the ER in patients with a MAP lower than 70 , between 70 and 
100 mmHg, and higher than 100 mmHg. Data are represented as median and interquartile 
range. p-value calculated using Kruskall-Wallis test and * indicates p<0.05 using Dunn’s post-
hoc test. B. Plasma iFABP concentrations measured at the ER in patients with Hb below and 
above than 80% of the normal values. Normal values for males and females are 6.8 mmol/L 
and 6.0 mmol/L, respectively. Data are represented as median and interquartile range. p-value 
calculated using Mann-Whitney U-test.
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Discussion
This study demonstrates that major trauma results in very early release of iFABP 
in the circulation. To our knowledge, we present the first evidence that compared 
with healthy controls, iFABP levels are already profoundly elevated at the trauma 
scene before hospital admission in patients with abdominal trauma and signs of 
hemorrhage (low blood pressure or Hb), and that iFABP levels are higher in non-
survivors compared with survivors. Furthermore, the amount of iFABP released is 
related to injury severity, presence of abdominal trauma, and signs of hemorrhage. 
The latter findings confirm previous research indicating elevated iFABP levels in 
trauma patients are related to injury severity and shock 9, 12. 
Our results concerning the relation between increased iFABP levels, indicative of 
intestinal injury, and mortality are in line with a previous study in a shock and 
surgical trauma two-hit model in baboons showing a relation between increased 
gut permeability assessed by plasma D-lactate measurements and mortality in 
a shock and surgical trauma two-hit model 14. In addition, this similarity further 
strengthens the suggestion that iFABP is a marker of gut permeability 9, 10.
Intestinal integrity is thought to play a major role in post-trauma complications 
2. Therefore, therapeutic interventions aimed to limit intestinal damage could 
be of benefit to trauma patients. We show substantial differences in plasma 
iFABP levels between patients with abdominal trauma and low Hb/MAP and 
patients with other trauma types and normal/high Hb/MAP. Previous studies 
in both trauma patients and a hemorrhagic shock model in rats display similar 
results, relating blood pressure with increased gut permeability or damage 12, 
15. Therefore, targeted interventions, such as (more aggressive or more goal-
directed) fluid resuscitation and/or hemodynamic support, may represent a viable 
treatment option in these subgroups of patients. Currently, iFABP is not used as 
a biomarker in clinical practice, but these observational correlations between 
shock and iFABP concentrations and the known relationship between intestinal 
damage and the increased incidence of late complications in trauma patients 
indicate that treatment focused on intestinal perfusion might be worthwhile. For 
instance, a previous study demonstrated that circulatory management based on 
goal-directed fluid administration to maintain the MAP above 60 mmHg during 
non-abdominal surgery in children results in adequate intestinal perfusion and 
normal plasma iFABP levels without increasing the volume of fluids administrate 
16. Currently, no studies are available that demonstrate that a therapeutic strategy 
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can to influence circulating iFABP levels and improve clinical outcome in trauma 
patients or any other patient group. Timing of intervention could be of interest 
for future studies, as our results display increase iFABP levels already in a pre-
hospital stage. Previous studies have suggested that fluid therapy before surgical 
intervention can control bleeding and could be able to improve outcome 17. 
Moreover, as Hb levels appear to be related to iFABP levels independently of MAP, 
pre-hospital blood transfusion rather than crystalloids or colloids in selected 
patients might be considered 18-20. Ongoing research addresses the question of 
what fluid treatment is most beneficial in hemorrhagic shock patients.
The present study has several limitations we want to acknowledge. Inherent 
to this type of study, a substantial number of patients were lost to follow-up, 
because of discharge from the hospital, transfer to another hospital, or death. 
Another weakness of the current study is the heterogeneity of the patients, which 
is typical for the multi-trauma patient population studied. Finally, the incidence 
of MODS and sepsis in our patient cohort was too low to relate these events to 
iFABP levels.
 
From this study we conclude that high ISS, abdominal trauma, and low Hb or MAP 
are associated with increased iFABP levels and thus intestinal injury that is present 
very early after trauma as well as at presentation on the ER. As intestinal injury is 
suggested to be related to late complications, such as MODS or sepsis in trauma 
patients, strategies to prevent intestinal damage following trauma could be of 
benefit to these patients.
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Abstract
Introduction Soluble urokinase-type plasminogen activator (suPAR) represents a 
marker for immune activation and has predictive value in critically ill patients. The 
kinetics of suPAR and its correlation with the immune response and outcome in 
trauma patients are unknown.
Methods Plasma concentrations of inflammatory cytokines and suPAR were 
determined in adult trauma patients (n=69) samples obtained by the Helicopter 
Emergency Medical Services (HEMS), at arrival at the Emergency Room (ER), and 
at day 1, 3, 5, 7, 10 and 14.
Results Initial SuPAR levels were unrelated to injury severity score and higher in 
non-survivors compared with survivors, although no difference was observed 
between early and late mortality. The area under the ROC curve to predict mortality 
was 0.6 (95%CI 0.48–0.72). SuPAR levels increased over time in 94% of patients, 
although suPAR increase did not precede death. TNF-α at the ER correlated 
with suPAR at that time point, while concentrations of other pro-inflammatory 
cytokines at the ER correlated with suPAR levels at days 1 and 5.
Conclusions After trauma, initial suPAR plasma concentrations are higher in non-
survivors compared with survivors, but its predictive value is low. SuPAR levels 
increase over time after trauma, and concentrations at later timepoints are related 
to cytokine levels at the ER.
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Introduction
Trauma is one of the main causes of death worldwide. In 2000, 9% of deaths and 
12% of disease burden could be attributed to trauma. Moreover, 50% of trauma-
related deaths concern young people between the ages of 15 and 44 years 1. 
Roughly, trauma deaths can be divided into early deaths attributable to the direct 
effect of trauma, such as blood loss or neurological damage and late mortality, to 
an important extent due to immunological complications 2, 3. Trauma can result 
in a systemic inflammatory response, predominantly induced by the release of 
danger associated molecular patterns (DAMPs) 4, These “danger signals” can 
either be components from ruptured cells and tissues or factors released by cells 
in stressed conditions 4. Pattern Recognition Receptors (PRRs), which recognize 
pathogen associated molecular patterns (PAMPs), can be triggered by DAMPs. 
Although the exact mechanisms are not completely elucidated yet, this can lead 
to pro-inflammatory responses as well as a refractory state of the immune system 
called “immunoparalysis”, which renders patients vulnerable towards secondary 
infections 5. Apart from injury severity scores, no predictors of mortality are 
available for this important patient group. 
Soluble urokinase-type plasminogen activator receptor (suPAR) is a recently 
identified biomarker for inflammation in infectious diseases that is superior in 
predicting outcome in various conditions compared with other markers 6, 7. SuPAR 
particularly appears to be of value in combination with other biomarkers 6, 8. The 
non-soluble form of suPAR, urokinase plasminogen activator receptor (uPAR or 
CD87) is expressed on immune cells, e.g. neutrophils, monocytes, macrophages 
and lymphocytes 9 and does play a role in fybrinolytic pathway 10, 11. Plasma 
levels of suPAR are increased in various infectious and inflammatory diseases 
12-14. Moreover, several observational studies demonstrate the relation between 
increased suPAR levels and outcome in critically ill patients 8, 15, 16. However, 
suPAR levels in trauma patients and their relation with outcome have not been 
investigated.
Considering the importance of the immune response in late mortality of trauma 
patients, and the high prognostic value of suPAR in inflammatory conditions, the 
objective of this study was to investigate the prognostic value (for both early and 
late mortality) of plasma suPAR levels in trauma patients and to study the relation 
with markers of systemic inflammation and injury severity in this specific group 
of patients.
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Materials and Methods
Study population
Adult trauma patients (n=69) admitted to the trauma care unit at the ER of the 
Radboud University Nijmegen Medical Center, a level I trauma center, were 
included in the study. Exclusion criteria were expected clinical risks of blood 
sampling, known HIV/AIDS, known malignancies and use of steroids or other 
immunomodulating medication. Two healthy male volunteers (aged 20 and 25 
yrs) were used as healthy controls.
The study has been carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. 
All patients or legal representatives were informed about the study details at the 
first opportunity, usually at day 1 after admission. The local ethical committee 
that approved the study protocol agreed that it was not possible to do this at 
an earlier stage. Written informed consent was obtained if venapuncture was 
necessary to obtain blood samples. Informed consent was waived in case blood 
could be sampled from existing arterial or venous catheters. All experiments 
were performed under the guidelines of The National Institutes of Health and in 
accordance with the declaration of Helsinki and its later amendments.
Sample collection
Blood was sampled shortly after trauma by the Helicopter Emergency Medical 
Services (HEMS), at arrival at the Emergency Room (ER), and at day 1, 3, 5, 7, 10 
and 14 following trauma. Ethylenediaminetetraacetic acid (EDTA) anticoagulated 
blood was centrifuged after withdrawal at 1,600 x g at 4⁰C for 10 minutes, after 
which plasma was stored at -80⁰C until further analysis.
Sample analysis
Plasma concentrations of suPAR were analyzed in one batch by ELISA (detection 
limits 1.1 – 22.5 ng/ml) according to the manufacturer’s instructions (SuPARnostic, 
Virogate A/S, Birkerød, Denmark). Plasma concentrations of Tumor Necrosis 
Factor (TNF)-α, Interleukin (IL)-6, IL-10, IL-8, Interferon (IFN)-γ, and Monocyte 
Chemoattractant Protein (MCP)-1 were analyzed by a Luminex assay according 
to the manufacturer’s instructions (Milliplex; Millipore, Billerica, MA, USA). Clinical 
parameters and demographic data were obtained from electronic patient files. 
Injury Severity Scores (ISS) and Abbreviated Injury Scale (AIS) were supplied by 
the Regional Emergency Healthcare Network.
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Statistical analysis
Data are expressed as mean±sem or median [IQR], according to their distribution 
as determined using the Kolmogorov-Smirnov test. Statistical tests used are 
indicated in the figure/table legends or text. All analyses were performed with 
available data of the corresponding time-points. Due to missing values at certain 
time points or patients that were lost to follow-up, patient numbers in the various 
analyses might not correspond with the original inclusion number. 
Linear regression coefficients were calculated from patients that had a follow up 
of 3 or more days (n=33) to quantify suPAR kinetics over time. 
A Receiver Operating Characteristics curve according to DeLong et al, sensitivity, 
specificity, positive predictive value and negative predictive value were calculated 
using MedCalc version 11.3.1.0 (MedCalc software, Ostend, Belgium). 
Other statistical analyses were performed using Graphpad Prism 5 software 
(Graphpad Software, La Jolla, USA). A p value of <0.05 was considered statistically 
significant.
Results
Patient characteristics
A total of 69 patients were included, of which the majority suffered from head/
neck injury and/or chest injury. 3 out of 69 patients suffered from penetrating 
injury. Patient characteristics shown in Table 1. 
Plasma suPAR concentrations after trauma
Mean plasma suPAR level at time point HEMS was 3.2±0.4 ng/ml and significantly 
increased over time (Figure 1A), further illustrated by positive regression 
coefficients in 94% of patients with a minimum follow up of 3 days (mean 
regression coefficient of 0.4±0.1 ng/mL/day, Figure 1B). Furthermore, mean 
plasma suPAR levels in patients were significantly different from mean suPAR 
levels found in healthy controls (2.7 ng/ml) from time point ER onwards (Figure 
1A). The concentrations we found in samples from healthy controls were similar 
to those found in healthy controls in previous studies 17-19.
There was no correlation (r=0.12, p=0.38) between suPAR and injury severity score 
(ISS). A weak, but statistically significant correlation was found between age and 
suPAR (r=0.29, p=0.02).
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Gender Male: n=48 (69.6%)
Female: n=21 (30.4%)
Age (median [range]) 50 [18-95]
Length of Stay in days (median [range])  9 [0-201]
28-day survival N=50 (72.5%)
Injury Severity Score (median [range])
Head/Neck injury (ISS region 1)
Face injury (ISS region 2)
Chest injury (ISS region 3)
Abdomen or pelvic contents injury (ISS region 4)
Extremities or pelvic girdle injury (ISS region 5)
External injury (ISS region 6)
29 [3-66]
N=53, 80.3%
N=17, 25.8%
N=42, 63.3%
N=24, 36.4%
N=40, 60.6%
N=31, 47.0%
Table 1 – patient characteristics
Figure 1 – suPAR levels after trauma A. Plasma suPAR levels were measured at 8 different 
time points following trauma. SuPAR levels increased over time (p<0.0001) according to one 
way ANOVA and were significantly higher than values of healthy controls (indicated in grey/
dotted-line) according to Bonferroni’s multiple comparison post-hoc test. Data are expressed 
as mean±SEM. Median age per time point is displayed in years (yrs). * p<0.05, ** p<0.01, *** 
p<0.001 compared with healthy controls B. Regression coefficients were generally positive 
(n=33, mean±SEM 0.38±0.05), indicating increasing suPAR concentrations over time.
Relation beween suPAR levels and early and late mortality
Initial suPAR levels (first sample of a patient, obtained at either time point HEMS, 
ER or day 1) were higher in non-survivors (n=22, 4.1±0.5 ng/ml) compared with 
survivors (n=45, 3.0±0.2 ng/ml, p=0.02). Furthermore, patients that died early 
(within 5 days) as well as those that died later (after 6 or more days) demonstrated 
195
10
SuPAR in trauma patients
higher suPAR levels in comparison with survivors (Figure 2A), although this 
difference was only significant between the survival and early mortality groups. 
No statistically significant difference in suPAR levels between the early and late 
mortality groups was observed. 
There was no difference in the increase in suPAR concentration between survivors 
and non-survivors, as regression coefficients between were similar (Figure 2B). 
Finally, no differences were observed in suPAR levels shortly before patients died, 
indicating that death itself is not preceded by an increase in suPAR (Figure 2C).
Figure 2 – suPAR and survival A. Initial plasma suPAR levels (determined at HEMS or ER) were 
significantly lower in survivors in comparison with non-survivors that died within 5 days after 
trauma. No differences in suPAR levels were observed between early and late mortality. Data 
are expressed as mean±SEM. * p<0.05 according to one way ANOVA with post-hoc Bonferroni’s 
multiple comparison post-hoc test. B. Regression coefficients were similar in survivors and 
non-survivors according to unpaired student’s T-test. C. Plasma suPAR concentrations in non-
survivors. Day 0 indicating day of death, days -7 to -1 represent the days preceding death. 
No increase in suPAR preceding death was observed. There were no statistically significant 
differences between time points according to one way ANOVA.
 Predictive value of early suPAR
A receiver operating characteristic (ROC) curve was produced using the first 
obtained suPAR value to evaluate its predictive value for mortality (Figure 3). 
The area under the curve was 0.60 (95% CI 0.48 – 0.72). The optimal cut-off point 
(>3.66 pg/ml) resulted in a sensitivity of 50% (95% CI 28.2 – 71.8), specificity of 
76.6% (95%CI 62.0 – 87.7), positive predictive value of 50% (95% CI 28.2 – 71.8) 
and negative predictive value of 76.6% (95%CI 62.0 – 87.7).
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Figure 3 – ROC curve suPAR 
Receiver operating characteristic 
(ROC) curve analysis showing 
the utility of first plasma suPAR 
concentration as a prognostic test 
predicting death in trauma patients. 
The area under the curve was 0.60 
(95% CI 0.48 – 0.72). 
Relation between cytokines at ER and suPAR levels 
Median plasma cytokine levels at ER were: IFN-γ 3 pg/ml [IQR 3-3], IL-10 45 pg/ml 
[IQR 20–206], IL-6 25 pg/ml [IQR 8-68], IL-8 11 pg/ml [IQR 7-26], MCP-1 422 pg/ml 
[IQR 269-806], and TNF-α 6 pg/ml [IQR 3-12]. According to Pearson’s correlation 
test after log transformation of cytokine values, plasma suPAR levels at time 
point ER correlated with plasma TNF-α measured at the same time point (r=0.43, 
p<0.01), while no correlation between other plasma cytokines and SuPAR levels 
at time point ER was found. However, pro-inflammatory cytokines IL-6, IL-8 and 
MCP-1 measured at the ER did correlate with suPAR levels at days 1, 3 and/or 5 
(Table 2). 
Discussion
Herein, we show that plasma suPAR levels increase over time in trauma patients. 
Moreover, this study is the first to demonstrate that suPAR levels shortly after 
trauma are higher in non-survivors than in survivors, although predictive value 
for mortality was low and death itself was not preceded by an increase in suPAR. 
Furthermore, early increases in pro-inflammatory cytokine levels are related to 
increased suPAR levels at later time-points. 
Several studies have demonstrated that suPAR is not as valuable as a single 
marker in clinical practice, mainly because of the lack of a clear cut-off value. 
Studies in (suspected) sepsis patients demonstrated ROC curves with an AUC 
between 0.5 and 0.75 and thus the value of suPAR in triage is unclear 6, 8. This is in 
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accordance with our results, as we demonstrate that the value of plasma suPAR 
concentration as a triage marker in individual patients is limited and its positive 
and negative predictive value is low. It is suggested that in sepsis or in patients 
with suspected infection at the ER, suPAR could be of value when combined with 
other biomarkers, which could also hold true for trauma patients 6, 8. 
Of interest, we demonstrated a relation between early cytokine production 
and subsequent increase of suPAR levels. Patients with an initial high cytokine 
response, had high plasma suPAR concentrations later on during their hospital 
stay. This finding may indicate that the increase of suPAR over time could be 
mediated by the initial inflammatory response in trauma patients, although we 
cannot demonstrate causality from our dataset. In accordance, previous in vitro 
studies have demonstrated that neutrophils can release suPAR in response to 
stimulation with IL-8 or TNF-α 20 and endothelial cells after stimulation with IL-
1β or PDGF 21. Although the exact mechanism behind suPAR release has not yet 
been elucidated completely 22, based on these and our results, it seems possible 
ER suPAR Day 1 suPAR Day 3 suPAR Day 5 suPAR
ER TNF-α r=0.43
p<0.01
n=51
r=0.08
p=0.60
n=38
r=-0.02
p=0.89
n=23
r=0.12
p=0.60
n=19
ER IL-6 r=0.20
p=0.15
n=51
r=0.17
p=0.28
n=38
r=0.46
p=0.02
n=23
r=0.47
p=0.04
n=19
ER IL-8 r=0.18
p=0.20
n=51
r=0.32
p=0.04
n=38
r=0.48
p=0.01
n=23
r=0.51
p=0.02
n=19
ER IL-10 r=0.03
p=0.81
n=51
r=0.11
p=0.49
n=38
r=0.21
p=0.33
n=23
r=0.26
p=0.28
n=19
ER MCP-1 r=-0.03
p=0.82
n=51
r=0.22
p=0.17
n=38
r=0.41
p=0.05
n=23
r=0.46 
p=0.04
n=19
ER IFN-γ r=-0.01
p=0.95
n=47
r=0.06
p=0.71
n=34
r=-0.20
p=0.37
n=21
r=0.10
p=0.69
n=16
Table 2: Correlation between cytokine levels at the ER and suPAR levels at various time-
points. Grey boxes implicate significant correlations
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that cytokines play a role in this process. Nevertheless, the mediator responsible 
for the increased plasma suPAR concentration directly after trauma is unclear. 
Cytokines are unlikely to play a role in this initial increase, regarding the lack of 
correlation between cytokine levels and plasma suPAR at the ER. Moreover, in 
our patient cohort, relatively low plasma cytokine concentrations were found 
compared with other conditions, such as sepsis 23. This might explain the relatively 
mildly increased suPAR levels (mean 4.1 ng/ml) in trauma patients at admission 
compared with those observed in patients with sepsis (median 8.9 [range 5.9-
12.7] ng/ml) 24. 
Our study has several limitations. Inherent to this kind of study, the number 
of patients that can be analyzed over time is limited as a substantial number 
of patients were lost to follow-up, for example because of death, transfer to 
another hospital or withdrawal from the study. However, the increase in SuPAR 
over time does not appear to result from the lost-to follow up, as the regression 
coefficients were positive in virtually all patients with a follow-up of at least three 
days. Moreover, the increasing trend in suPAR is also observed in the subgroup 
of patients that had a complete follow-up. Therefore, it appears unlikely that the 
increase in suPAR is the result of exclusion of less severely ill patients or patients that 
die during follow-up. Another weakness of the current study is the heterogeneity 
of the patients, which is inherent to the trauma patient population studied. Age 
could possibly have confounded our results. Various studies have assessed the 
relation between age and suPAR in several diseases, with  contradictory results. 
Some demonstrate no correlation 25, 26, while others demonstrate  higher 27,28 
or lower 29 suPAR levels in elderly patients. We found a weak, but statistically 
significant correlation between age and suPAR. We do not think that that the 
increased suPAR levels in trauma patients are the result of the higher age of the 
patient cohort, also because suPAR levels increased over time in our cohort, while 
median age did not.
Conclusions
In conclusion, early suPAR concentrations are higher in non-survivors than in 
survivors, and levels at later time-points are related to preceding cytokine levels. 
However, the predictive value of suPAR for mortality and therefore its clinical 
relevance is low. The steady increase over time related to the initial inflammatory 
response is not related to mortality.
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The immune system responds to invading pathogens, hallmarked by Pathogen 
Associated Molecular Patterns (PAMPs), but also to Danger Associated Molecular 
Patterns (DAMPs) that originate from the extracellular matrix or are released by 
injured, threatened, or dead cells 1-5. This could be of great relevance in intensive 
care-related conditions, in which it is implicated that large amounts of DAMPs 
are released. Furthermore, critically ill patients often suffer from immune system-
related complications 6, such as systemic inflammatory response syndrome (SIRS) 
or immunoparalysis. In the studies described in this thesis, the immunologic roles 
of DAMPs in critically ill patients were investigated. In this chapter, we discuss the 
findings of the studies performed, draw overall conclusions, and present future 
perspectives.
Part I - DAMPs in critically ill patients
In the first part of this thesis, we demonstrated that DAMPs are released in 
patients suffering from trauma, cardiac arrest, leukemia, and sepsis. Moreover, 
we found that in trauma and cardiac arrest, DAMP release is associated with the 
development of immunoparalysis, while in leukemia no such relationship could 
be established. In patients with septic shock, DAMP release was associated with 
markers of inflammation, shock, and organ damage. Finally, we have shown that 
several pattern recognition receptors (PRRs), that can bind DAMPs, demonstrate 
synergistic or inhibitory interactions.
Although we have established a correlation between DAMPs and immunoparalysis 
in both trauma and post-cardiac arrest patients, the observational nature of 
our studies does not allow us to conclude that a causal relationship is present. 
Although DAMPs were released in trauma, cardiac arrest, leukemia, and sepsis, 
substantial differences in the extent of general DAMP release (reflected by nDNA 
levels) between those conditions were found (Figure 1). Sepsis and trauma 
patients display similar levels of nDNA, which are much higher compared with 
patients following cardiac arrest or those receiving chemotherapy treatment 
for leukemia. This difference appears feasible, taking the major impact on the 
entire body in both sepsis and trauma into account 7. Although leukemic patients 
treated with chemotherapy display similar levels of circulating DAMPs as cardiac 
arrest patients, no relationship between DAMP release and immunoparalysis 
could be established in this specific group of patients. This difference might be 
explained by the profound changes in leukocyte phenotype and function due to 
the haematological malignancy. Differences in cell maturation, high percentages 
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of blasts, and chemotherapy treatment directed at leukocyte destruction might 
influence the effect of DAMPs on immune cells. Moreover, although nDNA is 
assumed to be a marker for general DAMP release, as it is a major cell component 
that is released in case of cell damage, it is plausible that due to different 
mechanisms of damage (e.g. inflammation, ischemia or physical damage), 
variable combinations and ratios of different DAMPs are released. This underlines 
the fact that multiple complex processes take place simultaneously in critically 
ill patients, making it difficult to distinguish causality from epiphenomena 
and unravel underlying mechanisms in observational studies. Nevertheless, 
some studies suggest that there is a causal relationship between DAMP release 
and inflammation and that there might be a role for DAMP neutralization as a 
therapeutic intervention. For instance, in a recent murine study, administration of 
DNAses (to remove free nucleic acids from the circulation) resulted in decreased 
coagulation and inflammation, suppression of organ damage, and improved 
outcome in a cecal ligation and puncture sepsis model 8. These findings imply that 
the presence of nucleic acids, such as nDNA and mtDNA described in our studies, 
could importantly impact prognosis and survival in sepsis patients. Moreover, 
the DAMP HSP70 has been shown to induce endotoxin tolerance in monocytes 
in vitro 9. Along these lines, HSP70 was shown to downregulate TLR-4 expression 
and as such modulate the immune response to LPS and other TLR-4 ligands 10. 
These findings suggest that this DAMP may play a direct role in suppression of the 
innate immune response in vivo, as observed in immunoparalysis. Future studies 
investigating inhibitors of specific DAMPs or their receptors could shed more 
light on the interaction between DAMPs and immunoparalysis. These data could 
Figure 1 – nuclear DNA in critically ill 
patients Plasma levels of nuclear DNA 
(nDNA), a marker for general DAMP release, 
expressed as fold change to a calibrator 
sample in patients after trauma, cardiac 
arrest, chemotherapy in leukemia, and 
sepsis, at peak time points (pre-hospitally 
[on the trauma scene], within 24 hours after 
cardiac arrest, 4-6 hours after initiation 
of chemotherapy, and on the first day of 
norepinephrine therapy, respectively). Data 
are depicted as median±interquartile range.
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also indicate whether DAMP neutralization has therapeutic potential. It should 
however be kept in mind that neutralization or administration of a single DAMP 
could present an unclear picture of the in vivo situation, as in patients, a multitude 
of DAMPs are usually involved.
Of special interest in terms of possible therapeutic or preventive intervention 
is the early phase in trauma patients, as discussed in chapter 2. A promising 
study in restoring immunoparalysis by inhalation therapy of IFN-γ, suggests an 
intervention can safely improve outcome in patients with an impaired immune 
response following trauma 11. Therapy was initiated days after hospital admission 
in this study. As we have demonstrated that immunoparalysis in trauma patients 
occurs already very early on, and median time to development of a hospital-
acquired infection was only 6 days, the possibility to intervene in an earlier stage 
seems appealing. However, caution is warranted in this early phase, as it is hard 
to distinguish patients that could benefit from such a treatment and patients 
that could potentially harmed. For instance, immunostimulatory treatment could 
also result in an overwhelming pro-inflammatory response, leading to Systemic 
Inflammatory Response Syndrome (SIRS), which could ultimately result in shock, 
organ failure, and death 12. This dilemma shows similarities with current paradigm 
in sepsis, in which it is believed that correctly timed immunostimulatory treatment 
could prevent deaths due to secondary infections, but only if correctly timed6. 
More studies focusing on the very early phase following trauma are crucial for 
further understanding of immunological pathways and mechanisms activated in 
this stage. For instance, more extensive knowledge is warranted on which DAMPs 
are released and to what extent, which DAMPs influence the immune response, 
and which immune cells and immune activation pathways are involved early after 
trauma. This data could help find suitable biomarkers that could identify patients 
that would benefit from immunostimulatory treatment.
As outlined above, DAMPs can have detrimental effects through inducing 
immunoparalysis. However, beneficial effects of some DAMPs have also been 
described. For example, neutralization of S100B exerted detrimental effects in 
an in vitro trauma model, indicating the protective properties of S100 proteins 
13. Moreover, rats subjected to CLP exhibited less sepsis-induced apoptosis in 
multiple organs when pre-treated with whole-body hyperthermia, which strongly 
induced HSP7014. Likewise, glutamine administration in rats resulted in increased 
expression of HSP70 and decreased mortality after CLP 15. The mechanisms 
behind these protective effects remain largely unclear, but it could be speculated 
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that the same immunosuppressive effects which may result in development of 
immunoparalysis are involved can be beneficial in case of a too pronounced or 
sustained pro-inflammatory response. One could argue that from an evolutionary 
point of view, an immunological “shut-down” following major DAMP release 
could be of benefit to prevent an overwhelming pro-inflammatory response and 
subsequent organ damage. However, caution is warranted in translating these 
results obtained in animal models to a clinical setting. For instance, a wide variety 
of anti-inflammatory therapies showed very promising results in preclinical sepsis 
models, but none of these have eventually proved to be of benefit in clinical trials 
20, 21 .
As alluded to before and inherent to the mechanisms of release of DAMPs, we 
can assume that in many conditions on the ICU, multiple DAMPs are released 
simultaneously. In case of cell rupture or uncontrolled cell death, many cellular 
components are released, resulting in a broad range of different DAMPs in the 
plasma or surrounding tissue. Moreover, as the stimuli inducing active release 
of DAMPs show many similarities, such conditions will also result in the release 
of a multitude of DAMPs. As we have demonstrated in chapter 6 of this thesis, 
ligation of multiple pattern recognition receptors (PRRs) simultaneously can 
result in either synergistic or inhibitory interactions. Therefore, it appears likely 
that such interactions occur in vivo in case of DAMP release. Next to interaction 
on receptor level, other mechanisms of interaction between DAMPs could occur. 
Several studies have addressed this aspect of immune activation/inhibition by 
DAMPs. For example, nucleic acids as DAMPs are suggested to be dependent on 
the release of other DAMPs, e.g. HMGB1, and can also affect the activity of other 
DAMPs 22. PRRs recognizing nucleic acids are generally present intracellularly, and 
internalization necessary for receptor-binding is stimulated by other DAMPs 22. 
Part II – DAMPs and ventilator-induced inflammation
The second part of this thesis comprises two studies on ventilator-induced 
inflammation, demonstrating that neither the mitochondrial DNA (mtDNA)/TLR9 
pathway nor the inflammasome plays a role in this phenomenon.
The DAMP mtDNA has gained increasing attention in recent years 23-27. 
Nevertheless, in the first part of this thesis, we did not find mtDNA to be released 
to a great extent or having considerable effects in the conditions studied. 
Subsequently, in chapter 7 we demonstrated in a murine ventilator-induced 
inflammation model, that mtDNA release and TLR9 signaling are not involved 
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mechanical ventilation-induced pulmonary inflammatory response. Combining 
those findings, it can be debated whether or not mtDNA/TLR9 signaling is a major 
contributor in critically ill patients. Several observational studies have shown 
that mtDNA levels in plasma of critically ill patients are increased 23, 24, 26, 28, 29, 
and animal studies on administration of exogenous mtDNA have demonstrated 
that mtDNA exerts pro-inflammatory effects 30, 31. Although it appears likely that 
mitochondria and/or mtDNA are released as a result of a hit, several mechanisms 
preventing downstream effects could also play a role. A process known as 
mitophagy could result in swift clearance of mitochondria, even before cell death 
occurs 32. Moreover, the bacterial-like appearance of mtDNA could result in rapid 
recognition and phagocytosis after release from damaged cells. Future studies on 
the role of mtDNA release in vivo are warranted. Even if this role appears minimal, 
measuring circulating mtDNA could still have value as a biomarker in clinical 
practice. For example, studies have indicated it has prognostic or diagnostic value 
in cancer 33, 34 and in traumatic brain injury 35. 
As demonstrated in chapter 8, the inflammasome does not play a role in 
the mechanical ventilation-induced inflammatory response, and therefore 
interventions aimed at inflammasome inactivation might not have beneficial 
effects. Our study demonstrates that neutrophils are important in the 
pathophysiology of mechanical ventilation-induced inflammation, thereby 
representing a potential therapeutic target. Subjects of future research should 
include inhibition of serine proteases, which are neutrophil factors that can cleave 
pro-IL-1β, through administration of α1-antitrypsin (AAT) 36, 37. Interestingly, 
patients with AAT deficiency demonstrate increased neutrophil influx 38, whereas 
AAT results in a reduction of neutrophil chemotaxis 39. Furthermore, AAT has 
demonstrated promising results in animal studies on for example the treatment 
of gouty arthritis 40 and diabetes 41. If AAT administration reduces neutrophil influx 
or serine protease activity following mechanical ventilation, it could possibly 
attenuate the ventilator-induced inflammatory response and reduce lung injury.
Part III – Biomarkers in trauma
The third part of this thesis describes the results of two studies with biomarkers, 
intestinal fatty acid binding protein (iFABP) and soluble urokinase plasminogen 
activator receptor (suPAR), in trauma patients. 
Using iFABP as a marker, we demonstrated that intestinal injury occurs 
immediately after trauma in patients with abdominal trauma, low blood pressure, 
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or low haemoglobin levels. Intestinal injury is suggested to be related to late (e.g. 
infectious) complications in trauma patients due to reduced intestinal barrier 
function and related increased bacterial translocation 42, 43. In rare, but severe 
cases, acute mesenteric ischemia can occur, a serious condition with mortality 
rates up to 85%44. Thus, intestinal damage as found in trauma patients should 
be prevented where possible. Although resuscitation therapies in pre-hospital 
care and at the emergency room are directed towards retaining adequate blood 
pressure, extra attention should also be paid to low haemoglobin levels. Although 
transfusion is a common therapy for anemia, it also poses risks that should well be 
considered 45, 46. Moreover, the optimal haemoglobin level for critically ill patients 
is still unclear, as such, the clinical benefits of targeting high haemoglobin levels 
remain to be determined.
We have also shown that, although the inflammatory marker suPAR is higher in 
patients that eventually did not survive trauma compared with survivors, the 
predictive value at the emergency room is low. This is in accordance with many 
other studies in several (intensive care) conditions, demonstrating similar results 
47-51. Overall, suPAR appears not a useful marker in diagnosis and/or prognosis at 
the ER, though several studies have suggested it could contribute in panels of 
biomarkers 47, 52. However, this contribution is only minor, e.g. adding 0.04 to the 
AUC of the ROC curve compared with using only SAPS II for prediction of 30-day 
mortality in SIRS patients 52. This suggests that the role for suPAR as a marker in 
clinical practice is limited. 
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The innate immune system is crucial in distinguishing between entities an 
immune response should be mounted to, and those it should ignore. Invading 
pathogens are recognized through detection of Pathogen Associated Molecular 
Patterns (PAMPs) by Pattern Recognition Receptors (PRRs). Following recognition, 
an immune response is initiated, accurately balanced between an overwhelming 
pro-inflammatory response that could result in too much “collateral damage” 
to the host and an anti-inflammatory response leaving the host susceptible for 
secondary infection. 
Danger Associated Molecular Patterns (DAMPs) that are released by injured, 
threatened, or dead cells, or originate from the extracellular matrix, can also 
influence the immune system. This is of great relevance in critically ill patients, in 
whom trauma- or surgery-related cell damage, hypoxia, ischemia, and infections 
can result in extensive release of DAMPs. As many patients at the intensive care 
unit suffer from immune system-related complications, DAMPs could serve as 
markers for the prognosis of these patients and represent possible therapeutic 
targets. For example, neutralization of DAMPs could possibly revert or prevent 
detrimental effects, such as systemic inflammatory response syndrome (SIRS) 
or immunoparalysis. This thesis aims to shed light on the role DAMPs and 
the associated immune responses play in conditions frequently observed in 
critically ill patients. Apart from DAMPs, we studied the predictive properties of 
immunologically inactive markers in severe trauma patients admitted to the ICU.
In chapter 1, we provided an overview of several well-known DAMPs (High 
Mobility Group Box 1, heat shock proteins, s100 proteins, nucleic acids, and 
hyaluronan) and their effects on the immune system. Furthermore, we discussed 
the role of DAMPs as markers or therapeutic targets in several conditions 
frequently encountered in critically ill patients, such as sepsis, trauma, ventilator-
induced lung injury, and cardiac arrest. Moreover, the aim and outline of this 
thesis was presented.
Part I: DAMPs in critically ill patients
The release of DAMPs can exert immunologic effects in critically ill patients and 
have an impact on outcome. Moreover, simultaneous ligation of multiple PRRs by 
various DAMPs, which is likely to occur in critically ill patients, could have different 
effects than ligation of single receptors.
A suppressed immune system, known as “immunoparalysis” in the sepsis research 
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field, may contribute to the increased vulnerability towards hospital-acquired 
infections in polytrauma patients. In chapter 2 we studied the time course of 
immunoparalysis in trauma patients, starting from the pre-hospital phase until 10 
days after the trauma and the relationship between markers of immunoparalysis 
and the development of infections in these patients. Moreover, the involvement 
of DAMPs was examined. We conclude that immunoparalysis, characterized by 
decreased HLA-DR expression and dysregulated cytokine production, is apparent 
within minutes/hours following trauma and appears to be related to release of 
DAMPs nDNA and HSP70 and production of large amounts of anti-inflammatory 
IL-10 in the pre-hospital phase. Moreover, further decreasing HLA-DR expression 
in the first days after trauma is associated with an increased susceptibility to 
develop infections.
An increased risk of infection has also been reported in cardiac arrest patients 
that are admitted to the ICU following out-of-hospital resuscitation. Therefore, in 
chapter 3 we investigated whether immunoparalysis develops following cardiac 
arrest and whether the release of DAMPs could be involved. In accordance with 
the results of our study in trauma patients described in chapter 2, we showed that 
release of DAMPS nDNA, HSP70, and EN-RAGE during the first days after cardiac 
arrest is associated with the development of immunoparalysis, characterized by a 
more anti-inflammatory cytokine response to LPS ex vivo. This could contribute to 
the increased susceptibility towards infections in cardiac arrest patients.
Chemotherapy used to treat haematological malignancies may result in the 
release of large amounts of DAMPs. Furthermore, it is well known that patients 
treated with chemotherapy are extremely vulnerable for infections, primarily due 
to chemotherapy-induced immune cell destruction. However, the function of 
remaining immune cells might also be compromised because of immunoparalysis 
and DAMP release might be involved. In chapter 4, we studied DAMP release 
and markers of immunoparalysis before and up to 8 days after initiation of 
chemotherapy. We found that in the early phase following chemotherapy, DAMP 
levels are profoundly increased, however, this does not induce immunoparalysis 
in this specific group of patients
In sepsis patients, a relationship between release of nucleic acids and mortality 
has been demonstrated. However, the intermediate factors and/or mechanisms 
contributing to this relation are largely unknown. In chapter 5, our aim was to 
determine whether plasma levels of nuclear DNA (nDNA) and mitochondrial DNA 
(mtDNA) are related to the markers of inflammation, shock, and organ damage in 
septic shock patients. We showed that during the first 5 days after onset of septic 
shock, nDNA, but not mtDNA levels consistently correlated with plasma cytokine 
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concentrations as well as with shock-related parameters (noradrenalin infusion 
rate and heart rate) and markers of organ damage (total bilirubin and creatinin). 
These results may explain the underlying mechanisms behind the relationship 
between plasma levels of nucleic acids and mortality in sepsis patients. 
In critical illness, multiple DAMPs are released simultaneously on many occasions, 
thereby triggering multiple PRRs at the same time. Interactions between those 
receptors could therefore be important. In chapter 6, we performed a systematical 
analysis of the interactions between PRR signaling pathways. A number of PRR-
dependent signaling interactions were found to be consistent, both between 
individuals and with regard to multiple cytokines. The combinations of TLR2 and 
NOD2, TLR5 and NOD2, TLR5 and TLR3, and TLR5 and TLR9 acted as synergistic 
combinations. Surprisingly, inhibitory interactions between TLR4 and TLR2, TLR4 
and Dectin-1, TLR2 and TLR9 as well as TLR3 and TLR2, were observed. These 
consistent signaling interactions between PRR combinations may represent 
promising targets for immunomodulation and vaccine adjuvant development, 
for example to activate the immune response by using multiple PRRs. Moreover, 
they can have implications for conditions in which multiple DAMPs and/or PAMPs 
are thought to play a role. 
Part II – DAMPs and ventilator-induced inflammation
Mechanical ventilation is an essential part of perioperative and intensive care 
medicine. However, mechanical ventilation can induce an inflammatory response 
in the lungs which compromises pulmonary function, and may cause injury 
to other organs. DAMPs are implicated to play a role in the ventilator-induced 
inflammatory response. In chapter 7, using a mouse model of ventilator-induced 
inflammation, we demonstrated that mechanical ventilation with either low or 
high tidal volumes elicits a pulmonary inflammatory response, but does not 
result in mtDNA release into the pulmonary compartment. Furthermore, using 
knockout mice, we showed that the receptor for mtDNA, TLR9, does not play a 
role in the ventilator-induced inflammatory response. In conclusion, the mtDNA/
TLR9 pathwya does not play a role in ventilator-induced inflammation.
Previous studies have shown that the pro-inflammatory cytokine IL-1β plays a 
pivotal role in the MV-induced inflammatory response. Cleavage of the inactive 
precursor pro-IL-1β to form bioactive IL-1β is mediated by several types of 
proteases, of which caspase-1, activated within the inflammasome, is the most 
important. In chapter 8, we demonstrated in a series of mouse experiments that 
the inflammasome/caspase-1 appears not to be involved in IL-1β processing 
in the ventilator-induced inflammatory response, which is driven by DAMPs. 
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Summary
The attenuated inflammatory response observed in ventilated anti-KC treated 
and neutropenic mice suggests that IL-1β processing in mechanical ventilator-
induced inflammation is mainly mediated by neutrophil factors.
Part III – Biomarkers in trauma
Although DAMPs could serve as biomarkers in the ICU, such as in severe trauma 
patients, immunologically inactive biomarkers could help determine prognosis 
and treatment options as well. 
One of these markers, intestinal Fatty Acid Binding Protein (iFABP), is a marker of 
intestinal injury. In chapter 9, we showed that plasma iFABP levels are increased 
immediately after trauma in patients with abdominal trauma, low MAP, or low Hb, 
and are related to the severity of the trauma. As intestinal injury is suggested to 
be related to late complications, such as multiple organ dysfunction syndrome 
(MODS) or sepsis in trauma patients, more attention to prevent intestinal damage 
following trauma could be of benefit in these patients. 
Soluble urokinase-type plasminogen activator (suPAR) has been identified as 
a marker for immune activation and has predictive value in multiple groups of 
patients. In chapter 10, we describe that in trauma patients, the first obtained 
plasma suPAR concentrations (measured before hospital admission or at the 
emergency department) are associated with mortality, although its predictive 
value is low. Furthermore, suPAR concentrations increase over time in these 
patients, and levels were related to the innate immune response observed in 
the ER. These results indicate that suPAR is an innate immune response-induced 
biomarker in trauma patients, but its clinical applicability is deemed low.
In conclusion, our major findings are that DAMPs are released in trauma, cardiac 
arrest, leukemia and sepsis. DAMP release is associated with the development 
of immunoparalysis in trauma and cardiac arrest, but not in leukemia, and with 
markers of inflammation, shock, and organ damage in septic shock. Mitochondrial 
DNA as a DAMP acting via TLR9 does not appear to play a role in the conditions 
studied, despite increasing attention in the past years. Future studies should 
focus on elucidating the exact (causal?) relationship between DAMPs and 
immunoparalysis, and the possible treatment options related. The pre-hospital 
phase in trauma, and possible biomarkers to identify patients that could benefit 
from treatment, should get extra consideration in this respect.
Chapter 12
222
Nederlandse samenvatting
Ernstig zieke patiënten op de intensive care hebben een vergrote kans op het 
ontwikkelen van infecties, bovenop hun bestaande aandoening. Hierdoor 
bestaat een grotere kans op complicaties, langer verblijf in het ziekenhuis of 
zelfs overlijden. Het afweersysteem is verantwoordelijk voor de bescherming 
tegen organismen die een infectie kunnen veroorzaken. Wanneer het niet goed 
functioneert, ontstaat een groter risico op infecties. Daarom is het van belang om 
zo goed mogelijk te begrijpen hoe het afweersysteem werkt bij deze ernstig zieke 
patiënten. 
Het aangeboren afweersysteem is cruciaal voor het onderscheiden van zaken 
waartegen een afweerreactie moet worden geïnitieerd van zaken die genegeerd 
dienen te worden. Patroonherkenningsreceptoren herkennen binnendringende 
ziekteverwekkers door de detectie van Pathogen Associated Molecular Patterns 
(PAMPs), zoals de celwand van bacteriën, DNA van virussen en sporen van 
schimmels. Na herkenning start een afweerreactie, waarbij nauwkeurig het 
evenwicht bewaard wordt tussen een overweldigende ontstekingsreactie die 
kan leiden tot teveel schade aan de patiënt en een anti-ontstekingsreactie die 
de patiënt vatbaar kan maken voor infecties. Naast deze PAMPs beïnvloeden 
gevaarsignalen (Danger Associated Molecular Patterns, DAMPs) - vrijkomend uit 
gewonde, bedreigde of dode cellen of weefsels van de patiënt zelf - eveneens 
het afweersysteem. Dit kan gevolgen hebben voor ernstig zieke patiënten, bij 
wie trauma- of chirurgiegerelateerde celschade, zuurstoftekort, bloedtekort 
of infecties kunnen leiden tot het vrijkomen van veel DAMPs. Aangezien veel 
patiënten op de intensive care aan het afweersysteem gerelateerde complicaties 
krijgen, kunnen DAMPs als markers dienen voor de prognose van deze patiënten. 
Bovendien zouden ze als mogelijke therapeutische aangrijpingspunten kunnen 
dienen, bijvoorbeeld wanneer neutralisatie van DAMPs de nadelige effecten, zoals 
ontsteking door het hele lichaam of slecht functioneren van het afweersysteem, 
op kunnen heffen of voorkomen. Dit proefschrift heeft als doel om licht te werpen 
op de rol die DAMPs en de bijbehorende afweerreacties spelen bij aandoeningen 
die vaak voorkomen op de intensive care. Daarnaast hebben we de voorspellende 
waarde van markers die niet als DAMP werken bij patiënten met een ernstig 
trauma bestudeerd.
In hoofdstuk 1 hebben we een aantal bekende DAMPs (High Mobility Group 
Box 1, heat shock eiwitten (HSPs), s100 eiwitten, nucleïnezuren, en hyaluronzuur) 
en hun effecten op het afweersysteem beschreven. Verder hebben we de rol 
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van DAMPs als markers of therapeutische aangrijpingspunten bij patiënten met 
sepsis, trauma, beademingsgeïnduceerde longschade en hartstilstand besproken. 
Bovendien hebben we het doel en de opzet van dit proefschrift gepresenteerd.
Deel I: DAMPs bij ernstig zieke patiënten
Het vrijkomen van DAMPs kan effecten hebben op het afweersysteem van ernstig 
zieke patiënten en daardoor de uitkomst van hun ziekte beïnvloeden. Bovendien 
kan gelijktijdige binding van meerdere receptoren door verschillende DAMPs, 
iets wat zeer waarschijnlijk gebeurt bij ernstig zieke patiënten, een ander effect 
hebben dan de binding van slechts een enkele receptor.
Een onderdrukt afweersysteem, ook wel “immuunparalyse” genoemd, kan 
bijdragen aan de verhoogde gevoeligheid van patiënten na een ernstig ongeval 
(traumapatiënten) voor ziekenhuisinfecties. In hoofdstuk 2 bestudeerden we 
het tijdsverloop van immuunparalyse bij traumapatiënten vanaf de pre-hospitale 
fase (direct na trauma, “op straat”) tot 10 dagen na het trauma. Ook keken we 
naar de relatie tussen de markers van immuunparalyse en het ontstaan van 
infecties bij deze patiënten. Bovendien werd de betrokkenheid van DAMPs 
hierbij onderzocht. We concludeerden dat immuunparalyse, gekenmerkt door 
verminderde expressie van HLA-DR (een belangrijk eiwit voor het afweersysteem) 
en ontregelde productie van ontstekingseiwitten, binnen minuten/uren na trauma 
ontstaat. Bovendien bleek de immuunparalyse gerelateerd aan het vrijkomen van 
DAMPs en de productie van grote hoeveelheden van het anti-ontstekingseiwit IL-
10 al voor de patiënt in het ziekenhuis is. Tenslotte bleek het nog verder afnemen 
van de HLA-DR expressie in de eerste dagen na het trauma geassocieerd met een 
toegenomen vatbaarheid voor infecties.
Ook bij patiënten die na een hartstilstand en daaropvolgende reanimatie buiten 
het ziekenhuis zijn opgenomen op de intensive care, wordt een verhoogd 
risico op infecties gemeld. Daarom hebben we in hoofdstuk 3 onderzocht 
of immuunparalyse ontwikkelt na een hartstilstand en of het vrijkomen van 
DAMPs hierbij betrokken is. Overeenkomstig met de resultaten van onze studie 
bij traumapatiënten, toonden we aan dat afgifte van DAMPs tijdens de eerste 
dagen na hartstilstand is geassocieerd met de ontwikkeling van immuunparalyse. 
De immuunparalyse werd gekenmerkt door een anti-ontstekingsreactie na 
blootstelling van het bloed aan een deel van een bacterie (LPS) in het laboratorium. 
Dit kan bijdragen tot de verhoogde gevoeligheid voor infecties bij patiënten na 
een hartstilstand.
Chemotherapie die gebruikt wordt voor het behandelen van bijvoorbeeld 
leukemie kan resulteren in het vrijkomen van grote hoeveelheden DAMPs. 
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Bovendien is het bekend dat patiënten behandeld met chemotherapie uiterst 
gevoelig voor infecties zijn, met name door de vernietiging van afweercellen door 
de chemotherapie. Echter, de functie van de resterende afweercellen zou ook 
aangedaan kunnen zijn als gevolg van immuunparalyse, waarbij het vrijkomen 
van DAMPs mogelijk een rol zou kunnen spelen. In hoofdstuk 4 bestudeerden 
we het vrijkomen van DAMPs en de markers voor immuunparalyse vóór en tot 
8 dagen na de start van de chemotherapie. We vonden dat in de vroege fase na 
chemotherapie behoorlijke hoeveelheden DAMPs aanwezig zijn. Dit resulteerde 
echter niet in immuunparalyse bij deze specifieke groep patiënten.
Bij patiënten met bloedvergiftiging (sepsis) is eerder een relatie tussen het 
vrijkomen van nucleïnezuren, zoals DNA, en sterfte aangetoond. De factoren en/
of mechanismen die bijdragen aan deze relatie zijn echter grotendeels onbekend. 
In hoofdstuk 5 onderzochten we of de plasmaspiegels van nucleair DNA (nDNA) 
en mitochondrieel DNA (mtDNA) gerelateerd zijn aan de markers van ontsteking, 
shock en orgaanschade bij patiënten met septische shock, een ernstige vorm van 
bloedvergiftiging. We toonden aan dat gedurende de eerste 5 dagen na het begin 
van septische shock de hoeveelheid nDNA, maar niet de hoeveelheid mtDNA, 
consistent gecorreleerd was met de hoeveelheid ontstekingseiwitten in het 
bloed, alsook met shock-gerelateerde parameters en markers van orgaanschade. 
Deze resultaten zouden de onderliggende mechanismen kunnen verklaren van 
de eerder aangetoonde relatie tussen plasmaniveaus van nucleïnezuren en 
sterfte in sepsispatiënten.
Bij ernstig zieke patiënten komen meerdere DAMPs gelijktijdig vrij, waarbij 
meerdere receptoren tegelijk geactiveerd worden. Mogelijke interacties tussen 
deze receptoren zouden daarom belangrijk kunnen zijn. In hoofdstuk 6 hebben 
we een systematische analyse van de interacties tussen receptorsignaalroutes 
uitgevoerd. Een aantal interactieroutes tussen receptoren bleken consistent 
te zijn, zowel tussen individuen als tussen meerdere ontstekingseiwitten. De 
combinaties van receptoren TLR2 en NOD2, TLR5 en NOD2, TLR5 en TLR3 en TLR5 
en TLR9 werden geïdentificeerd als synergistische combinaties. Bij het stimuleren 
van deze combinaties werden dus meer ontstekingseiwitten geproduceerd dan 
verwacht zou worden wanneer de individuele reacties bij elkaar opgeteld zouden 
worden. Opvallend genoeg werd een remmende wisselwerking waargenomen 
tussen TLR4 en TLR2, TLR4 en Dectin-1, TLR2 en TLR9 en TLR3 en TLR2. Deze 
combinaties resulteerden dus juist in minder ontstekingseiwitten die op basis van 
de som van beide individuele reacties verwacht zou worden. Deze consistente 
signaleringsinteracties tussen receptorcombinaties kunnen veelbelovende 
doelen voor therapeutisch ingrijpen op de afweerrespons en de ontwikkeling 
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van vaccinadjuvants vormen. Een vaccinadjuvant kan gebruikt worden om de 
afweerrespons sterker te maken, in dit geval via het stimuleren van meerdere 
receptoren. Bovendien kunnen deze resultaten gevolgen hebben voor onderzoek 
naar ziektebeelden waarin meerdere DAMPs en/of PAMPs geacht worden een rol 
spelen.
Deel II - DAMPs en beademingsgeïnduceerde ontsteking
Kunstmatige beademing is een essentieel onderdeel van zorg op de operatiekamer 
en de intensive care. Kunstmatige beademing kan echter een ontstekingsreactie 
in de longen induceren, die longfunctie kan verminderen en uiteindelijk ook 
schade in andere organen kan veroorzaken. Het is bekend dat DAMPs een rol 
spelen bij het ontstaan van de beademingsgeïnduceerde ontstekingsreactie. In 
hoofdstuk 7 bestudeerden we specifiek de rol van mtDNA en de receptor TLR9 
bij het ontstaan van beademingsgeïnduceerde ontsteking. Met behulp van een 
experimenten in muizen toonden we aan dat kunstmatige beademing met kleine 
of grote ademteugen een ontstekingsreactie in de long veroorzaakt, maar niet 
resulteert in het vrijkomen van mtDNA in de longen. Bovendien toonden we met 
behulp van genetisch gemodificeerde muizen zonder deze receptor aan dat de 
receptor voor mtDNA, TLR9, geen rol speelt bij de beademingsgeïnduceerde 
ontsteking. We concluderen dus dat de mtDNA/TLR9 route geen rol speelt bij 
beademingsgeïnduceerde ontsteking.
In eerder onderzoek is aangetoond dat het ontstekingseiwit IL-1β een 
centrale rol speelt bij beademingsgeïnduceerde ontsteking. Het inactieve 
pro-IL-1β kan door verschillende eiwitten omgezet worden in het bioactieve 
IL-1β. De belangrijkste daarvan is caspase-1, dat wordt geactiveerd in het 
inflammasoom. In hoofdstuk 8 hebben we in een reeks muisexperimenten 
aangetoond dat bij beademingsgeïnduceerde ontsteking, die wordt 
aangedreven door DAMPs, het inflammasoom/caspase-1 niet betrokken is bij 
de activatie van IL-1β. Vervolgexperimenten toonden aan dat IL-1β activatie bij 
beademingsgeïnduceerde ontsteking voornamelijk wordt gemedieerd door 
neutrofielen, specifieke afweercellen.
Deel III - Biomarkers in trauma
Biomarkers zijn factoren die iets kunnen zeggen over de prognose van of 
geschikte therapie voor patiënten. Ook stoffen die niet als DAMP werken kunnen 
als biomarker dienen.
Eén van deze markers, het vetzuurbindend eiwit van de darm (intestinal Fatty Acid 
Binding Protein, iFABP), is een marker van darmschade. In hoofdstuk 9 hebben we 
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aangetoond dat het iFABP niveau in plasma onmiddellijk na trauma is verhoogd 
bij patiënten met trauma aan de buik, een lage bloeddruk of laag hemoglobine, en 
verband houdt met de ernst van het trauma. Aangezien darmschade gerelateerd 
lijkt te zijn aan late complicaties (bijv. orgaanfalen of sepsis) bij traumapatiënten, 
zou meer aandacht voor de preventie van darmschade na trauma van nut kunnen 
zijn bij deze patiënten.
Oplosbare urokinase-type plasminogeen activator receptor (Soluble urokinase-
type plasminogen activator receptor, suPAR) is geïdentificeerd als een marker die 
voorspellende waarde heeft in verschillende patiëntenpopulaties. In hoofdstuk 
10 beschrijven we dat bij traumapatiënten de suPAR concentratie die kort na 
trauma werd gemeten, geassocieerd is met sterfte. De voorspellende waarde 
is echter laag. Verder zien we dat de suPAR concentratie met de tijd stijgt 
bij deze patiënten en dat de niveaus gerelateerd waren aan de hoeveelheid 
ontstekingseiwitten gemeten op de spoedeisende hulp. Deze resultaten geven 
aan dat suPAR een door het aangeboren afweersysteem geïnduceerde biomarker 
is bij traumapatiënten, waarvan de klinische toepasbaarheid echter laag wordt 
geacht.
Samengevat zijn onze belangrijkste bevindingen dat DAMPs vrijkomen bij 
trauma, hartstilstand, leukemie en sepsis. DAMP afgifte wordt geassocieerd met 
de ontwikkeling van immuunparalyse bij trauma en hartstilstand (maar niet bij 
leukemie) en markers van ontsteking, shock en orgaanschade bij septische shock. 
Mitochondrieel DNA als DAMP die werkt via TLR9 blijkt geen rol te spelen in de 
bestudeerde condities, ondanks de toenemende aandacht voor deze DAMP in 
de afgelopen jaren. Toekomstig onderzoek moet zich richten op het ophelderen 
van het precieze (oorzakelijke?) verband tussen DAMPs en immuunparalyse, en 
de mogelijke therapeutische aangrijpingspunten die daaraan gerelateerd zijn. De 
pre-hospitale fase na trauma, en mogelijke biomarkers om patiënten die zouden 
kunnen profiteren van de behandeling te identificeren, moeten extra aandacht 
krijgen in dit opzicht.
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Beste lezer,
Na het lezen van dit proefschrift, zult u zich vanzelfsprekend realiseren dat ik 
dit alles onmogelijk in mijn eentje gedaan kan hebben. Onderzoek is ondanks 
sommige eenzame momenten toch een teamsport. Ons  “team” heeft de afgelopen 
jaren leerzaam, gezellig en bijzonder gemaakt. Ik ben trots op het resultaat, maar 
bovenal op hoeveel ik heb mogen leren en meemaken. Ik wil dan ook iedereen 
die op wat voor manier dan ook een bijdrage heeft geleverd aan dit proefschrift 
ontzettend bedanken. Een aantal mensen zou ik hierbij specifiek willen noemen.
Allereerst professor Pickkers, beste Peter, ik ben blij dat je gaandeweg mijn 
promotie meer betrokken bent geraakt bij mijn project en het hebt helpen 
vormgeven. Jouw gevoel voor onderzoek doen is ongeëvenaard, al heb ik je 
(gelukkig?) nooit binnen een straal van 50 meter bij een pipet kunnen betrappen. 
Je zeer beschaafde gevoel voor humor en directe benadering maken het 
ontzettend fijn samenwerken met je. Daarnaast vind ik het bewonderenswaardig 
hoe je wetenschap, kliniek en privéleven combineert.
Professor Scheffer, beste Gert Jan, ik ben blij met alle vrijheid, vertrouwen en 
mogelijkheden die je me hebt gegeven om mijn onderzoek vorm te geven. Je 
was enthousiast over mijn ideeën en hebt me enorm geholpen ze te realiseren. 
Daarnaast heeft de afdeling anesthesiologie, waar jij aan het hoofd staat, me op 
alle mogelijke fronten bijgestaan.
Beste Matthijs, al voordat je zelf gepromoveerd was, werd je mijn co-promotor. 
Inmiddels mag je jezelf assistant professor noemen, wat ik als ervaringsdeskundige 
van jouw uitstekende begeleiding niet meer dan logisch vindt. Je bent een 
uitstekend onderzoeker en een fijn persoon, ik hoop dat onze paden in de 
toekomst nog regelmatig zullen kruisen.
Beste Michiel, ik ken weinig mensen die zo positief en bevlogen zijn als jij. Het is 
onmogelijk om je enthousiasme en eindeloze energie niet over te nemen. Je hebt 
tijdens jouw promotie-onderzoek het voorwerk gedaan voor mijn VILI-studies. 
Daarnaast is je inzet om mijn onderzoek van de grond te krijgen bij het MMT 
natuurlijk onmisbaar geweest.
Als student heb ik tijdens mijn hoofdvakstage enorm veel geleerd op het 
laboratorium experimentele interne geneeskunde van professor Netea en 
professor Joosten. Mihai en Leo, bedankt voor het nog verder aanwakkeren van 
mijn passie voor immunologie. Gelukkig dachten jullie aan Gert Jan Scheffer, 
toen ik bij jullie aanklopte voor mogelijkheden om te promoveren. Bedankt 
231
Dankwoord
13
ook voor alle experimenten die ik op jullie lab heb mogen uitvoeren en voor de 
overleggen die met name het VILI onderzoek verder hebben geholpen. Ook op 
de cytokinemeetings waar ik altijd welkom was, heb ik ontzettend veel input 
gekregen. Tijdens mijn presentaties op deze besprekingen was ik ook blij dat 
professor van der Meer de volledige medisch-wetenschappelijke literatuur uit het 
hoofd leek te kennen en altijd weer waardevolle suggesties voor vervolgstudies 
deed. Jos, ik ben vereerd dat je ondanks het emeritaat op wilde treden als 
voorzitter van mijn manuscriptcommissie. 
Professor van der Hoeven en Annemiek Broods hebben mij, als anesthesie-
onderzoeker, de mogelijkheid gegeven onderzoek te doen op de Intensive Care. 
Ik heb mij zeer welkom gevoeld op mijn werkplek op de IC en weet zeker dat mijn 
proefschrift niet hetzelfde zou zijn geweest zonder deze samenwerking. Hans, 
bedankt voor jouw visie op onderzoek en de klinische relevantie die je nooit uit 
het oog verliest. 
Jelle, pipetteerheld... Wat had ik zonder jou gemoeten? Duizend maal dank 
voor al die PCRs, ELISAs, celkweken en geprakte longetjes. Je vond het haast 
vanzelfsprekend om me op rare dagen of tijdstippen te helpen als dat nodig was. 
Het was super om met je te werken! Ik ben benieuwd naar je nieuwe huis, bijna 
bij mij om de hoek in Lent!
Ilona en Francien, wat jullie kunnen met microchirurgie en muizen grenst aan 
het onmogelijke, en daarnaast is het nog gezellig op jullie lab ook. Hoe vaak 
ik naar jullie toe kwam om “even snel” wat te halen, maar toch weer een half 
uur bleef hangen voor thee... Jullie mogen ook trots zijn op de artikelen met 
dierexperimenten in dit proefschrift. Ineke, jij hebt met de RIAs de resultaten van 
de muisexperimenten een stuk inzichtelijker gemaakt. Dankjewel!
Alle artsen, piloten en verpleegkundigen van het MMT van de lifeliner-3, 
enorm bedankt voor jullie hulp bij mijn onderzoek onder haast onmogelijke 
omstandigheden. Jullie maakten de wilde plannen voor pre-hospitale 
bloedafname waarheid, met een prachtig artikel als resultaat. Elke keer als iemand 
op een congres verbijsterd vroeg hoe ik DAT toch voor elkaar had gekregen, was 
ik weer trots op jullie. Ik denk dat het MMT-onderzoek in de toekomst nog een 
mooie vlucht gaat maken!
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Tijn, Aarnoud, Hetty, Marieke, Hellen, Chantal, Lisa en Yvonne, jullie ondersteuning 
is onmisbaar (geweest) voor het functioneren van de research IC. Jullie manier van 
meedenken met onderzoekers en jullie leergierigheid is meer dan prijzenswaardig. 
Ongelofelijk wat voor bergen jullie kunnen verzetten!
De Intensive Care artsen, verpleegkundigen en ander personeel zijn eveneens 
van groot belang geweest voor mijn proefschrift. Fijn dat ik steeds weer langs 
mocht komen met vragen, of om alweer een buisje bloed af te nemen. 
Sjef en Maikel, jullie zijn het lichtpuntje voor elke computergebruiker op de IC. 
Fijn dat jullie er altijd waren als ik een probleem had dat haast had, en dat jullie 
mij hielpen de data die ik nodig had uit de enorme databases van IC web, EPD of 
EPIC te halen. 
De medewerkers van de afdeling Anesthesiologie hebben op allerlei manieren 
mijn onderzoek gefaciliteerd. Het onderzoek op de afdeling wordt steeds beter, ik 
denk dat we daar allemaal trots op mogen zijn.
Ook de co-auteurs van de stukken in dit proefschrift, Astrid Hoedemaekers, 
Maarten van den Berg, Arjan van Laarhoven, Nicole Blijlevens, Özcan Sir, Michael 
Edwards, Jeroen van der Laak, Theo Plantinga, Gosse Adema, Selina van der Wal, 
Stephanie Janssen, Pauline Maassen, Carmen de Jong en Aaron John wil ik graag 
bedanken voor hun bijdrage aan dit proefschrift en de prettige samenwerking.
Gedurende mijn promotie heb ik veel studenten begeleid. Van allemaal heb 
ik nieuwe dingen geleerd over begeleiden, communiceren of lesgeven. Ik 
ben hen natuurlijk dankbaar voor hun hulp bij de inclusie van patiënten en 
laboratoriumwerk, maar nog veel meer voor deze belangrijke lessen.
Lieve mede-onderzoekers van de research IC, Annelies, Bart, Benno, Dorien, Eline, 
Esther, Jelle G, Jelle Z, Jenneke, Jonne, Lex, Linda, Lisanne, Lucas, Mark, Marloes, 
Matthijs, Mirrin, Paul, Rebecca, Roger en Suzanne, jullie collegialiteit is me heel veel 
waard. Toen ik begon met mijn onderzoek, pasten we nog met alle onderzoekers 
op één kamer en stonden de vriezers op de gang. Inmiddels hebben we een 
prachtige eigen researchunit met een lab(je), onderzoekskamer, vergaderruimte 
en kantoren. Met een beetje heimwee kijk ik terug op het tafeltennissen, de 
stapavonden, de congressen en de IC research weekenden met jullie. Het is fijn 
om op zo’n hechte afdeling gewerkt te hebben!
Esther en Lucas, roomies, jullie in het bijzonder hebben bijgedragen aan mijn 
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proefschrift en aan mijn persoon. Dank voor alle inhoudelijke inbreng, troost, 
lol, ervaringen en levenslessen, binnen en buiten het ziekenhuis. Het voelt voor 
mij niet meer dan logisch om jullie ook vandaag als paranimfen aan mijn zijde te 
hebben. 
Ik ben blij dat ik naast het werk altijd bij mijn BMW-vrienden terecht kon voor een 
goed (of kansloos) gesprek, een dinertje of andere gezelligheid. Naast het eens per 
week lunchen in het Radboud, onze altijd legendarische Varsseveldweekendjes, 
spelletjesavonden en vrouwendagen, konden we ook inhoudelijk discussiëren 
over onderzoeken en de wetenschap in het algemeen.We hebben inmiddels al 
heel wat meegemaakt met zijn allen. Ik hoop dat we over 30 jaar nog steeds samen 
terugblikken op die keer hoe we voor het eerst bij elkaar zaten in werkgroep 55. 
Dansen is altijd al mijn uitlaatklep geweest en het voelt nog steeds elke keer als 
thuiskomen als ik bij mijn dansvrienden ben. We zijn nog lang niet te oud voor 
een ETDS. Allemaal dank voor alle dansjes, gezelligheid, het “ok-dat-doen-we-
ook-wel-ff”-commissiewerk en natuurlijk voor de mentale uitputtingsslagen 
tijdens de “Wie is de mol?”-weekendjes. 
Je eenmaal per jaar weer helemaal kind voelen, hutten bouwen en levend stratego 
doen geeft genoeg energie om er weer even tegenaan te kunnen op het werk. En 
dat allemaal in het mooie Brabantse land! Ik krijg steeds weer een glimlach op 
mijn gezicht als ik het hele jaar door nog overal drankbonnen vind. Bovendien 
zijn we natuurlijk het allerbeste pubquiz-team. Dankjewel Groentjes! 
Lieve papa en mama, ik ben ontzettend dankbaar voor alle mogelijkheden die 
jullie me hebben gegeven en voor de fijne jeugd die ik bij jullie heb gehad. Ook al 
vonden jullie het soms spannend wat ik nu weer ging doen, jullie steun, interesse 
en liefde waren onvoorwaardelijk. 
Mijn allerliefste broertje en zusje, Reina en Wouter: Ik ben als grote zus trots op 
alles wat jullie bereikt hebben! Ik ben blij dat ik dit moment ook met jullie kan 
delen. Dankjewel voor alle uren duplo’en, hutten bouwen, en verstoppertje doen 
en voor hoe gezellig het nu nog steeds is wanneer we met zijn allen bij elkaar zijn.
Jasper, je vond het waarschijnlijk maar stom dat ik steeds maar moest gaan 
werken in plaats van met jou buiten spelen. Als je een paar jaar ouder bent, leg ik 
jou en je kleine broertje Wessel graag eens uit waar ik nou allemaal mee bezig ben 
geweest. Of we gaan gewoon lekker voetballen.
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Emile, ik bof maar met jou! Dankjewel dat je met me mee naar Nijmegen bent 
gegaan en dat je mijn leven zoveel waardevoller maakt. Ik kan de toekomst niet 
anders zien dan met jou.
Het spijt mij oprecht als ik ondanks mijn pogingen volledig te zijn, nog iemand 
vergeten ben. Wil je toch graag een persoonlijk bedankje? Schrijf dan je naam op 
het stippellijntje:
Beste ………..…….., jouw bijdrage aan dit proefschrift is niet in woorden uit te 
drukken. Dankjewel!
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Curriculum Vitae
Kim Timmermans werd geboren op 11 april 1987 te Loon op Zand. Na het behalen 
van haar VWO diploma aan het Sint Odulphuslyceum te Tilburg begon zij in 
2004 aan de studie Biomedische Wetenschappen aan de Radboud Universiteit 
Nijmegen. Zij koos hierbij voor het hoofdvak Humane Pathobiologie, het 
bijvak geneesmiddelenonderzoek en een aantal keuzevakken immunologie en 
infectieziekten. In het kader van de studie werd een viertal stages gelopen. De 
bachelorstage, met als onderwerp de calcium transporter TRPV5, werd uitgevoerd 
onder supervisie van Prof. Bindels, Prof. Hoenderop en Dr. Renkema op de afdeling 
celfysiologie van het Radboud Institute for Molecular Life Sciences (RIMLS). In het 
kader van het bijvak geneesmiddelenonderzoek liep Kim stage op de afdeling 
farmacologie en toxicologie van het RIMLS en werd hierbij gesuperviseerd door 
Prof. Russell en Dr. Wittgen. Tijdens dit project bestudeerde zij het transporteren 
van antibiotica uit cellen door multi-drug resistance proteins. Vervolgens heeft zij 
aan de Universitas Muhammadiyah te Yogyakarta, Indonesië, onder begeleiding 
van Dr. Zulhah, een onderzoek uitgevoerd naar mogelijke behandelingen van 
anemie. Kim sloot haar studie af met een stage op de afdeling experimentele 
interne geneeskunde van het Radboudumc, waar zij onder begeleiding van Prof. 
Netea en Dr. Plantinga de interacties tussen verschillende pattern recognition 
receptors bestudeerde.
Na het behalen van het masterdiploma begon Kim in december 2009 als junior 
onderzoeker aan de afdeling pathologie van het UMC Utrecht. Hier deed 
zij onderzoek naar de mechanismen van cardiac allograft vasculopathy na 
harttransplantatie. In februari 2011 startte zij vervolgens met een promotie-
onderzoek op de afdelingen Anesthesiologie en Intensive Care van het 
Radboudumc. De onderzoeksresultaten staan in dit proefschrift beschreven en 
werden bovendien gepresenteerd op verscheidene nationale en internationale 
congressen, wat onder meer resulteerde in prijzen voor beste presentatie op de 
wetenschapsdagen van de Nederlandse vereniging voor Anesthesiologie in 2013 
en 2015.
Kim woont samen met Emile Brink en hun twee zoons Jasper en Wessel in Lent.
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